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Craniofacial bone defects have poor outcomes under current treatments: implants 
become infected, loosen, and displace; bone grafts resorb and weaken over time; and 
there are no satisfactory pediatric options. To improve outcomes, this thesis develops a 
novel osteoinductive biomaterial, the methods to 3D-print the biomaterial, and the tools 
to design of that 3D-printed scaffold for the mechanical loads of the craniofacial skeleton. 
Further, it combines the scaffold with key regenerative agents – autologous stem cells – 
to facilitate boney regeneration in the implanted scaffold. The feasibility of the scaffold 
and cells approach is tested by implementation in preclinical models and assessment of 
bone and vascular outcomes. Aim 1: To create an osteoinductive biomaterial, trabecular 
bone was decellularized, cryo-milled, and mixed with polycaprolactone. This 
thermoplastic material mixture was then 3D-printed and demonstrated osteoinductive 
effects on cells. Aim 2: As regenerative autologous cells, the stromal vascular fraction of 
adipose tissue was isolated in a point-of-care manner and timeframe and the stem cell 
yield, surface markers, in vitro and in vivo regenerative potential for vascular and bone 
tissue was demonstrated. Aim 3: Then the means to design 3D-print the biomaterial with 
controlled tissue engineering properties – pore size and porosity – at human craniofacial 
scales and for human physiologic loads was developed and tested. Aim 4: Finally, the 
biomaterial, cells, and design and manufacturing were implemented in a patient-specific, 
large-animal, preclinical model of zygomatic arch regeneration in swine. Implant design 
and manufacture was successfully validated, and the implanted scaffolds and cells 
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CHAPTER 1  
INTRODUCTION: REGENERATING CRANIOMAXILLOFACIAL BONE  
WITH TISSUE ENGINEERED BONE SCAFFOLDS  
 
 
There is a high incidence – over 200,000 annually1 – of craniomaxillofacial 
skeleton reconstructions in the US every year, and those reconstructions suffer 
from poor healing outcomes, treatments that create donor-site morbidities, or 
infection. A regenerative medicine treatment could address those complications 
and improve outcomes of craniofacial reconstructions. However, the inherent 
complexity of regenerative materials and designs, compounded due to the scale, 
shape, and mechanical function of the craniofacial skeleton has been a barrier to 
such treatments. This thesis works to overcome those complexities and improve 
craniofacial outcomes by developing a regenerative implant treatment. By 
producing tissue engineered scaffolds through 3D-printing of bone material, a 
regenerating defect could be vascularized to fight infection, integrated with the 
surrounding bone, and eventually become indistinguishable from surrounding 
bone; thus, poor healing outcomes, co-morbidities, and rates of infection could be 
reduced. This chapter establishes (i) the context and function of the CMF skeleton, 
(ii) the common pathologies and treatments of CMF bones, (iii) the potential of 
regenerative medicine to improve treatments of CMF boney defects, and (iv) 
outlines the organization of the dissertation.   
Form and Function of Craniofacial Bones 
First, the craniofacial skeleton provides an important set of mechanical 
functions: it enables respiration, mastication, communication, and it is the primary 
2 
protection of the central nervous system. The airway begins in the mouth and nose 
and connects with the sinus system as well as continuing down the trachea. The 
bones surrounding the nose, and lining the sinus are thin and precisely defined to 
allow for respiration and mucosal production. Mastication is due to the motion of 
the mandible, which pulls against the zygomaxillofacial complex, the temple, and 
the frontal bone, and the reaction forces of that movement on the maxilla.   
Second, the CMF skeleton has important functions in communication. 
Facial expression is fully dependent on the craniofacial skeleton and 
communication via facial expression is one of mammals' first conscious skills2. 
Facial recognition is one of the first skills infants use—within minutes of birth.  
Facial identity is not only crucial to communication, but it is foundational to self-
identity3. The CMF skeleton is also crucial for speech and verbal communication.  
Embryologically, the bones of the face (mandible, maxilla, and zygoma) are 
outgrowths of pharyngeal arches and develop via intramembranous growth until 
skeletal maturity. This developmental process differs from that of the bones of the 
neurocranium, which begin with intramembranous ossification, and join together 
at sutures that maintain growth during development via fibrous (non-endochondral) 
edge ossification4. Importantly, these processes are distinct from the endochondral 
formation and growth of long bones throughout the remainder of the body. Further, 
the process of fracture healing in cranial bones is different, with a delayed 
osteoblastic response5. 
Geometrically, CMF bones are thin (<2cm) and encompass a narrow 
marrow cavity or air sinus—resulting in even thinner wall structures. The facial 
bones have jutting prominences, while the cranial bones form a reinforced sphere 
3 
around the brain. Orbital bones are exceptionally thin (on the order of a few 
millimeters) and facilitate the movement, position, and protection of the orbit. Facial 
bones are thinner and weaker than the cranial bones, and a more common source 
of fracture and morbidity while the cranial bones are more often injured during 
operations to access or treatments of malignancies in the central nervous system. 
Pathologies of Craniofacial Bones 
Craniofacial skeletal defects commonly arise from trauma, congenital 
malformation, or cancerous re-sectioning (Figure 1-1). Trauma, such as gunshot 
wounds6, blast injuries, or motor vehicle accidents7 can severely fracture the 
craniofacial bones and render the fragments non-viable. Non-viable fragments are 
removed to prevent necrotic masses, resulting in a void in the skeleton. These 
injuries often involve multiple bones and soft tissues. Compared to congenital or 
resection injuries, these involve a healthy, skeletally-mature population.  
 
Figure 1-1 Examples of CMF Pathologies.  
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Congenital malformations such as Goldenhar syndrome8,9 and hemifacial 
microsomia10,11 present early in life (0 – 6 months). They typically involve 
malformation (as absence or undergrowth) of the mandible, the 
temporomandibular joint, or the maxilla. Additionally, there are cases of premature 
synostosis of the sutures, resulting in a misshapen cranial vault. These disorders 
can be grouped together because of the large volumes of bone that must be 
corrected as well as the dynamic nature of the pediatric craniofacial skeleton. 
Disorders of cleft palate also present with malformation of the craniofacial skeleton. 
However, cleft palate can be treated with soft tissue reconstruction.  
Defects also arise as a secondary morbidity such as resection due to 
cancer12, radio-osteonecrosis13, or through the failure of a previous craniofacial 
implant. These defects are often massive (>50 cm2) and occur in an elderly or 
otherwise infirm population that may have reduced healing or integration capacity.   
While bone is a self-healing organ, defects of large sizes are slow or 
impossible to heal, result in functional failings of the CMF skeleton, and can cause 
disfigurement and associated psychosocial pathologies14. Many researchers in the 
field characterize defects in animal studies as 'critical sized' or non-healing in the 
life of the animals. In human treatment, such a concept is very poorly tested, as 
nearly all defects are treated with a packed granule/cement or implant. Generally, 
it is used to refer to defects that are >6cm in width. Reconstructive surgery is the 
primary treatment for these defects. In the US, there are 200,000 
craniomaxillofacial reconstructions a year, at a cost of $610M1.  
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Shortcomings of Standard-of-care Interventions 
These anatomically complex reconstructions are treated with bone grafts 
and implants, each with disadvantages (Figure 1-2). Filling the defect with bone 
or a solid implant maybe replace the shape and rigidity of the deficient bone, but 
such treatments do not restore multifaceted biology activity of the original native 
bone.  
Solid implants suffer from infection rates of 8-20%15 due to poor 
vascularization (thereby not enough blood supply of immune cells to clear 
infections) and soft tissue thinning on the surface of the implant (the soft tissue 
cannot integrate with implants and detaches and thins as a result). Implant 
materials, such as titanium, can be stiffer than bone and cause stress shielding 
from the surrounding bone, resulting in the adjacent bone weakening and the 
implant loosening or dislodgement.  
Autologous bone grafts are the gold standard treatment because they can 
become vascularized and have a small degree of integration with the surrounding 
hard and soft tissue, and they fill the defect with living bone. With autologous bone 
grafts, there is initially a high degree of implanted viable bone, at the cost of 
anatomic shape. However, these grafts necessarily cause donor site morbidity and 
experience high rates of resorption16.  
Allograft bone implants were initially unable to meet demand, but they have 
increased in supply over the last decade as bone banks have become 
established17. While allograft is still true bone material (collagen and mineral) like 
autografts, allografts are acellular, less bioactive, and have high resorption rates 
compared to autologous bone grafts. While precise surgical planning has improved 
6 
the speed and cosmetic outcome of bone grafting operations, bone grafts remain 




Figure 1-2 Different Craniofacial Bone Therapies 
Each of the current standards of treatment have different advantages 
and disadvantages.  A. Bone autograft from the fibia to the maxilla, with 
3D-printed cutting guide and fixation hardware. B. Patient-specific PEEK 
manufactured with a casting process. C. Ceramics made through a high-
temperature sintering or baking process. D. 3D-printed tissue 
engineering scaffold.  
 
 
Plastic implants are the common alternative to bone grafts. The leading 
material, polyetheretherketone (PEEK), can be manufactured to match exact 
anatomic shape (e.g. patient-specific products from Stryker and Synthes). 
However, plastic implants suffer from moderate rates of infection and displacement 
or extrusion15. These patient-specific implants are the cutting-edge in implant 
Current gold standard: 
free fibular flap 
(reconstruction via
pieces of fibula)
“Critical size” ≥6 cm 
defect that will not 
spontaneously heal 
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technology, but they are often not appropriate for pediatric cases as the 
craniofacial skeleton is continuing to grow and the implants do not grow with the 
patient. There are no satisfactory pediatric options19,20.  
More recently, solid implants of hydroxyapatite (HA) ceramics and 
bioglasses have been developed for patient-specific use. While their mineral 
nature supports osteoconduction and bone integration, these implants are typically 
brittle and non-resorbable21.  
3D-printed thermoplastics, such as polycaprolactone (PCL), can be 
manufactured in a patient-specific manner and have a high porosity that is 
appropriate to bone tissue ingrowth and regeneration through the bulk of the 
implant. Osteopore (PCL Scaffold Bone Void Filler, Singapore) has a 3D-printed 
implant line (non-patient specific) which has FDA approval, with the important 
caveat that the implant must not be load bearing. However, the porous and plastic 
properties of these grafts result in mechanical weakness and plastics are generally 
bioinert.  
Promise of Regenerative Interventions for Bones 
Regenerative approaches differ from classical implants and grafts by 
intending to fully replace the missing tissue and thereby restore the function of the 
bone, whereas implants aim to fill the defect with bone-like material that falls short 
of fully recapitulating the bone. Even bone grafts—which can fill the void with viable 
living tissue—have a poor rate of integration and do not properly remodel 
according to the implant location.  
Tissue engineering is classically defined as a combination of cells and 
biomaterials to manufacture a replacement tissue22. These replacement tissues 
8 
can be designed to fully integrate with the surrounding tissue, and work with the 
host ingrowth to endogenously replace the tissue, finishing with the eventual 
degradation of the implant and regeneration of the native tissue. Bone is a 
promising target of tissue engineering because healing of most bone injuries 
occurs naturally throughout many stages of life.  
Thorough vascularization is a hallmark of a healing tissue, and both fully 
heathy or regenerated bone has an intricate and pervasive vascular network. The 
vascular response is critical for the bone growth and remodeling process as well 
as for providing the immune response to fight off infection. The avascular nature 
of implants and allografts, and the poorly vascularized nature of allografts might 
be a major source of their poor outcomes.  
Outcomes of large CMF bone defects would be improved by a regenerative 
treatment. Regenerative medicine treatments will be highly vascularized and able 
to resist infection, eventually being composed entirely of living bone that will not 
be extruded by the body. However, no regenerative medicine treatments for large 
CMF bone defects currently exist. This shortcoming is primarily due to the complex 
design requirements of such an approach. Early treatments have had problems 
that include implanted cell death, a lack of cell permanency, and weak biomaterials 
that degrade asynchronously with regeneration. While biodegradation is needed 
to eventually create the space for a total regenerative response it weakens the 




Figure 1-3 The Effect of Osteoinduction and Biodegradation on Implant Stability 
A. Primary implant stability degrades over time due to the 
biodegradation of the implant and the parts used to fixate it in place. 
This degradation needs to be matched with increases in stability from 
the boney regeneration into and throughout the implant (secondary 
stability). The combination of these stabilities cannot drop below the 
level of the forces acting on the implant.  
B. Schematic of primary and secondary stability in the context of 
scaffold degradation and bone growth into and throughout the 
scaffold. Osteoinduction would increase the rate of formation of 












Tissue Engineering Approaches to Regenerate Bone 
Bone tissue engineering combines cells and a rigid scaffold together to 
recreate the mechanics and biology of bone—collagen fibrils mineralized with 
apatite crystals, assembled into porous bone trabeculae, where the porous space 
is lined and filled with bone cells and blood vessels. Often, this re-creation is 
achieved through the additional combination osteoinductive agents (such as 
growth factors PDGF-BB or BMP-2) (Figure 1-4).   
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Figure 1-4 Scale of Bone Tissue Engineering Components  
The different materials used throughout this dissertation are many 
different scales, but all interact with the key regenerative agent: the cells. 
i. Osteoinductive agents such as GFs and small molecules. ii. DCB 
particles. iii. Bone forming cells. iv. Biological apatites form on the 
extracellular matrix – collagen fibers. v. Collagen fibers are deposited by 
the implanted cells. vi. Bone has a natural porosity on the scale of 50-
100µm pores and trabeculae. vii. 3D-printed scaffolds are much larger, 
and contain struts and pores on the scale of millimeters.  
 
 
Regenerative bone scaffolds necessarily must be cellular, as cells are a 
vital part of the remodeling and vascular features of bones. However, cell and 
blood vessel growth into large implants is unreasonably slow. Osteoconduction is 
a process where the bone edge of the host grows into the implant (7-70µm/hr for 
osteoblasts)23. The scale of defects and therefore scaffolds is much larger (>6cm), 
resulting in months to a year for osteoblasts to migrate to the bulk of the scaffold. 
Placing cells (that can form bone and vascular tissue structures) throughout the 
scaffold, is therefore an indispensable feature of the scaffolds. Further, the scaffold 
should have signals (osteoinductive, angiogenic) in the component materials 
directing the implanted cells to form the desired bone and vascular tissues.  
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ASCs have been used as an autologous bone cell alternative throughout 
the bone tissue engineering (BTE) literature because they can be induced to create 
a strong mineral deposition in vitro over the course of as few as 10 days, without 
the morbidity or pain of harvest. Their manner of deposition is similar to 
osteoblasts, with caveats for in vitro vs in vivo scale and complexity. This timescale 
applied to volumetric defects is similar to the bone callus formation that occurs in 
fracture healing. Finally, these cells have been used in a large number of clinical 
trials and have been shown to be generally safe24 (non-immunogenic, non-
tumorigenic).  
The rigid scaffolds, if acting as a load-bearing implant, are made up of struts 
of material with a network of pores throughout for the cells to invade and fill with 
tissue. Firm fixation with the adjacent host bone is required for the connection of 
host and graft tissue – even millimeter scale motion will prevent tissue from joining 
across the implant-host border. The material itself must be highly biocompatible 
and biodegradable. Often, engineers include an osteoinductive factor with the 
material to increase the bone forming potential of the implant.   
Cost reductions in 3D-printing has enabled many researchers to use this 
manufacturing process to create regenerative implants that match the geometric 
shape of the bone, or that have a characteristic porous interior. 3D-printing 
technology has the potential to enable the manufacture of the material phase of 
tissue engineered bone scaffolds at human scale, and in a highly patient-specific 
manner.  While there are a number of different 3D-printing (additive manufacturing) 
systems, fused deposition is commonly used for bone scaffolds because it does 
not require alterations or additives to deposit solid material (like light/resin 
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crosslinking 3D-printing systems) nor does it require high temperatures (like 
selective laser sintering systems) that discourage the inclusion of bioactive factors, 
which are sensitive to temperature.  
There are three common methods to drive the extrusion from a fused 
deposition print head: pneumatic pressure, filament flow, and screw extrusion. The 
first parts of this dissertation use a pneumatic pressure system because it affords 
small batch manufacturing with minimum volumes as low to 5mL, which enables 
the rapid testing of different materials. The latter parts of the dissertation used a 
filament driven system, because that enables the larger scale manufacture of 






Figure 1-5 3D-Printing Systems Used in the Dissertation   
A. The pneumatic deposition system was advantageous for small batch 
testing but was limited in scale <1cm and continually clogged.  
B. Filament driven system has fewer printing complications but requires 




Figure 1-6 Overview of Proposed Intervention 
A. Patient with severe midface osteotomy following cancer 
resectioning.  
B. CT provides patient-specific anatomy, and normative anatomy can 
be reflected (green) across the midline of the face to create the 
shape of the implant.  
C. The implant can be manufactured with FDM 3D-printing  
D. Stem and endothelial cells can be isolated from the patient's own 
adipose lipoaspirate.  
E. Cells loaded into the scaffold and acutely implanted back into the 
patient in a single surgical session.  
 
 
Dissertation Goals  
This dissertation builds directly upon and integrates the work of two 
previous doctoral researchers in the Grayson Lab: Daphne Hutton-Hosmane and 
Ben Hung. Daphne developed methods to regenerate vascularized bone from 
adipose-derived stromal/stem cells25,26. These methods are key to facilitate rapid, 
cell-driven regeneration of boney tissues. Importantly, she demonstrated that a 
single cell source – ASCs – could develop into both blood vessels and mineralizing 
matrix.  In part, this work seeks to further the application of these cells to blood 
vessel and bone formation, and it works to do so in a clinically relevant iteration of 
the cells—the uncultured stromal vascular fraction cells.  
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Ben pioneered the idea of incorporating bone extracellular matrix in 3D-
printed scaffolds to create an implant with bone-forming bioactivity27. While his 
system had promising in vitro osteoinductivity, manufacturing was practically 
infeasible. An enduring bone-forming signal throughout the implant is crucial for 
implanted stem cells or surrounding endogenous progenitors to fully regenerate 
the bone. This dissertation improves the manufacturing of such scaffolds, and fully 
characterizes the scaffolds in the context of other clinical technologies.  Further, it 
develops an open and replicable method of designing 3D-printed tissue 
engineered scaffolds. Together, the scaffold and cells represent a powerful 
technology to affect bone regeneration.  
In addition to furthering and integrating these two technologies, the personal 
goal of this dissertation is to translate those technologies to a human-scale 
intervention and acute clinical context, from small-scale in vitro and murine 
platforms (Figure 1-6). Herein, studies break new ground in the design, 
manufacturing, and implementation of implants of human scale and quality, and 
the effect thereof combined with acutely grafted SVF cells on regeneration of 
craniofacial bones.    
Organization of the Dissertation 
The dissertation is grouped into five parts: (1) background, (2) biomaterial, 
(3) cells, (4) scaling design and manufacturing, and (5) clinical feasibility and 
translation. Part 1 develops the background in 3D-printing and bone tissue 
engineering.  
Chapter 2. 3D-printing technology is a powerful tool for manufacturing the 
shapes of the craniofacial skeleton. This chapter reviews the different ways the 
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technology can be used to manufacture products that aid in the reconstruction, 
repair, or regeneration of craniofacial bone.  
Chapter 3. Growth factors and extracellular matrix cues are key tools for 
tissue engineers as they provide instructive cues for cells to develop certain types 
of tissue. This chapter reviews the growth factors that are important for bone tissue 
formation and the different methods of using them.  
Part 2 characterizes the 3D-printed biomaterial and the resulting scaffolds 
for bioactivity and osteoinductivity.  
Chapter 4. Decellularized bone particles are the key bone forming signal in 
this dissertation. This chapter considers the materials and the methods of 
preparing particles polycaprolactone, as well as the process of 3D-printing them in 
combination. Further, it evaluates the different methods used to assess these 
scaffolds.  
Chapter 5. Scaffolds containing DCB are compared with other clinically 
used bone-forming ceramics in their manufacturability, material properties, 
osteoinductivity, and in vivo behavior in mice. It finds that the scaffolds prepared 
with particles containing extracellular derived particles have increased 
osteoinductivity in vitro, and equivalent bone formation in murine cranial defects.  
Part 3 concerns the cells (both SVF and ASCs) used to accelerate up the 
growth of bone tissue.  
Chapter 6. New blood vessels are hallmarks of regeneration and are 
essential to supply oxygen and nutrients to the bulk of the implant. This chapter 
looks at the ability of ASCs to undergo vasculogenesis and form blood vessels 
through in vitro pseudo implant conditions and in vivo implantation in the 
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subcutaneous space. It finds that the cells form blood vessels and are more likely 
to survive harsh implant conditions if they are able to assemble for a period of four 
days.  
Chapter 7. Clinical implementation requires cells that are available 
intraoperatively and in large quantities. This chapter compares such a cell 
source—SVF—to the common cultured form of cells—ASCs—to determine their 
relative osteogenic and vasculogenic potential. It uses a high number of donors to 
demonstrate that the trend of regenerative potential eclipses donor-to-donor 
variability. It finds that SVF is an appropriate cell source for our scaffold system.   
Part 4 focuses on designing and manufacturing 3D-printed craniofacial 
scaffolds at human scale and with a mechanical integrity that can endure the loads 
of the implant condition.  
Chapter 8. Inherently, porous PCL-DCB scaffolds deform easily and are 
mechanically inferior to bone. This weakness stems from the soft plastic character 
of PCL, and the thin strands of material that result from 3D-printing. Patterning 
areas of human-sized craniofacial scaffolds with stiffer regions to increase the 
mechanical strength without sacrificing overall porosity might alleviate this short-
coming. This chapter develops optimization software to find optimal patterns of stiff 
regions and porous regions throughout the implant in response to the exact 
anatomic shape, surgical fixation, and physiologic loading. Using this software tool 
results in designs that are superior generic homogenously patterned implants.  
Chapter 9. The ability to 3D-print scaffolds with different pore sizes, 
porosities, and mechanics throughout the shape is lacking in the field, despite 
being within the capabilities of most 3D-printing systems. This chapter develops a 
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versatile MATLAB approach to control the manufacture of scaffolds with many 
different porous regions. Characterization of those different regions and the quality 
of the transitions between them finds a range of different porous or stiff patterns 
that can be faithfully manufactured. Importantly, this approach can be combined 
with the designs in chapter 8 to manufacture functionally heterogeneous implants.  
Part 5 tests the different technologies developed in parts two, three, and 
four at human scales, and comments on the challenges of implementing them in 
clinical use.  
Chapter 10. Bone regeneration at a human scale remains a challenge for 
the field of bone tissue engineering. This chapter takes the biomaterial and cells 
from parts two and three and tests them in a novel porcine—human scale—model 
of craniofacial bone regeneration.  
Chapter 11. Actual translation of these technologies into clinical use will 
require the clearing of different hurdles in the technical, clinical, and regulatory 
dimensions of craniofacial care. Challenges and future perspectives are 
considered for the proposed scaffold system and for the field of craniofacial 
regenerative medicine as a whole. 
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CHAPTER 2§  
3D-PRINTING FOR CRANIOFACIAL RECONSTRUCTION,  
REPAIR, AND REGENERATION 
 
Summary   
The treatment of craniofacial defects can present many challenges due to 
the variety of tissue-specific requirements and the complexity of anatomical 
structures in that region. 3D-printing technologies provide clinicians, engineers and 
scientists with the ability to create patient-specific solutions for craniofacial defects. 
Currently, there are three key strategies that utilize these technologies to restore 
both appearance and function to patients: rehabilitation, reconstruction and 
regeneration. In rehabilitation, 3D-printing can be used to create prostheses to 
replace or cover damaged tissues. Reconstruction, through plastic surgery, can 
also leverage 3D-printing technologies to create custom cutting guides, fixation 
devices, practice models and implanted medical devices to improve patient 
outcomes. Regeneration of tissue attempts to replace defects with biological 
materials. 3D-printing can be used to create either scaffolds or living, cellular 
constructs to signal tissue-forming cells to regenerate defect regions. By 
integrating these three approaches, 3D-printing technologies afford the opportunity 
to develop personalized treatment plans and design-driven manufacturing 
solutions to improve aesthetic and functional outcomes for patients with 
craniofacial defects.  
 
                                            
§ Adapted from Nyberg, E. L., Farris, A. L., Hung, B. P., Dias, M., Garcia, J. R., Dorafshar, A. H., 
& Grayson, W. L. (2017). 3D-printing Technologies for Craniofacial Rehabilitation, 
Reconstruction, and Regeneration. Annals of Biomedical Engineering, 45(1), 45-57. 
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Introduction 
Craniofacial defects arise as a direct result of trauma, oncological resection, 
or congenital differences. They cause soft tissue or bone deficits, or a combination 
of both leading to non-healing composite tissue wounds. Defects in the craniofacial 
region in particular are difficult to treat because of the emphasis on positive 
aesthetic outcomes and the number of tissue types (bone, cartilage, muscle, and 
skin) and structures (auricle, orbit, nose, oral cavity) in close proximity. The current 
options for reconstructive surgery to treat these defects include grafts, local tissue 
rearrangement which fills defects with adjacent healthy tissue, microsurgical tissue 
transfer whereby one area of the body is transferred with its blood supply to 
another area7,28, and vascularized composite allotransplantation whereby a portion 
of the body containing skin, muscle and/or bone is transplanted from one patient 
to another29. However, the major challenges with using traditional reconstructive 
surgery to treat large craniofacial defects are donor-site morbidity and procuring 
sufficient donor tissue with the same properties, including skin color, quantity and 
contour of bone, and quantity and quality of subcutaneous tissues, as the 
surrounding recipient tissue to restore normal anatomic structure and primary 
organ functions.  
The challenge of integrating the various tissues of the face while 
maintaining or improving aesthetics motivates collaboration between the fields of 
prosthetic rehabilitation, craniofacial reconstruction, and regenerative medicine.   
Prosthetic Rehabilitation refers to the use of custom-made facial 
prosthetics to restore normal facial appearance (Figure 2-1A).  
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Reconstruction of the craniofacial region can be performed using a variety 
of plastic surgery techniques to replace structures and is aided by the precise 
manufacture of cutting guides, fixation devices, practice models and implanted 
medical devices (e.g. Figure 2-1B).  
Regeneration aims to stimulate regrowth of damaged or malformed 
craniofacial tissues using stem cells and biologically active scaffold materials. 
(Figure 2-1C). For a particular defect, these approaches may be employed 
individually or in conjunction with one another. However, a common thread is the 
need for patient-specific treatments that fit a particular defect site to achieve both 
aesthetic cosmesis and functional replacement. As such, 3D-printing techniques 
that can create highly complex craniofacial geometries with high fidelity are well-




Figure 2-1. Examples of Rehabilitation, Reconstruction, and Regeneration.  
(A) Custom PDMS midfacial and ocular prosthesis. (B) Cutting and 
placement guides for auricular autogenous reconstruction. (C) 3D-
printed maxilla, porous PCL scaffold. 
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Anatomical geometries can be captured using medical imaging such as 
computed tomography (CT), magnetic resonance imaging (MRI), or light scanning 
and then 3D-modeled digitally to create useful 3D-printed products. The particular 
method of 3D-printing affects the print outcome and may be selected based on the 
particular applications (Table 2-1). The primary methods for 3D-printing include 
fused deposition manufacturing (FDM), stereolithography (SLA), selective laser 
sintering (SLS), inkjet printing, inkjet bioprinting, extrusion bioprinting, and laser 
assisted bioprinting, which have been reviewed extensively30,31. Briefly, in FDM, 
molten material is extruded layer-by-layer onto a bed; once the material cools and 
solidifies, it serves as the foundation for the layer above it. While this method is 
easily applied to many materials – any material that can be melted and extruded – 
it requires support structures for printing overhangs. SLA uses a laser to solidify 
photocurable liquid polymers in a layer-by-layer fashion.30 In contrast, SLS creates 
structures by sintering a powder bed layer-by-layer. The powder that is not sintered 
therefore serves as the support structure. A variation of this method, inkjet writing, 
also uses a powder bed, but uses a chemical binder instead of a laser to bind the 
particles together. The similarly named, inkjet bioprinting, uses acoustic, thermal, 
or electromagnetic forces to eject hydrogel droplets, which could contain cells or 
biological molecules, onto a platform in an additive fashion, onto a clean print bed 
or a binding solution.30 Extrusion bioprinting is similar to inkjet printing, but uses 
pumps, screws, or pneumatic systems to extrude cell slurries with viscosities too 
high for inkjet printing. Finally, laser-assisted bioprinting consists of a laser source, 
a glass “ribbon” covered with a layer of cells in hydrogel solution, and a receiving 
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substrate. The laser vaporizes a small portion of the hydrogel solution, which forms 
a bubble that can then fall as a droplet onto the platform below30. 
In this review, we examine how recent developments in 3D-printing enable 
more effective personalized treatment of complex craniofacial defects. We 
highlight advances in 3D-printing as applied to prosthetic rehabilitation, surgical 
reconstruction, and tissue regeneration for non-healing defects in the craniofacial 
region and identify avenues for further research.  
3D-Printing for Prosthetic Rehabilitation 
Recapitulation of patient specific coloring, texture, stiffness, and shape for 
prostheses is currently a labor-intensive process, which could be streamlined using 
3D-printing.  Prosthetic rehabilitation may be used in cases where successful 
surgical reconstruction is not a viable option due to factors such as poor prognosis, 
co-morbidities, compromised healing due to poor vascularization32, and patient 
refusal of further surgical interventions33. Further, the economic burden and 
treatment time for prosthetic rehabilitation is lower than that of surgical 
reconstruction34. Typical sites for craniofacial prosthetic rehabilitation include oral, 
orbital, nasal, and auricular regions35,36. Prosthetic rehabilitation can also serve as 
an interim strategy during the period of treatment planning for a later surgical 
reconstruction37. Besides providing an aesthetic solution to covering an affected 
area, prosthetic devices are considered medically necessary due to the functional 
benefits they offer to warm incoming air, maintain humidity of moisture filled 
cavities, protect fragile tissue, modulate speech, and provide support for corrective 
eyeglasses. 
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Treatment of craniofacial defects with prostheses traditionally involves the 
creation of a custom made device generally made of polydimethylsiloxane (PDMS) 
to replace missing tissue and cover underlying tissue35,36. The workflow for 
creating these devices has gone relatively unchanged since the 1970’s. However, 
the use of advanced 3D imaging techniques (including surface laser scanning and 
stereo photogrammetry) combined with 3D-printing is changing what was once a 
traditionally based workflow to include several facets achieved through digitally 
analogous methods (Figure 2-2). Only one study to date has reported a clinically 
viable workflow for directly 3D-printing these devices38. It is still limited, however, 
as it does not result in a fully colorized prosthesis with physical properties similar 
to the PDMS devices typically made by traditional methods. An alternate approach 
has been to 3D-print a negative multiple-piece mold that can be used for casting 
the final PDMS prosthesis. Advanced digital technologies and additive 
manufacturing techniques can thus be leveraged in craniofacial cases to increase 
the quality of outcomes for prosthetic rehabilitation. Future development of 
methods to directly print fully colorized PDMS prosthetics could significantly 
improve manufacture time and costs for craniofacial prostheses. A number of 
companies are developing technologies to directly print PDMS39–41 and new 
techniques to precisely color complex and soft constructs (such computational 
hydrographic printing42) offer exciting methods to fully recapitulate the appearance 




Figure 2-2. Example prosthetic design process.  
(A) Orbital mold 3D model obtained through a fully digital workflow. (B, 
C) Resulting 3D-printed 3-piece mold that can be used for casting PDMS 
prosthesis. (D) The final PDMS prosthesis can be colored and provide 
satisfactory cosmesis. Photos used with author’s permission. (Perry, R. 
The Development of an Orbital Prosthesis Workflow Using Advanced 
Digital Technologies, A thesis submitted to Johns Hopkins University in 
conformity with the requirements for the degree of Master of Arts, 
Baltimore, Maryland October, 2015) 
 
 
3D-Printing for Surgical Reconstruction 
3D modeling and manufacturing tools can provide aid in the personalized, 
surgical reconstruction of complex craniofacial defects by precisely cutting tissues 
according to preoperative plans, decreasing the total time and cost of surgery, and 
planning the shape of alloplastic and metal materials. Furthermore, such tools 
have helped to improve precise shaping and positioning of the newly incorporated 
tissues and improved the cosmetic and functional outcome of reconstructive 
operations43 and are useful for patient education44. Tools that are used transiently 
in the reconstruction process, such as placement or cutting guides, are produced 
using FDM or SLA out of sterile and bioinert materials such as acrylonitrile 
butadiene styrene (ABS), poly(methylmethacrylate) (PMMA), or polypropylene45. 
Implanted products additionally require long-term biocompatibility and mechanical 
strength and are often laser sintered from titanium or bioglass. Both types of 
products are often accurate to the millimeter scale.  
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VSP and Guides 
Advances in 3D imaging and manipulation of the resulting datasets have 
enabled surgeons to plan surgeries using computer models of the patient, virtually 
moving bones and other tissue to assess different approaches, options, and 
outcomes (Figure 2-3). This virtual surgery planning, together with rapid physical 
modeling of the defects and custom cutting and positioning guides, has vastly 
improved preoperative planning techniques compared to more traditional 
approaches, and has significantly aided the surgeon in his or her approach to 
complex craniofacial reconstruction46,47. 3D modeling and virtual planning aids 
intraoperative precision and efficiency of the surgery to match the preoperative 
design. Models of the defect site and the transferred bone segments can be 
manufactured to practice positioning, fixation, and evaluate aesthetic outcomes48. 
Such planning segues easily into precise, custom cutting and placement guides, 
increasing cosmesis and reducing ischemia and total surgery time. Consider the 
clinical standard for reconstruction of mandibular bone, the free fibular flap49: the 
fibula and the defect site are first scanned using CT (Figure 2-3A), then cuts are 
made in the fibula to adequately position the grafted bone into the defect site 
(Figure 2-3C). To aid in the precision of harvesting and repositioning the pieces of 
fibula, cutting and placement guides are designed and rapidly manufactured, often 
through FDM (Figure 2-3D). Finally, custom surgical guides have been essential 
in enabling the advent of facial transplants—in addition to the planning and guide 








Figure 2-3. Virtual Surgery Plan and 3D-printing Cutting and Placement Guides.  
From the Synthes Pro Plan. (A) Pre-operative CT Scan of the right 
fibula. Graft pieces are labeled beginning 6.6 cm from the distal end of 
the fibula. (B) Planned cutting guide superimposed over the fibula. (C) 
Planned fibular flaps in the context of the remaining zygoma, using the 
positioning guides and exact graft pieces. (D) 3D-printed parts delivered 
to the surgeon include an anatomic guide, the fibula cutting guide, and 




Rapid prototyped models of the defect, or the predicted defect, are also 
used to pre-bend generic off-the-shelf implants such as reconstruction plates and 
titanium meshes to fit the specific anatomy of the patient. Such precise and 
methodical pre-bending can result in improved functional and aesthetic 
outcomes12, decreased subjectivity51, and reduced surgery and ischemia time47. 
Stereolithographic models of the defect site have also been used to mold PMMA 
to fashion an alloplastic bone-graft alternative52. In addition, 3D-printing models of 
ideal and patient-specific anatomy produced by mirroring a normal contralateral 
side has been used to press fit a composite titanium and porous polyethylene 
implant, and then guide the surgical placement in order to reconstruct the orbital 
floor after facial trauma53. These methods allow for the customization of patient 
implants without significantly changing the manufacturing process of the device, 
which is a major regulatory and production hurdle.  
Materials for Patient Specific Implants 
Non-resorbable implants can be designed and manufactured specific to 
individual patients and can used in lieu of autologous tissue54.  Many materials 
including metals, bioglasses, and bio-inert plastics can be used in a number of 
manufacturing processes and maintain biocompatibility over time. For example 
polyetheretherketone (PEEK) has strong biocompatibility, mechanical strength, 
and radiographic translucency and can be 3D fabricated into patient specific 
implants through laser sintering or Computer Numerical Control (CNC) 
machining55. In addition, patient-specific titanium mesh can be manufactured via 
direct metal laser sintering to hold grafted bone in place and re-create contours 
29 
and structures of the facial bone56. Bioglasses (such as S53P4, 6P53B, and 13-
93) have been widely used in craniofacial surgery as a bone graft substitute due 
to their biocompatibility, strong mechanical strength, and osteoconductivity57,58. 
Bioglass structures can be manufactured by mixing glass particles into a solution, 
cold-printing in a layer-by-layer fashion, and then dehydrating at high temperatures 
to sinter the glass particles together and remove the solution59,60. Others have 
reported formulations of bioglass (such as 13-93 which has the composition 
53SiO2, 6Na2O, 12K2O, 5MgO, 20CaO, 4P2O5; wt.%) which can be laser sintered 
into anatomic shapes61. Hydroxyapatite (the main component of bone) implants, 
via a resin carrier, can be produced through SLA and have been used to 
reconstruct large (>20 cm2) defects with resolutions less than 0.4mm 62.  Finally, 
in 2012 a titanium mandible was laser sintered and implanted into an 83-year-old 
patient. The patient was able to speak and swallow the same day, and exhibited 
excellent restoration of facial aesthetics63. While titanium is the industry standard 
in orthopedic implants, the cost of materials, unknown long-term efficacy, and 
manufacturing remain limiting. There is particular concern of implant exposure and 
infection over time as there is often only a thin layer of soft tissue covering the 
implant.  
As the intersection of 3D imaging, manipulation, design, and manufacturing 
develops further, these tools for surgeons will broaden from individual case studies 
to common practice. The past decade of developing these tools apace with the 
maturation of 3D technology will likely revolutionize surgical standards, just as 3D-
printing has revolutionized transradial prostheses64,65. Increased efficiency and 
accuracy provided by these tools will be driving factors of their widespread 
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adoption while regulatory, biocompatibility, and reimbursement challenges 
remain66. Innovation stimulated and facilitated by these 3D technologies will also 





Figure 2-4. Features of 3D-printed scaffolds for regeneration.  
(A) The scaffold should have appropriate micro-architecture, 
encompassing pore size and porosity. Using direct ink writing of a 
ceramic powder in a viscoelastic solution, different well-defined pore 
geometries were manufactured and visualized under scanning electron 
microscopy. Scale bars represent 500 µm. Adapted from 67. (B) Cells 
residing within the scaffold should be signaled appropriately to 
regenerate tissue. Sintered tricalcium phosphate scaffolds were 
implanted in critically sized iliac defects in sheep. Bone formation by 
resident cells, denoted by the red stain, is evident when compared 
against other osteoinductive materials (bone morphogenetic protein and 
autologous bone graft). Adapted from 68. (C) The mechanical properties 
of the scaffold must be appropriate for the tissue being regenerated. 
Selective laser sintering of polycaprolactone was used to fabricate a 
porous cylinder, which was tested mechanically to result in a stiffness of 
15 MPa, within the range of trabecular bone. Adapted from 69.  
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3D Printing for Craniofacial Bone Regeneration  
The goal of a 3D-printed construct for regeneration is to fill the defect with 
biological tissue. To accomplish this, an appropriately shaped construct can be 
produced that is populated uniformly with tissue-forming cells that are signaled to 
regenerate tissue. This can be accomplished in two ways: printing of acellular 
scaffolds that can be populated with cells prior to implantation or the printing of 
living, cellular constructs, termed ‘bioprinting’.  
Acellular Printing 
Several key parameters should be considered and optimized for scaffold 
development: (1) macro-geometry (Figure 2-1C), (2) micro-architecture, (3) 
bioactivity, and (4) mechanical properties (Figure 2-4). The strengths and 
weaknesses of these currently investigated printing approaches to achieving the 
four considerations outlined above are discussed below. 
Incorporating micro-architecture, which encompasses pore geometry and 
pore size, is critical for uniform cell distribution and cell migration into the scaffold; 
interconnected pores can improve integration of regenerated tissue with native 
tissue.70 For bone tissue engineering in vivo, higher porosity has been correlated 
with increased bone ingrowth into scaffolds.71 Designing pore architecture results 
in higher pore connectivity and uniform cell distribution compared to random 
architecture resulting from salt-leaching methods, despite similar porosity, pore 
size, and surface area72. Pore size and interconnectivity also improves nutrient 
diffusion into and waste diffusion out of scaffolds.73 Scaffold vascularization, a 
critical component of tissue survival, has been shown to increase with increasing 
pore size; pore sizes between 160-270 μm resulted in extensive vessel formation 
32 
in both mathematical and experimental models74,75. Osteoblast proliferation and 
migration through collagen-glycosaminoglycan scaffolds also depends on pore 
size, with larger pores around 300 µm resulting in higher cell numbers throughout 
the scaffold76. In the context of 3D-printing, some methods are better suited to 
creating defined pores. For instance, FDM relies on rapid cooling of an extruded 
molten material, resulting in well-defined scaffold struts and well-defined pores77. 
In contrast, chemical binding-based approaches rely on dispensing a liquid binder 
onto a powder substrate and result in pore sizes less than 100 µm due to binder 
flow78. 
The scaffold should also provide biological signals to resident cells to form 
tissue. For bone, the most widely used strategy is incorporation of mineral phases 
in scaffolds for osteoinductivity79; similar strategies have been investigated with 
3D-printed scaffolds. For example, a phosphoric acid binder was used to bind 
calcium phosphate together, creating a mineralized structure that can house 
cells78. Another method used polycaprolactone (PCL) with incorporated tricalcium 
phosphate particles in FDM80. In addition, incorporation of bioactive molecules, 
such as bone morphogenetic proteins (BMPs), have been investigated; however, 
given most 3D-printing methods rely on high temperatures, up to 1300 °C for 
sintering methods81, use of growth factors in 3D-printing remains a challenge. 
Chemical binding methods have the distinct advantage of printing at room 
temperature, creating potential for application of the method to growth factor 
incorporation, though careful choice of binder is required to prevent pH-related 
damage. A second approach is to load growth factors onto a scaffold post-printing, 
which circumvents these issues but adds another step to scaffold manufacturing. 
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Finally, in the replacement of craniofacial bone, the scaffold must provide 
structural support for both resident cells and for transduction of mechanical forces 
through the craniofacial skeleton. Target scaffold stiffness depends on anatomical 
location, with the elastic modulus of human trabecular bone within the mandibular 
condyle ranging between 120-450 MPa or within the mandible from midline to 
ramus ranging from 112-910 MPa.82 Many current 3D-printed scaffolds have 
achieved stiffness within the 10-100 MPa range78,82–84. Testing mechanical 
properties of polymeric scaffolds under physiological conditions is crucial as 
groups have shown changes in compressive moduli at different temperatures and 
in aqueous media.84 It should be noted that increased porosity leads to lower 
mechanical properties – a study using sintered PCL reported that the stiffness of 
printed porous scaffolds was around 15 MPa, compared to 300 MPa for a solid 
PCL piece85. As such, the importance of porosity for cellular ingrowth and 
proliferation must be balanced against the importance of structural scaffold 
properties for mechanical support and force transduction. 
The importance of these four criteria is clearly demonstrated  in the clinical 
regeneration of soft and osseous tissue holding the left mandibular cuspid in 
place86. Using the patient’s CT scan the exact macroscopic geometry of the 
scaffold was determined. The scaffold was printed using SLS of PCL containing 
4% hydroxyapatite for osteoinductivity. In addition, the scaffold was designed to 
release platelet-derived growth factor BB (PDGF-BB), a factor known to support 
vascularization and mineralization87,88, in a burst manner from pre-formed 
channels. Due to the high printing temperatures associated with sintering, the 
scaffold was first printed without growth factor and immersed in PDGF-BB solution 
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for 15 minutes after printing. The use of PCL as the main biomaterial was justified 
from a mechanics standpoint: the stiffness of PCL scaffolds manufactured using 
SLS has been reported to be ~15 to 300 MPa, depending on porosity85, values 
that fall within the reported range for human trabecular bone. 
The scaffold porosity or micro-architecture was not reported, though the 
lack of interconnected pores was noted as a limitation of the approach. The 
implantation of the scaffold was successful – the image-based geometry fit the 
defect well – and the printed channels for growth factor release successfully 
dispensed PDGF-BB in a burst manner86. As a shortcoming, the patient presented 
with scaffold exposure and wound failure past 13 months post-implantation. Upon 
removal of the scaffold, histological analysis indicated a preponderance of 
connective tissue formation and little bone regeneration, suggesting the lack of 
internal micro-architecture prevented the infiltration of regenerative and vascular 
cells and therefore precluded regeneration. Combined with the slow-degrading 
properties of PCL, the authors concluded that the scaffold’s low porosity served to 
block tissue regeneration. As such, while the macro-geometry and mechanical 
properties were appropriate (over the 13-month period, the scaffold did not fail 
mechanically despite being in a region of load), the lack of micro-architecture 
inhibited the bioactive and regenerative properties of the scaffold. 
This example of the clinical application of 3D-printing scaffolds for 
craniofacial regeneration highlights strengths and necessary improvements. The 
combination of image-based extraction of craniofacial geometry and the ability to 
3D-print shapes with high fidelity resulted in a scaffold tailored to the specific 
defect. The ability to incorporate bioactive factors into the printed scaffold was also 
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demonstrated. Finally, the choice of PCL as a printable biomaterial illustrated the 
ability to print mechanically appropriate scaffolds for load-bearing craniofacial 
regions. In addition to the group featured in this case study, other groups have 
commercialized FDA-approved PCL scaffolds fabricated by FDM89. 
A relatively underexplored area of 3D-printed scaffolds involves printing 
biological and mechanical gradients. For example, printing scaffolds with 
hydroxyapatite gradients could improve bone formation with exterior areas having 
more mineral to encourage growth of compact bone and interior areas having more 
diffuse mineral to mimic trabecular bone. While printing with growth factors has 
been a challenge due to printing conditions for many techniques surpassing 
biological pH and temperatures at which these molecules are stable, several 
groups have printed bioactive ceramics or extracellular matrix (ECM)27,90. The 
incorporation of ECM enhanced scaffold bioactivity, but high ECM concentrations 
decreased scaffold mechanics. Printing extracellular matrix proteins in 3D spatial 
gradients has been achieved by using mask-based SLA to stimulate assembly of 
genetically engineered photoactive proteins, though this was used as a surface 
modification for tissue culture rather than an implantable 3D construct91. Another 
group used inkjet printing to create gradients of laminin and used their materials to 
study cell alignment92.  
Printing mechanical gradients by varying pore structure and size could also 
assist with building tissue that mimics native function, particularly in the bone 
example. One group has recently demonstrated that gradient pore sizes created 
by FDM can slightly improve both chondrogenesis93 and osteogenesis94, although 
they did not investigate different geometries. By designing scaffold pore sizes and 
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geometries based on biological mechanical requirements, these improvements 
may be further enhanced.   
Bioprinting 
Bioprinting differs from the traditional tissue engineering approach of 
seeding cells onto preformed scaffolds by depositing cell and scaffold 
simultaneously, forming a predesigned structure95. Bioprinting is the computer-
aided deposition of living cells into 3D patterns. It is currently performed with 
micron-scaled precision31. As cell viability must be maintained during the printing 
process, the methods used for bioprinting differ from those used for traditional 3D-
printing. Important parameters of 3D-bioprinting scaffolds include (1) cell 
positioning, (2) bioink selection, and (3) mechanical strength. In many cases, the 
type of bioink used and the required resolution dictates the optimal printing 
technique for a particular application. 
Bioprinting offers a key advantage over the traditional approach of seeding 
cells into 3D-printed scaffolds: digitally designing layer-by-layer deposition of cells 
to precisely regulate 3D cell distribution. This is advantageous when designing 
vascularized soft tissue, as adequate nutrient and oxygen supplies are necessary 
during tissue regeneration96.  For example, Kolesky et al. developed a bioprinter 
that could print up to four cell types simultaneously and created complex 3D 
patterns of fluorescently labeled human dermal fibroblasts and human umbilical 
vein endothelial cells97. However, there are also several challenges associated 
with cellular printing. 
Another disadvantage of bioprinting compared to acellular printing is that 
the mechanical strength of bioinks is typically lower than thermoplastic polymers. 
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Originally, the majority of bioinks were natural hydrogel polymers, particularly 
alginate and fibrin, which when printed have compressive moduli of approximately 
5 kPa98. Human bone and cartilage typically have moduli of about 10-20 GPa and 
700 kPa, respectively99. In order to print tissues having similar load-bearing 
capacities to native bone and cartilage, PEG-based hydrogels have been printed 
with compressive moduli between 300-350 kPa100. Another method used to 
improve mechanical strength is integrating acellular and cellular bioprinting. 
Merceron et al. used a combination of FDM and extrusion bioprinting to print two 
thermoplastic polymers along with C2C12 and NIH/3T3 cells to create a 3D-printed 
muscle-tendon unit101 and Kang et al. integrated FDM and extrusion bioprinting to 
print vascularized bone, muscle, and cartilage102. Printing hybrid scaffolds with 
cellular and acellular components may be one way to improve mechanical strength 
of bioprinted scaffolds. These limitations are some of the reasons that bioprinting 
has not yet been used to regenerate craniofacial tissues in human patients. 
Of the tissues necessary for craniofacial reconstruction, skin bioprinting is 
the nearest towards clinical translation, with studies conducted in vivo using mice 
and pigs. One study of note compared bioprinted scaffolds to a commercially 
available engineered skin graft (Apligraf)103. A current limitation of engineered skin 
grafts such as Apligraf is that they lack microvasculature to maintain cell viability 
over time and instead rely upon diffusion to transport oxygen and nutrients to cells. 
Bioprinting can overcome this limitation by precisely patterning microvascular 
structures for skin grafts. Bioprinted scaffolds were trilayered with the top layer 
composed of collagen and printed keratinocytes, the middle layer composed of 
fibrin and endothelial cells, and the bottom composed of collagen and fibroblasts. 
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Apligraf is a bi-layered material cast with two collagen layers: one containing 
dermal fibroblasts and the other containing keratinocytes104. The group found that 
wound contraction, which if excessive can be a marker for joint contraction, 
malfunction, and poor aesthetic outcomes decreased in the bioprinted scaffolds 
compared to Apligraf and no treatment, which were statistically similar. 
Additionally, the mice with printed grafts healed between 14-16 days, whereas 
those with no grafts or with Apligraf healed within 21 and over 28 days, 
respectively. Histologically, the printed groups showed microvessel formation by 
implanted human endothelial cells in the printed scaffolds. Macroscopic images of 
skin regeneration in Apligraf and bioprinted groups can be seen in Figure 2-5A-F. 
Patterning endothelial cells to form lumenized microvessels to improve graft 
viability could allow for scale up in terms of graft thickness and area by reducing 
oxygen and nutrient diffusion limitations. Binder et al105 have developed a 
promising in situ bioprintier for skin, but initial preclinical tests in pigs demonstrated 
unsatisfactory healing outcomes in wound closure rates, which the authors 
suggested was due to an insufficient cell density (2.0 x 105 cells/cm2). While the 
bioprinted materials have improved skin wound healing in terms of decreasing 
wound contraction and healing time in vivo is a promising advance for skin 
bioprinting, but such methods are still inferior or comparable to cell spraying 
techniques105.  
Bioprinting of bone has also moved forward, with some preliminary 
bioprinting studies conducted in vivo. Of particular import is a pilot study conducted 
by Keriquel et al. that investigated the use of laser assisted bioprinting to 
manufacture hydroxyapatite scaffolds directly into a calvarial defects in mice, as 
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seen in Figure 2-5G, H106. When bone formation was measured by X-ray micro-
tomography at the group observed considerable variation in bone formation 
between individual mice and did not provide quantitative data for bone ingrowth. 
Though these results are preliminary, they do show that bioprinting in vivo is 
possible and may have potential for clinical use with the proper bioink and cell 
source.  
The precise patterning of biological molecules and cells through bioprinting 
may be useful in creating tissues with complex spatial orientations. Though the 
field is young, promising results have been achieved for skin and bone engineering 
in vivo. Studies have investigated cartilage107, muscle101, and adipose108 tissue 
engineering using bioprinting, though these have not yet advanced to in vivo 
studies. The expensive specialized equipment necessary to use bioprinting 
technologies and the added regulatory burden of incorporating cells into a 
biomaterial, acellular printing may be the preferred regenerative method for 
treating craniofacial defects. Bioprinting could be further improved by widening the 
selection of available bioinks, decreasing print time, increasing print resolution, and 

























Figure 2-5.  Bioprinting for engineering skin and bone tissues.  
Full thickness dermal wounds after 4 weeks of healing with (A) Apligraf 
applied, denoted by the yellow circle and (B) 3D-bioprinted skin applied 
denoted by the blue circle. Severe wound contraction and scaffold drying 
took place in the Apligraf scaffold compared to the bio-printed scaffold 
with microvessels. C-E. H&E stains of (C) Apligraf, (D) no treatment, and 
(E) 3D-bioprinted skin scaffold. (F) A higher magnification image of 2 
weeks of healing following application of 3D bioprinted skin.  Adapted 
from 103. (G) Schematic of laser-assisted bioprinting directly into mouse 
calvarial defect. nHA slurry refers to a nano-hydroxyapatite suspended 
in a glycerol solution for printing. (H) H&E stain 3 months after calvarial 
defects were made. Bone healing observed in the area where the 3D 
bio-printed scaffold was applied (denoted by the star) and no bone 
healing in the no scaffold control (denoted by the arrow). G and H 




Craniofacial deformities, when they arise, are particularly debilitating as 
they impact emotional, psychosocial, and functional well-being of the affected 
individual. They are difficult to treat due to the geometrical requirements and 
multiplicity of tissue types that are impacted. However, recent advances in 3D-
printing technologies hold tremendous promise for advancing treatment options 
available to patients. The requirements of 3D-printed products differ depending on 
the size and severity of the defects, which together with patient-specific factors 
determine whether the primary treatment modality is prosthetic rehabilitation, 
surgical reconstruction, or regeneration. For rehabilitation, the use of 3D-printing 
technologies to either directly create PDMS prosthetics or print molds has the 
potential to significantly streamline the associated workflows for this process. The 
prostheses are flexible, non-degradable, and need to incorporate patient-specific 
skin tones. They differ considerably from 3D-printed guides or alloplastic implants 
used in reconstructive surgeries. Perhaps the most transformative applications, of 
3D-printing lie in the realm of tissue regeneration.  This area remains relatively 
nascent to date and significant research efforts are being dedicated to its continue 
rapid advancements that include the development of biodegradable scaffolds as 
well as bioinks used for printing live cells.  The successful implementation of these 




CHAPTER 3**  
GROWTH FACTOR ELUTING SCAFFOLDS  








Growth factors are essential orchestrators of the normal bone fracture 
healing response. For non-union defects, delivery of exogenous growth factors to 
the injured site significantly improves healing outcomes. However, current clinical 
methods for scaffold-based growth factor delivery are fairly rudimentary and there 
is a need for greater spatial and temporal regulation to increase their in vivo 
efficacy. Various approaches used to provide spatiotemporal control of growth 
factor delivery from bone tissue engineering scaffolds include physical entrapment, 
chemical binding, surface modifications, biomineralization, micro- and nano-
particle encapsulation, and genetically engineered cells. Here, we provide a brief 
review of these technologies, describing the fundamental mechanisms used to 
regulate release kinetics. Examples of their use in pre-clinical studies are 
discussed, and their capacities to provide tunable, growth factor delivery are 
compared. These advanced scaffold systems have the potential to provide safer, 
more effective therapies for bone regeneration than the systems currently 
employed in the clinic.   
                                            
** Adapted from Nyberg, E., Holmes, C., Witham, T., & Grayson, W. L. (2016). Growth Factor-
eluting Technologies for Bone Tissue Engineering. Drug Delivery and Translational 
Research, 6(2), 184-194. 
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Introduction  
Skeletal injuries from trauma, tumors, infections, and degenerative 
diseases often require a significant intervention, such as bone grafting, to facilitate 
healing. While 1.6 million bone grafting procedures are performed per year in the 
United States, the current gold standard – autologous bone grafts – is expensive, 
inefficient, causes donor site morbidity, and is limited in supply and size109. 
Therefore, there remains a critical need for effective alternatives to bone grafts.  
Growth factors are key components in the regenerative process leading to 
scarless bone regeneration. A complex spatiotemporal cytokine cascade 
orchestrates healing following bone fracture110.  Inflammatory cytokines cause an 
invasion by lymphocytes, plasma cells, macrophages, and osteoclasts. Invading 
macrophages clean up necrotic centers in the graft and release tumor necrosis 
factor (TNF), which drives increased osteoclast activity. Osteoclasts resorb 
fractured bone matrix, releasing incorporated insulin-like growth factor (IGF) and 
bone morphogenetic proteins (BMPs), and these cause osteoblastic differentiation 
of progenitor cells111,112. Neovascularization of the fracture site occurs early in this 
process as endothelial cells begin sprouting angiogenesis in response to vascular 
endothelial growth factor (VEGF) and low oxygen tensions in the graft113. 
Endothelial cells are the primary source of BMPs within the fracture site driving 
osteogenesis of osteoblasts. Osteoid production by those osteoblasts begins on 
the outside of the fracture, creating a callus and mechanically integrating the 
bone114. Platelet-derived growth factor (PDGF), transforming growth factor-β 
(TGF-β), and fibroblastic growth factor (FGF) released from plasma cells, 
macrophages, and osteoblasts support cellular proliferation and 
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differentiation112,115,116. Finally, remodeling into organized continuous bone 
progresses over several months according to Wolff’s law. 
Several of the key growth factors identified above as having critical roles 
during normal healing (Table 3-1) have been utilized in various clinical approaches 
to treat bony non-unions. The timing of therapeutic growth factor delivery is crucial 
to optimize tissue induction while minimizing adverse or inhibitory effects. 
However, growth factors have short half-lives and rapid clearance rates in vivo, 
particularly when delivered systemically117,118. Bone tissue engineering (BTE) 
scaffolds have been used as a feasible treatment methodology to provide 
temporary mechanical support for cellular ingrowth and to actively guide tissue 
organization. Additionally, 3D scaffolds can localize and control the temporal 
delivery of protein growth factors and/or genes required for optimal in situ bone 
development and/or repair. The incorporation of growth factors into scaffolds has 
considerable potential to enhance healing outcomes. Here, we review growth 










Table 3-1. Clinically Applied Growth Factors for BTE 
Factor Action References 
Bone Morphogenetic 
Proteins (BMP) 
Bone induction 119–125 
Vascular Endothelial Growth 
Factor (VEGF) 
Angiogenesis 126–130 
Platelet Derived Growth 
Factor (PDGF) 




Fibroblast Growth Factor 
(FGF) 
Angiogenesis, proliferation 
and osteogenic differentiation 
116,133–136 
Insulin-like Growth Factor 
(IGF) 
Osteogenic Differentiation 111,137–140 







Growth Factor Incorporation Strategies  
A wide variety of factors – ranging from scaffold material and architecture, 
to the dosing and release kinetics of the incorporated growth factors – must be 
optimized in designing an inductive scaffold-based delivery system for BTE 
applications. The scaffold should exhibit suitable mechanical properties and a 
biodegradation rate that enables both controlled growth factor delivery and 
integration with host tissue. These scaffold properties are determined by the 
materials employed and the processing and biofactor incorporation strategies 
utilized. Decades of research into drug delivery materials have yielded a broad 
array of naturally- and synthetically-derived, biodegradable materials which can be 
employed to produce 3D scaffolds of varying architectures (reviewed in142–144). 
Controlling growth factor dosage and release kinetics is key to optimizing 
tissue induction while avoiding adverse or inhibitory effects145–147. Currently, the 
growth factor dosage ranges being used are quite broad and clinical applications 
typically employ supraphysiological concentrations. Although some of this dosage 
variation is due to differences in the animal models utilized, there remain many 
questions regarding optimal target doses and release kinetics. In a study 
comparing burst release from collagen sponges (100% over 2 days) to 
polyurethane scaffolds with slow (~20% over 19 days) or fast (60% over 9 days) 
release of BMP-2 (all systems loaded with 2 µg), fast-releasing scaffolds showed 
the greatest in vivo bone formation (45 mm3) in a rat femoral critical-sized defect 
model after 4 weeks, followed by the burst-release collagen scaffold (30 mm3) and 
the slow release scaffold (10 mm3)148. This suggests that an initial burst release 
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followed by a slow sustained release might be best means of delivering BMP-2 for 
bone formation.  
However, the optimal therapeutic dosage and timing of release will depend 
heavily on the individual growth factor(s) and the particular application. One has to 
account for factors such as the anatomical location, size, and nature (e.g. trauma 
vs. tumor re-sectioning) of the bone defect, the extent of vascularization in the 
surrounding tissue environment, conjunctive therapies (e.g. chemotherapy or the 
use of metal supports), and the health of the surrounding tissues. For example, in 
comparing quick and slow release of BMP-2 for induction of bone formation in 
orthotopic and ectopic sites in dogs, Geuze et al found that while ectopic groups 
formed more bone in response to quick BMP-2 release, bone formation in the 
orthotopic site was independent of the release profile146. Furthermore, some 
growth factors are non-effective at low doses, require co-delivery of a second 
agent to be effective, or are harmful to cells with prolonged exposure. For example, 
high doses and/or prolonged exposure to BMP-2 in anterior cervical spine fusion 
cases has resulted in high rates (23%) of adverse effects in patients149,150, while 
failure to shut down TGF-β in reparative processes can lead to a number of fibrotic 
diseases151. Finally, indefinite release is not required; rather growth factor delivery 
need only be maintained – at most – until the defect has healed, which potentiates 
bone repair technologies to transient gene therapy techniques144–146.  
In native tissues, growth factors are typically encrypted within the ECM 
where they are protected from enzymatic and hydrolytic degradation. Once they 
are released from these encrypted sites, the half-life of growth factors in vivo is 
short – on the order of several minutes – due to enzymatic degradation, chemical 
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and physical deactivation, and degradation processes such as hydrolysis, 
oxidation, isomerization, and aggregation152,153.  Therefore, one of the most critical 
challenges in scaffold-based growth factor delivery is maintaining native protein 
conformation and bioactivity throughout scaffold loading and for the duration of in 
vivo release154. The architectural design, processing and storage of scaffold 
materials and the protein loading strategies must all be optimized to ensure 
delivery of functional growth factor for the duration of in vivo release. For example, 
Madurantakam and colleagues demonstrated that exposure of BMP to organic 
electrospinning solvents during growth factor loading affected its tertiary and 
quaternary protein conformation and impaired its bioactivity. In contrast using a 
50% dilution in an aqueous buffer retained the bioactivity of the incorporated 
BMP155. Similarly, degradation products of scaffold carrier polymers, such as 
polyesters, can increase local acidity and lead to protein denaturation or 
degradation, while secondary protein-polymer interactions can trigger protein mis-
folding and aggregation156. Efforts have also been made to prevent enzymatic 
degradation of growth factors by tailoring scaffold pore- size to reduce protease 
penetration into scaffold153. Employing a more biomimetic approach, heparin-
binding is commonly used to maintain and enhance BMP presentation and 
bioactivity and increases the half-life of BMP in culture medium 20-fold157–159.  
To date, a variety of methods have been explored to incorporate drugs, 
protein growth factors, and DNA into 3D polymeric and composite scaffold systems 
and control their delivery. These approaches encompass bulk incorporation 
strategies and surface modification techniques, with the current trend moving 
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towards hybrid approaches to produce tissue engineering systems capable of 








Figure 3-1. Methods of growth factor delivery  
(A) Bulk incorporation of GFs (blue) released with degradation of the 
bulk (black) material    (B) Hydrogels (green) can be modified for 
increased biomimetic affinity (red) to increase binding of GFs (black 
dots) and natural presentation to cells (blue)    (C) Growth factors (blue 
dots) can directly adsorb to the scaffold surface (grey) without specific 
chemical modification  (D) Biomineralization traps GFs (black dots) in 
the crystal formation (mediated by Ca++ in white) in simulated body fluid 
(SBF), and released as the crystals degrade in vivo   (E) Multilayer 
coating can facilitate multiagent (GF1 = black dots / GF2 = blue dots) 
delivery and staggered release of GFs over time (F) Nano and 
microparticles can deliver GFs (blue dots) to cells (blue) and can be 
functionalized with adhesion molecules (red) (G) Cells can be 
genetically engineered (red) to secrete GFs (black dots) to surrounding 













Table 3-2. Advantages and Disadvantages of different drug eluting technologies  
  



















































Physical Entrapment Strategies  
One of the simplest approaches to producing inductive tissue engineering 
systems is bulk incorporation, whereby the biofactors to be delivered are blended 
directly into hydrogels or within solid scaffold polymers and physically entrapped. 
Protein and/or DNA release kinetics from these bulk incorporation systems is 
typically characterized by an initial burst followed by slower release that is 
controlled by the diffusion and degradation rate of the matrix, which are in turn 
dependent on such properties as matrix, porosity, swelling behavior, polymer 
cross-linking density, and polymer chemistry (i.e. molecular weight, 
hydrophobicity/hydrophilicity, charge density). Loading efficiencies within bulk 
incorporation systems are generally high and are determined by factors including 
polymer and biofactor interactions, solubility, and concentration ratios, as well as 
the types of cross-linking interactions and processing times and temperatures 
employed. These parameters can be specifically tuned (within limits) for various 
localized, controlled release applications via careful design of polymer composition 
and scaffold processing techniques.  
Solid Scaffold Polymer Blending 
In solid polymer or composite scaffolds, biofactors can be directly blended 
with core polymers via formation of polymer-solvent and biomolecule-water 
emulsions and subsequent freeze-drying160, or via gas foaming161, which 
eliminates the need for organic solvents that can potentially denature or degrade 
proteins. For example, super-critical CO2 processing was used to incorporate 
rhBMP-2 within PLA scaffolds (96 µg BMP-2) yielding systems, which released low 
amounts (674 ng over the first 48 hours, followed by 100 ng/mL per 72 hr) over a 
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period of at least 24 days. Although less than 5% of the initially loaded BMP-2 
appeared to be released cumulatively, subcutaneous implantation in a rat model 
resulted in bone formation at 6 weeks (~12 mm3) and persisted until at least 26 
weeks162,163. Growth factors can also be directly incorporated within the strands of 
electrospun fiber-based scaffolds via blending prior to electrospinning, emulsion 
electrospinning, or coaxial electrospinning (reviewed in 201).  Srouji and colleagues 
used coaxial electrospinning to produce scaffolds composed of core-shell fibers 
with an inner rhBMP-2/PEO core and outer PCL/PEG shell. They found that the 
degree of porosity of the outer shell determined the BMP-2 release rate, and that 
slower-releasing scaffolds (which released 12 – 15% of the loaded BMP-2 in 27 
days, with 5% released in the first 4 h) resulted in greater in vivo bone formation in 
a rat cranial defect model (80% coverage vs. 55% at 8 weeks), than faster-
releasing scaffolds (76% in 27 days, with ~67% released in the first 4 h) 164. BMP-
2 has also been successfully incorporated into a variety of electrospun scaffold 
architectures composed of natural and synthetic polymers, including silk, PCL, 
PLLA, and PLGA, as well as polymer-ceramic composite fibers which integrated 
hydroxyapatite nanoparticles164–168. These direct blending strategies are limited in 
the scaffold architectures that can be produced, and generally display initial 
diffusive burst-release. Care must be also taken to ensure that processing 
conditions for the scaffolds do not reduce the bioactivity of the incorporated growth 
factors. 
Hydrogel Encapsulation 
Hydrogel encapsulation of drugs and biomolecules is one of the simplest 
and most popular strategies for producing 3D controlled delivery systems for tissue 
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engineering. Direct physical entrapment of proteins, drugs and DNA within 
hydrogels can be achieved via blending with matrix polymers prior to chemical or 
physical cross-linking. One of the key advantages to using hydrogels for controlled 
growth factor delivery is the wide array of stimuli-responsive polymeric hydrogels, 
which can be employed to produce on-demand release systems. However, 
hydrogel systems are severely limited in the scaffold architectures and mechanical 
properties that can be produced and are thus often used in hybrid strategies where 
they are infused into other scaffold structures. Furthermore, the hydrogel cross-
linking strategy employed in growth factor encapsulation must be chosen so as to 
minimize any chemical or physical modifications of protein structure (e.g oxidation 
reactions, photo-degradation, or cross-linking with polymer chains). 
A variety of “smart” hydrogel systems have been developed that respond to 
changes in temperature, pH, mechanical forces, electromagnetic fields, irradiation, 
ultrasound, or the presence or absence of certain solutes by dramatically altering 
properties such as their swelling behavior, network structure or degradation rate 
(reviewed in202). Similarly, biochemically-responsive hydrogels, which incorporate 
enzymatically-cleavable peptide linkage or cross-linking groups, such as matrix 
metalloproteinases (MMPs), result in cell-based enzymatic degradation and 
release of encapsulated growth factors. Holloway and colleagues developed such 
MMP-sensitive, cell-degradable hyaluronic acid hydrogels for BMP-2 
encapsulation (100 ng BMP-2) and demonstrated that faster degrading gels (100% 
mass degradation and BMP-2 release in 6 days in the presence of collagenase in 
vitro) resulted in improved bone formation in a rat cranial defect model compared 
to slower degrading gels (100% degradation and release in 10 days)203.  
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Chemical and Affinity Binding Strategies 
Protein growth factors can also be covalently bound or linked via biomimetic 
interactions to the polymers that make up the hydrogel matrix in order to more 
precisely control their loading, distribution, presentation, stability, and delivery. 
Such chemical and affinity binding strategies generally reduce burst release and 
prolong growth factor delivery. However, care must be taken in designing the 
linkage strategy so that growth factor bioactivity is preserved. 
Covalent Binding  
A variety of covalent binding strategies can be employed to attach protein 
growth factors to matrix polymers thus enabling on-demand biofactor release. 
Such linkage strategies can be designed such that release is mediated either by 
hydrolysis, reduction reactions, or enzymatic degradation of the covalent bonds. 
For example, BMP-derived peptides functionalized with azide groups were 
covalently conjugated to PEG-based hydrogels via click chemistry and the 
resulting system was found to induce osteogenic differentiation of bone marrow 
stromal cells in vitro204. In designing such covalent protein-binding systems, 
however, one must ensure that the linkage process does not affect the biological 
activity of the proteins by blocking active sites or causing denaturation, and that 
those growth factors which require cellular internalization for proper function are 
bound via cleavable linkage strategies. 
Biomimetic Binding Interactions 
In strategies which mimic the natural interactions between proteins and 
glycosaminoglycans (GAGs) within the extracellular matrix (ECM), electrostatic 
and affinity interactions can be employed to aid in hydrogel growth factor loading. 
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In addition to retaining and delivering the growth factor over a longer period of time, 
one of the key advantages to utilizing such biomimetic strategies is that ECM- and 
GAG-bound growth factors are maintained in a more bioactive form than when 
diffusively released or presented via covalent tethering strategies136,169. Thus 
ECM-binding might allow for the use of more physiologically relevant quantities of 
growth factors rather than the currently employed supra-physiological 
concentrations. 
Modification of hydrogel polymers with GAGs, such as heparin, which has 
been shown to bind protein growth factors, including BMP-2, FGF, and TGF-β 
170,171, can increase growth factor loading, and prolong growth factor release, as 
well as protect encapsulated proteins from thermal degradation and proteolysis. 
Jeon and colleagues developed heparin-modified PLGA scaffolds which 
demonstrated ~99% BMP-2 loading efficiency and prolonged in vitro release over 
at least 14 days (19% day 1, steady rate until day 14) compared to similar 
unmodified PLGA scaffolds which demonstrated burst release (~100% over 4 
hours). These heparin-modified scaffolds subsequently demonstrated 9-fold 
higher bone formation at 8 weeks compared to unmodified BMP-loaded scaffolds 
(both loaded with 1 µg BMP-2) in an ectopic bone formation rat hind-limb muscle 
model157 In stark contrast, Bhakta et al found that hyaluronan-based hydrogels 
modified with heparin and loaded with BMP-2 (5 µg) resulted in less in vivo bone 
formation in a similar rat hind-limb muscle model than unmodified BMP-loaded 
hydrogels, and theorized that it was due to a lack of early burst release (~14 % 
during day 1 and a total release of ~ 68% vs. ~26% release on day 1 and a total 
release of ~84%)172. These disparate results utilizing different core scaffolds (i.e. 
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PLGA solid scaffolds vs. hyaluronan hydrogels) but the same growth factor imply 
that growth factor dosage and release kinetics alone may not dictate successful in 
vivo bone formation, but that scaffold architecture, porosity, and mechanical 
properties likely play key roles.  
Another widespread biomimetic strategy for controlling biofactor delivery 
from hydrogels involves the incorporation of ECM peptide sequences. For 
example, Hubbell et al mimicked the blood clot microenvironment that forms after 
skeletal fractures by replicating fibronectin subdomains and attaching them to fibrin 
gels, thus resulting in improved retention of growth factors, such as PDGF, FGF-2 
and TGF-β, over time and improved bone healing outcomes173,174. Similarly, 
Hamilton and colleagues screened a phage-display library of peptide sequences 
to identify BMP-2 binding peptide sequences that they then incorporated within 
injectable collagen matrices along with BMP-2, resulting in more than 10-fold 
higher BMP-2 loading, and increased bone formation and maturity in vivo in a rat 
ectopic bone formation model, compared to collagen matrices containing only 
BMP-2175.  
Surface Modification Strategies 
In contrast to bulk incorporate strategies, surface modification techniques 
enable growth factor incorporation while preserving underlying scaffold 
architecture and properties. While surface modification strategies generally result 
in lower levels of growth factor incorporation, they enable delivery from a much 
wider variety of scaffolds and implant systems and materials, particularly those 
with increased mechanical strength. Techniques used to functionalize biomaterial 
surfaces with proteins, peptides, drugs and/or DNA, include simple surface 
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adsorption; “grafting-to” and “grafting-from” strategies; incorporation within 
electrostatic layer-by-layer films; and biomineralization.  
Surface Adsorption 
Simple surface absorption of biofactors onto scaffolds via dipping or 
incubation is one of the most commonly utilized techniques to produce localized 
delivery systems. Biofactor adsorption onto biomaterial surfaces is governed by a 
combination of non-specific physical forces, such as electrostatic interactions, van 
der Waals forces, hydrophobic/hydrophilic interactions and hydrogen-bonding 
interactions, which in turn are determined by a complex interplay of factors 
including the species and concentrations of biomolecules present in the 
incubation/dipping solution, the temperature, pH and ionic strength of the solution, 
and material surface properties such as topography, chemistry, charge, and 
wettability176. BMP surface adsorption onto various polymeric and composite 
scaffold systems, particularly collagen-based matrices, has been widely 
investigated, with varying strategies utilized to maximize the amount of adsorbed 
BMPs, such as increasing incubation time, altering the pH and ionic concentration 
of the solution, and introducing charged functional groups to the scaffold 
surface177.  Non-specific surface adsorption onto scaffold surfaces typically results 
in low levels of biofactor loading and poor control of release kinetics.  Better control 
of biofactor release from scaffold surfaces, meanwhile, is more easily achieved via 
surface immobilization methods.   
Surface Immobilization 
Direct immobilization of proteins and gene delivery vectors to scaffold 
surfaces, via covalent cross-linking or strategies involving antibody/antigen- or 
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biotin/avidin- binding, has been widely studied 205,206.  In the case of covalent 
surface immobilization, chemically- or physically-based methods are often 
employed to introduce reactive functional groups onto scaffold surfaces in order to 
activate them for subsequent grafting. Once a scaffold surface has been 
chemically functionalized, via partial surface hydrolysis, oxidation, aminolysis or 
plasma treatment, various reactions targeting primary amines and carboxylic acids 
can be utilized to immobilize protein growth factors, such as BMPs. Such surface 
conjugation of growth factors tends to increase protein loading and stability and 
prolong release compared to surface adsorption strategies. For example, when 
BMP-2 was immobilized onto the surface of aminolysed PCL scaffolds via 
sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (sulfo-SMCC) 
crosslinking, the resulting scaffolds demonstrated increased loading efficiency 
(~38.5 vs. ~9%), slower release (7% vs. 27% over 15 days) and increased in vitro 
osteogenic differentiation of  bone marrow stromal cells, compared to similar PCL 
scaffolds with surface-absorbed BMP-2207. As in the case of covalent linkage of 
bio-factors within bulk hydrogels, covalent surface immobilization strategies must 
be sure to preserve protein confirmation and bioactivity and enable the release of 
growth factors which require cellular internalization for function.  
Polyelectrolyte Multilayer Film Coating 
Deposition of polyelectrolyte multilayer films has been widely investigated 
for surface-based controlled release of drugs, bioactive proteins, and plasmid DNA 
(reviewed in 178). A simple and versatile technique developed by Decher and 
colleagues179 electrostatic layer-by-layer (LbL) deposition involves the sequential 
surface adsorption of alternating layers of oppositely charged polyelectrolytes 
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(PEs) on nearly any charged substrate surface. Careful selection of the 
polyelectrolytes used and the layer architecture and chemistry employed enables 
both the tailoring of release kinetics and sequential delivery of several different 
proteins and/or genes180,181.  LbL films can be composed from a wide variety of 
synthetic and natural polymers, and bioactive proteins, DNA and gene delivery 
vectors can be incorporated within PE multilayers without any need for covalent 
attachment182 and can maintain a structure close to their native conformation. The 
deposition of PE multilayers onto 3D scaffolds has enabled scaffold-based delivery 
of both genes and proteins183–185.  For example, 3D printed β-tricalcium 
phosphate/polycaprolactone scaffolds coated with LbL films consisting of a poly 
(β-aminoester) (“poly 2”), chondroitin sulphate (CS), and BMP-2, resulted in a 
system that successfully induced in vivo bone formation when implanted 
intramuscularly in rats184.  Meanwhile, Hammond et al developed LbL nanolayer 
coatings of BMP-2 and PDGF on PLGA membranes and found that low-dose dual 
delivery resulted in better outcomes (healing rate, bone volume, mechanical 
properties, and histology) in a rat calvaria defect model than BMP-2 delivery alone 
(at both 200 ng and 2 µg doses of BMP-2)208.   
Biomineralization 
Inspired by the in vivo process by which bone apatite crystals are formed, 
surface biomineralization methods can be utilized to incorporate protein growth 
factors on scaffold surfaces, while simultaneously improving osteoconductivity 
(reviewed in 194). Surface biomineralization techniques involve immersing a 
material in simulated body fluid (SBF), which leads to formation of a calcium 
phosphate surface phase similar to that found in native bone195.  Biomimetic 
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mineralization has been used extensively to form coatings on orthopedic and 
dental implants, as well as on polymeric and composite tissue engineering 
scaffolds, resulting in enhanced osteogenic activity, and/or bone formation both in 
vitro and in vivo196–199. More importantly, biomineralization has been used to 
incorporate bioactive growth factors, such as bone morphogenetic proteins 
(BMPs), within the formed surface coatings, thus further enhancing bone formation 
and tissue integration23,200.   
Nanoparticles and macroparticles  
Polymeric nano and microparticles can be loaded with GFs via internal 
encapsulation, bulk mixing, or surface attachment. Such particles can then be 
integrated into 3D scaffold systems via the bulk and surface-based incorporation 
strategies already discussed. For example, Yu et al developed hydroxyapatite 
microspheres (3-5 µm diameter), which incorporated BMP-2 and VEGF by means 
of a layered mineral coating. By varying layer thickness release kinetics could be 
tailored, with sustained release profiles of over 50 days possible186. Microparticles 
can also utilize heparin-growth factor binding, as demonstrated by Xu et al who 
altered the heparin content in hyaluronic acid hydrogel particles (~1.1 µm in 
diameter, pore size ~24 nm) and obtained a tunable BMP-2 release system that 
demonstrated a constant dosage over two weeks and a near zero-order release 
profile, which induced highly efficient chondrogenesis of MSCs187.  Beyond 
engineering to control release and cellular uptake rates124,135, these small particles 
can be employed to enable multi-factor and/or sequential delivery, as well as 




 Natural bone development and repair involve the precise temporal and 
spatial orchestration of a variety of signaling cascades and cell types. Thus, current 
trends in scaffold-based protein and gene delivery are extending beyond 
controlling dosage and release kinetics to encompass multi-agent delivery and 
spatially controlled release. Many groups have created concentration gradients of 
growth factors within hydrogels using a variety of methods (reviewed in ref209), with 
the most common being utilization of a gradient maker which mixes two or more 
types of hydrogel precursor solutions (with/without the growth factor) and then 
subsequently cross-links them210,211. Meanwhile zonal protein delivery was 
demonstrated employing a scaffold composed of microspheres loaded with either 
VEGF or PDGF in an in vivo angiogenesis model, with VEGF delivery from one 
scaffold area resulting in formation of small blood vessels while sequentially 
delivery of first VEGF and then PDGF in another scaffold zone led to fewer but 
larger and more mature vessels212.   
 Many studies have highlighted the importance of multi-agent delivery in 
enhancing bone tissue formation and vascularization within tissue engineering 
scaffolds. For example, dual release of low doses of BMP-2 and TGF- β3 proteins 
from hydrogels seeded with bone marrow stromal cells (BMSCs) induced bone 
formation when implanted subcutaneously in mice, while supra-physiological 
concentrations of either factor alone did not induce significant bone formation213. 
Meanwhile, porous PLGA scaffolds delivering both VEGF protein and poly-
ethyleneimine (PEI)-condensed BMP-4 plasmid and seeded with BMSCs induced 
greater bone formation in critical size rat cranial defects compared to delivery of 
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any other combination of these factors214. Similarly, dual delivery of covalently 
incorporated BMP and osteopontin-derived peptides within hydrogels enhanced in 
vitro bone marrow stromal cell mineralization, osteogenic differentiation and 
vasculogenic differentiation215. Finally, Yilgor et al affixed PLGA nanoparticles with 
release profiles of 20 days and PHBV nanoparticles with release profiles of 40 
days to the surface of chitosan scaffolds to enable the sequential delivery of 
emulsified BMP-2 and BMP-7, resulting in increased alkaline phosphatase activity 
and mineralization of scaffold-seeded rat BMSCs124,216.  In multi-agent delivery 
systems, the timing of growth factor release can be of even more importance, as 
the temporal regulation of the influx of each growth factor into the defect site can 
be critical to enhancing the sequential steps of bone healing. 
Cells as Drug Eluting Systems 
 As cells naturally secrete GFs, osteogenic progenitor cells can be pre-
seeded within scaffolds to provide an inherently bioactive supply of GFs to a defect 
site. Adipose-derived stem cells and mesenchymal stem cells naturally secrete 
relevant GFs for bone healing in response to cues from the microenvironment—
such as hypoxia or ischemia—and cease secretion once bone is healed. These 
cells can also be genetically engineered ex vivo to maintain an increased secretion 
profile of a specific GF through a variety of gene delivery strategies, including 
transfection via nucleofection, and viral and non-viral delivery vectors141,189–191 
(reviewed in detail, specficially for BMP gene transfection, by Wilson et al217). Such 
cell-based therapies are limited by the tendency of the implanted cells to migrate 
away from the defect site or be cleared by the host.  
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Alternatively, inductive tissue engineering scaffolds can be utilized for 
material-based in situ gene delivery. Naked plasmid DNA or DNA complexed with 
viral, lipid-based, or polymeric delivery vectors can be integrated within 3D 
scaffolds using the bulk- and surface-based incorporation strategies discussed 
previously. A variety of scaffold-based gene delivery systems have been 
investigated for bone tissue engineering. For example, Elangovan et al developed 
collagen sponge scaffolds with surface immobilized PEI-plasmid DNA complexes  
[encoding PDGF-BB] which demonstrated impressive healing over 4 weeks, 
recovering 50% of lost bone volume (14-fold greater than empty control and 44-
fold greater than a control scaffold) in a rat cranial defect model192. Using a 
liposomal vector in a collagen gel, Park et al delivered the BMP-2 gene to peri-
implant bone defects (defect 10 mm diameter, 7mm depth) in a pig model. BMP-2 
producing cells were present in increased number (compared to controls) at 1 
week, and they remained at 4 weeks. Bone matrix formation was accelerated in 
BMP-2 treated groups at week 1, and resulted in increased osseointegration and 
bone regeneration193.    
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Conclusion  
Effective regenerative outcomes for large non-union bone defects relies on 
appropriate scaffold properties coupled with optimized patterns of cell and growth 
factor delivery. Indeed, the controlled delivery of osteoinductive and angiogenic 
factors that act in concert to orchestrate the formation of bone tissues remains a 
major engineering goal. Currently, delivery of BMPs to non-union defect sites via 
collagen sponge carriers is the clinical standard for growth factor eluting scaffold 
technologies. Although generally successful in promoting fusion, the poor control 
over release kinetics and the supraphysiological BMP concentrations required to 
induce sufficient bone formation lead to a number of complications and adverse 
effects – particularly in the craniofacial area – that include heterotopic bone 
formation, edema, seroma, and even cancer218,219. The emerging technologies 
described above can facilitate greater spatiotemporal control of growth factor(s) 





CHAPTER 4††  
MATERIALS AND METHODOLOGY FOR 3D-PRINTING DE-CELLULARIZED 








This chapter examines the central methods and materials used in this 
dissertation. Each of the technical chapters have detailed method sections, but the 
key systems and materials forming the foundation of the work in this dissertation 
merit an in-depth consideration and explanation, particularly as they are often 
inherited or experiential expertise and were not discovered as aims of the 
research. First, it describes the materials: decellularized bone and 
polycaprolactone. Second, it examines the 3D-printing system used for the small-
scale development and testing of the biomaterial. Third, the cell system and choice 
of in vitro biochemical assessments are discussed. Finally, the murine in vivo 
preclinical model and some results of studies using that model are explored.  
Overall, this chapter sets the starting point for translating this scaffold system from 
mouse to human scale.  
 
                                            
†† Parts adapted from Rindone, A. N., Nyberg, E., & Grayson, W. L. (2017). 3D-Printing 




At the outset of developing this technology system at Johns Hopkins, the 
Grayson Lab wanted to develop a bone replacement that would be patient-specific 
and regenerative. The research team arrived at a tissue engineering scaffold 
approach220,221: the combination of a biomaterial that could be 3D-printed into the 
needed anatomic shape and stem cells that could affect regeneration within the 
3D-printed shape (Figure 4-1).  
Polycaprolactone was chosen as the biomaterial. While PCL is bioinert, it 
had a low melting temperature which would enable 3D-printing. Further, PCL was 
widely approved by regulatory agencies in a number of other implants, lowering 
the burden of translation to the clinic. Finally, PCL degrades in aqueous 
environments, and could slowly erode as bone regenerates within the construct—
enabling a full volume regenerative effect. Other 3D-printed polymers suffer from 
disadvantages such as acidic degradation by-products, much higher melt 












Figure 4-1 3D-printing of patient-specific bone TE scaffolds.  
(A) Workflow of 3D-printing process. The patient’s CT scan is used to 
create an STL file for the graft that precisely fits into the defect site (2). 
This STL file is then converted into GCODE and 3D-printed into a 
customized TE scaffold (3). (B) Examples of porous, biodegradable PCL 
scaffolds that were 3D-printed based upon the specific geometry of the 




The lab was able to 3D-print these scaffolds and fill them with stem cells, 
and, in vitro, fill them with mineralized tissue using a cocktail of media signals to 
induce mineral deposition26. However, in vivo, the signals from the media would 
no longer be present to direct the stem cells, so the team began looking for ways 
to modify the system to present bone-forming cues to the stem cells after 
implantation.  
Concurrently in 2013, colleagues down the hall at the Elisseeff lab did a 
series of experiments with de-cellularized extracellular matrix of different 
tissues222. Uniquely, they used a cryo-milling process to render the tissue to 
particle size instead of using a digestive enzyme or dissolving solution. When they 
looked at the resulting bone particles, they found they specifically induced stem 
cells to deposit boney mineral.  
 
Figure 4-2. 3D-printed, porous DCB:PCL scaffolds.  
(A) Two-layer PCL scaffolds with various weight percentages of DCB. 
The Alizarin red stain (top row) increases with the amount of DCB in the 
scaffold, demonstrating that the scaffolds have higher mineral content. 
Surface roughness also increases with the amount of DCB in the 
scaffold, as shown by the SEM images (bottom row). (B) 3D-printed PCL 
and PCL:DCB scaffolds for the human temporomandibular joint condyle. 
Alizarin Red staining demonstrates that DCB particles are dispersed 
throughout the DCB:PCL scaffold. 
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Around the time that I joined the lab in 2014, Ben Hung had the idea of 3D-
printing these bone particles directly with the PCL (Figure 4-2, 4-3), so that the 
osteoinductive signals of the particles would provide bone-specific bioactivity to 
the otherwise inert scaffolds27. He successfully did so, and demonstrated that the 
resulting scaffolds had increase surface roughness and cell attachment. Further, 
the stem cells seeded on the scaffold had increased amounts of mineral 
deposition, had higher expression of bone-related genes, and caused increased 
amounts of bone formation in vivo.  
This chapter details these materials and methods, their advantages and 
limitations. The specifics of ASC isolation characterization, and function are not 
addressed here, but in chapter 7. The 3D-printing methods described in this 
chapter were used for the work in chapters 5, 6, and 7—however the 3D-printing 
in chapters 9, 10, 11, and 12 uses methods developed and described in  
chapter 9. 
 
Figure 4-3 Schematic of Scaffold System  
A cross-section view 3D-printed strut (blue) containing DCB particles. 
The strut is surrounded by cells (red) encapsulated within a fibrin 
hydrogel (grey).  
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Decellularized Bone Matrix 
Bone has been used as a bioactive biomaterial since 1668, as auto and 
allografts223,224. Urist, in the 1960s, isolated the growth factors present in bone that 
are the putative source of the bone forming signals in bone grafts119,225. These 
BMPs have been used in several bone healing products since then, with some 
significant adverse events149 and with structural abnormalities226. Additionally, 
decellularized, demineralized bone has been used as a void filling, non-load 
bearing biomaterial. Smaller particles of bone have also been used as a more 
structural filler227,228.  
Decellularization of bone removes the antigen and immunogenic signals 
from cells that cause problems with human allografts and xenografts. After 
decellularization, the bone retains its trabecular architecture, and highly ordered 
osteon structure—hydroxyapatite crystals woven in collagen 1, and encased in 
non-collagenous proteins that guided the assembly of the shape and prevent the 
crystals from degrading. Decellularized bone is remarkably stable in vivo, 
undergoing surface resorption via osteoclasts over a period of years. While 
allografts and autografts of bone can integrate with the skeleton at the grafting site, 
they do not generally reform into the bones they are replacing or undergo 
systematic remodeling.   
Cryo-milling to reduce the size of bone into particles increases the surface 
area of the material, exposes the interior portions of the trabeculae, which might 
enable the offloading of non-collagenous proteins, hydroxyapatite crystals, and 
ions. The resulting DCB particles  consist of inorganic hydroxyapatite mineral and 
organic matrix components, including collagen, glycosaminoglycans, and growth 
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factors229,230. The biochemical composition and micro- and nano-structure of DCB 
promotes stem cell attachment, proliferation, and differentiation into bone 
cells230,231. When added to 3D-printed PCL scaffolds, DCB significantly enhances 
in vitro adipose-derived stem cell (ASC) osteogenesis, even in the absence of 
other osteogenic factors27,232.  
Bone Harvesting 
Bovine calf knees are obtained from a nearby butcher and either used fresh 
or stored frozen at -20°C or -80°C. If frozen, calf knees are thawed overnight at 
4°C, and then brought knees to room temperature 1 hour before harvesting. The 
femur is separated from the tibia by cutting the tissue around the knee socket. After 
separating the joint, the muscle, ligaments, and other connective tissues are cut 
away from the knee. Connective tissue will interfere with the bone sawing process, 
so it is essential to remove as much of it as possible. Using a band saw suitable 
for cutting bone (i.e. Mar-Med Inc. Bone Band Saw; Cleveland, OH), bone is cut 
into approximately 1 cm3 pieces. Any cortical bone (present in the diaphysis) or 
cartilage (present on joint surface and in growth plates) is discarded. Bone pieces 
are decellularized directly or stored at 20°C. 
 
 
Figure 4-3. Obtaining bone particles for 3D-printing.  
Stereoscope images of bone after (A) sawing, (B) washing with water, 
(C) and decellularizing/lyophilizing. (D) Scanning electron micrograph of 
<40 um bone particles after cryomilling. Scale bars for stereoscope and 





Bone pieces are washed with a high-pressure water faucet to clear out the 
bone marrow (Figure 4-3). The bone pieces have an off-white color after washing 
is complete. The bone pieces are then washed with a series of detergent solutions 
at 2-3 times the bone volume, at 250rpm: 
1. 0.1% EDTA in 1x PBS without Ca2+, room temperature, 1 hour 
2. 0.1% EDTA, 10 mM Tris buffer in 1x PBS without Ca2+, 4°C for at least 12 
hours. 
3. PBS for 1 hour at room temperature. 
4. 0.5% SDS, 10 mM Tris buffer in 1x PBS without Ca2+, room temperate, 24 
hours.  
5. 3x PBS for 1 hour, room temperature 
6. Twice with 50 units/mL DNAse I, Grade II (Sigma Aldrich) and 1 unit/mL RNAse 
in 0.1% EDTA, 10 mM Tris buffer in 1x PBS without Ca2+, then PBS for 1 hour, 
at room temperature 
 
The washed bone pieces are frozen at -20°C for at least 4 hours to prepare for 
lyophilization, and then the bone pieces are lyophilized overnight to prepare for 
cryo-milling.  
Cryo-Milling 
The bone pieces and impactor are loaded into medium or large-sized 
grinding vials, such that they are able to move freely.  The grinding vial is loaded 
into the cryo-mill (6875 Freezer/Mill with mid or large polyvial set and large vial 
opener, SPEX SamplePrep; Metuchen, NJ) according the manufacturer’s 
instructions.   
The cryo-mill is filled with liquid N2 until it is ~75-80% full, then slowly closed, 
and powered on. The cryo-mill is run three times with the following setting: Cycles: 
15, Pre-cool: 3 min, Run: 1 min, Cool: 3 min, Rate: 10 CPS. The cryo-mill is 
monitored every 15 minutes to ensure the liquid nitrogen is not below the level of 
the vial. At the conclusion of cryo-milling, the vial is opened in a sterile 
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environment, transferred to 50mL conical tubes, and the particles are stored at -
20°C. This cold, dry storage prevents the degradation of the collagenous and non-
collagenous proteins in the particles.  
 
Figure 4-4 DCB Particles Across a Range of Sizes 
SEM images of DCB particles that were passed through a 40µm filter. A 
= 200x, B = 500x, C = 1000x, D = 2500x. 
 
Particle Size Separation and Characterization 
SEM of the particles shows they vary across a wide range of sizes: there 
are a number of them in the nanoparticle range as well as the micrometer range 
(Figure 4-4). Particles greater than 40um are separated using a sieve shaker, as 
they might aggregate and clog the 3D-printer. The range of sizes is broad due to 
the fine nature of bone trabeculae (average thickness) and the random 




(repeating the 15-cycle loop greater than three times) reduces the fraction of large 
particles present after cryo-milling. Because the range of particle sizes is so great, 
further characterization would be best done through separation of particles into 
different ranges (<10nm, <100nm, <1um, and <100um) by using sieves and 
characterizing these smaller ranges with tools for visualizing nanoparticles and 
microparticles. 
Polycaprolactone 
One of the most widely studied materials is polycaprolactone (PCL), a 
thermoplastic, aliphatic polyester233,234. Polycaprolactone is common in a number 
of implanted medical devices: Monocryl sutures235, Capronor, and SynBiosys. 
Many people also know it as InstaMorph plastic, which can be heated to a putty in 
a microwave or boiling water, molded to shape, and then sets at room temperature 
into a hard plastic.  
PCL is a desirable material for bone tissue engineering because it is 
biocompatible (bioinert), has mechanical properties similar to trabecular bone, and 
has a slower biodegradation rate than other thermoplastics236,237. Because it 
degrades in a hydrolytic manner238–240, dry storage of PCL and PCL-products is 
essential to preventing pre-mature degradation. Moreover, the material properties 
of PCL, such as its low melting temperature and good melt viscosity, allow PCL to 
be readily fabricated with 3D-printing26,241. However, there are complications with 
other thermal properties, as PCL offloads heat and solidifies much at much lower 
rates than other thermopolymers, such as ABS or PLGA or PVA241,242.  
PCL is a long starch, and forms micelles as it crystalizes into spherulites. It 
nucleates on itself or on any small dopants within the mixture. The mechanical 
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property of the polymer stems from the strand entanglement between the different 
spherulites, which depends on the cooling rate and the molecular weight of the 
polymer.  
Because of the inert, hydrophobic nature of PCL, it has to be treated with a 
weak acid, sodium hydroxide 3M, for 20 minutes before using it with cells. This 
treatment accelerates the surface degradation and reduces the hydrophobicity of 
the construct. This treatment is key to preventing bubbles in porous constructs and 
creates a wicking effect when seeding scaffolds with hydrogels. To further enable 
cell attachment, PCL can also be treated with a serum wash, which allows proteins 
to coat the surface and support more rapid cell attachment.  
 3D-Printed Scaffolds 
The 3D-printing fabrication process involves the generation of a computer 
aided design (CAD) file that defines the overall geometry and pore design of the 
scaffold. This CAD file is then converted into a G-code that is uploaded into the 
3D-printer. The scaffold material is printed layer-by-layer onto a bed according to 
the instructions in the G-code. Once the scaffold is printed, post-processing steps 
such as removal of support material, sintering, or surface modification may be 
performed to attain desired scaffold geometry and properties. 
Mixing DCB with the PCL polymer adds bioactivity to the resulting construct, 
and that construct can be created using fused deposition modeling to deposit 
small, molten fibers of the mixed material in specific patters. Fused deposition is 
advantages to other additive manufacturing systems because it creates less waste 
material, does not require a high energy or high temperature laser, and has 
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become low cost. The interlayer fusion from the deposited molten fibers into the 
previously deposited and solidified fibers creates a mechanically rigid construct.  
The resulting quality of the print can be affected by a number of 
manufacturing miscoordinations. (1) The speed of the extruding head and the rate 
of material extrusion might be mis-matched. While the settings can be calibrated 
beforehand, variability in the extruding method (such as the pneumatic pressure 
or material resistance) can cause in-print variability. Additionally, for filament-
based FDM systems, any variation in the diameter of the filament directly creates 
variability in extrusion flow rate. This error results in over or under deposition and 
is realized by the thinning or thickening of the deposited fibers beyond the effect 
of die-swell.  
(2) The molten-solid transition can take a long time, especially for PCL, and 
is controlled by matching the melt temperature and the cooling fans. If the extruder 
head moves away before the recently deposited fiber has solidified, it can draw the 
fiber away from the deposited location, deforming the shape of the scaffold and 
creating trailing drawn strand along the travel path. Additionally, when the fiber 
deposition path crosses space without underlying material (creating a strut or 
bridge-like structure), gravity will draw molten material downwards, creating a 




Figure 4-5. Schematic of Scaffold Manufacturing and In Vitro System  
DCB and PCL are mixed and placed into the print chamber, where they 
are melted and then subject to pressure. The pressure drives the molten 
mixture outwards to create fibers which form the 3D-printed scaffold.  
 
3D-Printing Manufacturing Tools and Materials 
The pneumatic-driving fused deposition system (Figure 4-5) used for the 
studies in chapters 5, 6, and 7 was built on an XYZ Positioning Arm (Syil X4 CNC 
Mill, Syil America, Coos Bay, OR).  A stainless-steel extrusion / thermal chamber 
was attached to the end of the arm and had an adaptor for tubing (Nordson EFD 
5225K711). This tubing connected to a pressure regulator (Ultimus V, Nordson 
EFD, Providence, RI), which was in turn attached to an air compressor (30 – 130 
PSI).  
The chamber was heated at the base by a heating element (Type K 
thermocouple, Watlow), and the heat was controlled by a PID controller (Series 
CV Temperature Controller, Watlow). The material was loaded into the chamber, 
molten, and extruded through an extrusion nozzle (460µm diameter, Nordson EFD 
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#322018) onto a heated print surface (Flexible Heater Rectangular 115V 270W, 
Rapid Industrial Supply connected to a Variable Voltage Regulator 4098 Variac 
Transformer TDGC-0.5KM, Circuit Specialists). 
Design of Scaffolds 
Scaffold were designed as thin, two-layer sheets which could be easily 
punched or cut into sizes appropriate for in vitro and murine studies. To create the 
CAD design, TinkerCAD (www.tinkercad.com) was used to design a box object 
3cm x 3cm x 0.782mm. The CAD file was then loaded into slic3r (www.slic3r.com) 
where it was sliced with the following settings: layer height: 0.46mm, nozzle 
diameter: 0.46mm, fill density: 40%, fill pattern: rectangular, perimeters: 0, 
horizontal shells: 0. By setting the perimeters and shells to 0, the only part of the 
print was the infill struts. At the thin height of the cad file, there was only room for 
two layers of infill, which generated a crosshatch pattern. Post-hoc measurements 
revealed that the resulting pores were 800um. The resulting GCODE file was 
loaded onto the Mach 3 software used to control the mill machine.  
3D-Printing 
The material mixture was loaded the print chamber and set to melt 
temperature (80°C) for 30 min using the PID controller and the heating element. 
The heated bed was set to 50-65°C.  The arm position was calibrated such that 
the origin of the coordinate system matched the front left corner of the heated bed. 
The extrusion rate was calculated by performing a test extrusion for 1 min. The 
length of the extruded material was measured and used to calculate mm/min 
extrusion rate.  
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The GCODE was modified with the measured extrusion rate by opening the 
GCODE file in a text editor and replacing the “F###” in the GCODE with the 
calculated rate “F###.” For instance, if the rate is 100 mm/min, a value of “F100” 
was placed wherever an F value appears in the GCODE. The print was then 
launched from the software and monitored for any inconsistencies, such as 
clogging or a change in extrusion rate. After print completion, the scaffold was 
allowed to cool for 20 min before removal from the print surface. Scaffolds were 
stored in desiccating conditions at room temperature or at -20C.  Prior to use for 
cell culture or implantation, scaffolds are washed with 3M NaOH for 20min, 3x PBS 
for 20min, and sterilized in 70% EtOH overnight. The sterile scaffolds are washed 
with sterile PBS 3x 20min, and finally incubated in serum-containing media for a 




Figure 4-6 Time-lapse of 3D-printed PCL Implant Bending 
Light force causes the implant to significantly deform at thin part (Arrow).  
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Mechanical Analysis  
Mechanical function of bone implants is critical, so that the implant does not 
break or displace under the incident forces. To measure mechanics, large cubic 
scaffolds (1 cm3) were printed for mechanical testing. Solid and porous scaffolds 
were printed to measure both the effective modulus of the porous structure and 
the base compressive modulus of the material.  Samples were tested on a 
compressive testing machine with a 50 kN load cell at a strain rate of 4 mm/min. 
The compressive modulus of solid PCL is approximately 120 MPa232,236. Porous 
scaffolds typically have a lower modulus that is proportional to the reduction in the 
load-bearing cross-sectional area by the porous space.  
While the mechanical properties of porous PCL prints are appropriate for 
trabecular bone, PCL prints of large anatomic shapes deform under handling due 
to thin, highly porous portions (Figure 4-6).  
Assessing DCB Content in 3D-printed Scaffold 
As the bioactive signal in the 3D-printed scaffolds, it is important to validate 
that the DCB is present throughout the scaffold at the level intended, evenly 
spatially distributed, and without clumping. Using Raman spectroscopy, the 
phosphate and collagen portions of the DCB can be detected. Raman 
spectroscopy is limited by the penetrating power of the incident light, indicating the 
DCB is present near or on the surface of the printed fibers.  With scanning electron 
microscopy, the particles present on the surface of the visualized (Figure 4-7 
A&B). In chapter 5, we can see that the particles are preferentially distributed 
towards the center of the deposited fibers rather than at the surface.  
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Serendipitously, the DCB particles fluoresce under blue light into the green 
channel, which enables the visualization of large particles throughout the 2-layer 
scaffolds (Figure 4-7D). CT scans show the average mineral density of these 
scaffolds, around 220mg HA/cc, which is approximately one third that of native 
bone, and corresponds well to a 30:70 mixture of DCB and PCL. uCT at 8nm 
reveals individual DCB particles throughout the scaffold, similar to the images 
obtained using fluorescent light (Figure 4-7C).  Finally, scaffolds can be incubated 
in a weak acid (0.5M HCl) to dissolve the calcium in the scaffold which can then 
be measured with the calcium assay described in this chapter. 4mm diameter two-
layer scaffolds generally contain 100ug of calcium.  
Cellular Activity and Assessment  
Because the lab worked with ASCs and intended to use ASCs or SVF in the 
eventual therapy, ASCs were the natural choice of cell type to assess the 
bioactivity of the scaffolds in vitro. Additionally, previous work in the lab compared 
ASCs with bone marrow derived cells and found them to be similar for tissue 
engineering bone, especially when treated with PDGF243. As a cell that could be 
induced, ASCs are most similar to fibroblasts, and generally require a significant 
intervention of dexamethasone to differentiation into osteoblasts. Other cells used 
to study bone formation—such as osteosarcoma cell lines or primary periosteal 
cells—might react differently to the scaffold material.  
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Figure 4-7 Confirming DCB Presence in 3D-Printed Scaffolds.  
(A) SEM of the surface of pure PCL scaffold (B) SEM of the surface of 
a scaffold containing DCB particles (yellow circles). (C) µCT of scaffold 
with DCB particles in white. (D) Fluorescent image of PCL-DCB scaffold 
with fibrin hydrogel. DCB particles are green, the gel is purple.  
 
Additionally, it is important to understand that primary or early passage 
ASCs from human donors have donor-to-donor and isolation-to-isolation 
variability. This variability might cause variations in the measured calcium 
deposition response, proliferation, and differentiation. In this dissertation, all of the 
SVF and ASC samples used have responded to the DCB:PCL material with 
increased calcium deposition and bone gene expression, albeit at different 
magnitudes.  
The mineral deposition by ASCs in vitro is dissimilar to that observed in 
normal bone growth or fracture healing. The calcium and DNA assays used do not 
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differentiate between the structured (ordered hydroxyapatite crystals) mineral 
deposition of bone and the calcium precipitation process that can spontaneously 
occur from media containing serum244. However, the gene expression of the cells 
can be observed and used to determine they are expressing bone-related genes, 
which supports the idea that the cells in the scaffold are differentiating into 
osteoblast-like cells and depositing boney matrix.  
Finally, the cells are encapsulated in a fibrinogen-thrombin hydrogel 
system. The majority of the cells are suspended in the hydrogel and have no 
physical contact with the 3D-printed scaffold and do not directly sense its 
mechanics, surface roughness, or bone content. Instead, they are more likely to 
respond to the vasculogenic cues of the fibrin fibers.  However, as cells remodel 
and pull on the fibrin fibers, it tends to tear apart and compress onto the struts 
(seen in vitro at days 7-14 in ASCs, and earlier in SVF). A different process might 
occur in vivo as imaging of murine cranial scaffolds has revealed tight banding of 
capillary structures perpendicularly along the scaffold struts.  
Cell Culture and Hydrogel Encapsulation 
ASCs isolated from lipoaspirate were grown in standard culture conditions 
using expansion medium: 10% fetal bovine serum, (Atlanta Biological), 1% 
penicillin-streptomycin, and 1 ng/mL FGF-2 (Peprotech) in high-glucose DMEM 
with sodium pyruvate (Gibco). FGF-2 encourages cell proliferation and was added 
to growth medium just before feeding the cells because the protein degrades 
rapidly in solution. During differentiation, osteogenic medium was used: 10% fetal 
bovine serum, 1% penicillin-streptomycin, 10 mM β-glycerophosphate (Sigma 
Aldrich), and 50 μm ascorbic acid (Sigma Aldrich) in low-glucose DMEM with 
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sodium pyruvate (Gibco). The phosphate provides the available ion supply for 
mineral growth, and the ascorbic acid provides the biomass for collagen 1 
generation. Ascorbic acid was added to the media at the time of feeding because 
it precipitates out of solution.  
Cells were generally seeded into scaffolds in a fibrin gel at a concentration 
of 20 x 106 cells/mL. This concentration is used because the resulting hydrogel 
has cells not more than one cell width from other cells enabling the rapid 
establishment of cell-cell contact. Studies of vascularization of the scaffolds 
showed that higher concentrations of cells led to increased vascular 
outcomes245,246. Finally, more cells in a scaffold generally leads to more mineral 
deposition.  
The hydrogel was prepared as follows. For the fibrinogen solution: 10 
mg/mL of fibrinogen (Sigma Aldrich) in PBS without Ca2+, sterile filtered. Thrombin 
solution: 10 units/mL of thrombin (Sigma Aldrich) in PBS with Ca2+, sterile filtered. 
Just before scaffold seeding, scaffolds were prepared by drying them on a 
sterile KimWipe and placing them in a well plate (N.B. Coating the well plates with 
a thin layer of 2% sterile agarose (~500 μL in 24 well plate) prevents the outgrowth 
of ASCs onto the well-plate as the scaffolds are cultured). 
A cell pellet of ASCs was prepared with the desired number of cells and 
resuspended in the fibrinogen solution. Aliquots of the cell-fibrinogen solution were 
prepared and kept on ice. Each aliquot contained enough solution for casting one 
to four gels. For 4mm, two-layer scaffolds, 12uL was used to seed the scaffold. At 
the time of casting, thrombin solution is added to the aliquot at a ratio of 1:4. The 
solutions were rapidly mixed and pipetted into the scaffolds—from the addition of 
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the thrombin gelation is observed in 20-30 seconds. Scaffolds were incubated in a 
cell culture incubator for 30 min to allow the fibrin to completely crosslink. Warm 
osteogenic medium was added to each well and thereafter scaffolds were fed 3 
times per week with osteogenic medium for 3-4 weeks to allow for bone 
regeneration to occur. 
Biochemical Assessment of Mineralization and Differentiation 
Biochemical assays can be used to examine the mineral deposition in the 
scaffold construct, and the behavior of the cells in the construct over time. In 
osteogenic media conditions, cells have the available resources (phosphate ions, 
calcium ions, ascorbic acid) to deposit mineralized extracellular matrix. The tools 
in this section were used to look at the scaffold en bloc 
Alizarin red staining is used to visually see calcium deposited in the matrix 
of the scaffold. Alizarin red S, an anthraquinone dye, binds to calcium. A solution 
of 40 mM Alizarin Red S (Sigma Aldrich) is prepared in dH2O. Enough Alizarin Red 
stain is used to immerse the entire scaffold. The scaffolds are incubated at room 
temperature for 10-20 minutes. After washing with dH2O extensively, the stained 
scaffold can be imaged. Fibrin hydrogels without any mineral deposition can retain 
the stain through a number of washes (10-15 washes), so including a control 
scaffold to ensure enough washes were used to remove non-specific staining. This 
stain gives a spatial indication of calcium deposition, and we always observe that 
the entirety of the gel region in osteogenic treated scaffolds was uniformly stained 
(Figure 7-4). Although not used here, the stained samples can be dissolved, and 
the amount of stain can be measured fluorescently to determine the amount of The 
scaffolds are robustly vascularized in the cranial defect environment (Figure 4-10), 
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due to their thin nature (<1mm) and the highly vascularized dura and dermal layers 
sandwiching the implant. We observe this vascularization in gross dissection and 
in intravital imaging248. calcium in the construct. 
The number of cells in the scaffold is determined through a DNA assay to 
quantify the amount of double stranded DNA Quant-iT PicoGreen dsDNA Assay 
Kit, Invitrogen). The whole scaffold is transferred to lysing solution immediately 
after the end of the culture period and lysed for 10min. Samples are then incubated 
at 50°C for 15-16 hours to denature the DNA. The PicoGreen DNA Assay is 
performed according to manufacturer’s instructions to determine the concentration 
of DNA in each scaffold. By using a day 0 sample with a known concentration of 
cells, the proliferation and number of cells in the scaffolds can be assessed.  
Ca2+ was quantified with a calcium (CPC) LiquiColor Test (Stanbio 
Laboratory; Boerne, TX). Deposited mineral was solubilized with a weak acid (0.5 
M HCl). Sufficient volume of the acid must be used to overcome the solubility limit 
of calcium ions, generally 50-100x. Samples were incubated in the acid on a 
shaker at 4°C overnight. The calcium quantification assay was performed 
according to manufacturer’s instructions. Scaffolds containing DCB will create a 
background calcium signal which must be measured and deducted from 
measurements of deposited scaffolds.  
One of the key metrics in this thesis is the measure of calcium deposited 
per cell. Normalized Ca2+/DNA ratios for scaffolds is found by dividing the mass of 
Ca2+ by the mass of DNA, as determined during DNA quantification.  
Beyond bone formation in vivo, the most convincing in vitro data is the 
protein expression of the cells. The expression is assessed with isolated mRNA, 
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which was used to produce cDNA. cDNA was subject to real-time polymerase 
chain reaction (RT-PCR) for osteogenic genes Col1a1, Runx2, osteopontin, 
osteocalcin, and osteonectin. Collagen 1 is the major extracellular matrix 
component of bone, although it is also expressed in other tissue types. Runx2 is a 
controlling transcription factor and is considered a master regulator of osteoblast 
differentiation. Osteocalcin, osteopontin, and osteonectin have extracellular roles 
in nucleating hydroxyapatite crystals, controlling crystal growth, and preventing the 
degradation of those formed crystals247.  
Then primers for genes of interest are used to amplify those proteins and 
measure their presence relative to housekeeping gene. For bone differentiation, 
the most stably expressed gene throughout the differentiation of the cells is β-actin. 
Because the scaffolds are seeded with an unpurified cell population, the results 
can be somewhat noisy—not all the cells are differentiating or are doing so at the 
same time. Timepoints early in the culture process are especially noisy (but when 
runx2 is most expressed), but at later timepoints (14 and 21 days post-induction) 
the noise is reduced as a number of cells have differentiation and are stably 
expressing mineralization genes such as collagen 1 and osteopontin.  
For analysis, the delta-delta Ct method was used in which β-actin served 
as the housekeeping gene, and gene expression was normalized to that of cells 
cultured in PCL scaffolds under control conditions at Day 21, or undifferentiated 
SVF cells before exposure to tissue culture plastic or cow serum. This normalizes 
the measured gene expression to the number of cells present in the sample, as 
well as the baseline expression of that gene in uninduced or differentiated cells. 
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The fold change of the proteins can vary between 10 to 1000-fold depending on 
the normalizing sample.  
Critical-Sized Mouse Cranial Defects  
Because of the thin nature of the 3D-printed, two-layer scaffolds, they were 
ideal implants for cranial bone defects in the parietal bones of mice. These defects 
were created using a 4mm-diameter circular saw. Mice were always male, 6-8 
weeks of age (young adult) and either wild-type (C57/BL6) or nude 
immunocompromised (fox1n1-null). Immunocompromised mice had a mutation 
which prevented the maturation of T-cells, so they would not reject human cell 
implants.  
 
Figure 4-8 Surgical Outcomes for Murine Cranial Implants 
Red: PCL-DCB implant fills the defect and is well integrated with the 
surrounding bone. Green: an empty control defect does not heal over 12 
weeks.  
 
3D-printed scaffolds were 816µm thick and were press-fit into the 
surrounding bone that was 100-200µm thick (Figure 4-8). The scaffolds have a 
40% infill setting, but from a top-down 2D-view, the scaffold covers 80% of the 
defect area. Overall, the scaffold provides structured porous areas across the 
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defect area for bone regeneration. The scaffold is not thick enough to have 
diffusion limitations leading to cell necrosis, and both the dura and the overlying 
skin are highly vascularized and rapidly vascularize the implant. Generally, 
scaffolds are press-fit into the defect and then the cell-fibrinogen-thrombin mixture 
is pipetted into the scaffold in situ, filling the entire defect and helping to hold the 
scaffold in place. Pre-seeded scaffolds suffer disruption to the gel during the 
implantation process, and are kept in media containing serum prior to implantation, 
which is impossible to fully wash out of the scaffold and can cause unwanted or 
complicated effects in vivo.  
In numerous studies, I have found untreated, PCL alone, and PCL with 
ASCs defects to be non-healing, which establishes the critical size of this defect. 
However, when I treated the defects with the infuse acellular collagen sponge 
(INFUSE, Medtronic) with 2µg of BMP2, the defect fully regenerated, 





Figure 4-9 Outcomes of Positive and Negative Murine Cranial Treatments 
In 4mm-diameter cranial defects at 12-weeks, BMP-2 treatment 
completely filled the defect with bone (A), while the untreated, empty 
defect remained unhealed (B). A DCB-PCL scaffold (C) filled the defect 




Over the course of using PCL or PCL-DCB scaffolds in over a hundred 
mice, I have never observed inflammation, swelling, or excessive fibrosis in this 
cranial defect, intramuscular site, or subcutaneous site. This serves to confirm the 
bio-inert nature of the material and that the 3D-printing process and resulting 












Figure 4-10 Live Imaging of Vascularization of Cranial Implants 
(A) White light with a 496nm long pass filter is used to visualize the 
hemoglobin (absorption of 570nm light) in blood vessels present across 
a PCL scaffold at 12-weeks. (B) Laser speckle contrast was used to 
identify regions of relative blood flow in the scaffold area. Green and red 






























CHAPTER 5‡‡  
COMPARISON OF 3D-PRINTED POLYCAPROLACTONE SCAFFOLDS 
FUNCTIONALIZED WITH DECELLULARIZED BONE, HYDROXYAPATITE 
 
Summary 
3D-printing facilitates rapid, custom manufacturing of bone scaffolds with a 
wide range of material choices. Recent studies have demonstrated the potential 
for 3D-printing bioactive (i.e. osteo-inductive) scaffolds for use in bone 
regeneration applications. In this study, we 3D-printed porous poly-ϵ-caprolactone 
(PCL) scaffolds using a fused deposition modeling (FDM) process and 
functionalized them with mineral additives that have been widely used 
commercially and clinically: tricalcium phosphate (TCP), hydroxyapatite (HA), Bio-
Oss (BO), or decellularized bone matrix (DCB). We assessed the ‘print quality’ of 
the composite scaffolds and found that the print quality of PCL-TCP, PCL-BO, an 
PCL-DCB measured ~0.7 and was statistically lower than PCL and PCL-HA 
scaffolds (~ 0.8). We found that the incorporation of mineral particles did not 
significantly decrease the mechanical properties of the graft, which were on the 
order of 260 MPa for solid blocks and ranged from 32-83 MPa for porous scaffolds. 
Raman spectroscopy revealed the surfaces of the scaffolds maintained the 
chemical profile of their dopants following the printing process. We evaluated the 
osteoinductive properties of each scaffold composite by culturing adipose-derived 
stromal/stem cells (ASCs) in vitro and assessing their differentiation into 
osteoblasts. The calcium content (normalized to DNA) increased significantly in 
                                            
‡‡ Adapted from Nyberg, E., Rindone, A., Dorafshar, A., & Grayson, W. L. (2017). Comparison of 
3D-printed poly-ɛ-caprolactone scaffolds functionalized with tricalcium phosphate, hydroxyapatite, 
bio-oss, or decellularized bone matrix. Tissue Engineering Part A, 23(11-12), 503-514. 
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PCL-TCP (p<0.05), PCL-BO (p<0.001), and PCL-DCB (p<0.0001) groups relative 
to PCL only. The calcium content also increased in PCL-HA but was not 
statistically significant (p>0.05).  Collagen 1 expression was 10-fold greater than 
PCL in PCL-BO and PCL-DCB (p<0.05) and osteocalcin expression was 10-fold 
greater in PCL-BO and PCL-DCB (p<0.05) as measured by qRT-PCR. This study 
suggests that PCL-BO and PCL-DCB hybrid material may be advantageous for 
bone healing applications over PCL-HA or PCL-TCP blends. 
Introduction 
The treatment of critical-sized or non-union bone defects resulting from 
congenital diseases, trauma, or cancer resection often requires bone grafts. The 
use of autologous grafts – the gold standard – is associated with additional pain, 
co-morbidities, and high costs 249–252. Metallic (stainless steel and titanium) 
implants have been used to treat these defects but have limited lifespans (25 
years) and excessive material strength, causing stress shielding253. Tissue 
engineering approaches combine biodegradable scaffolds with bioactive factors 
and cells to regenerate the regions of tissue loss254. The application of 3D-printing 
or, more broadly, additive manufacturing (AM) techniques to manufacturing of 
scaffold components has enabled precise patient-specific customization of macro-
scale scaffold geometry (e.g. from CT images). Further, AM has also enabled 
greater control and optimization of the micro-scale porous structure which can be 
used to optimize bone healing and vascular infiltration.  
 A growing number of tissue engineering studies are utilizing 3D-printed 
scaffolds for bone regeneration26,102,255–258. Scaffolds have been manufactured 
using fused deposition manufacturing (FDM)27, selective laser sintering69, and 
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digital light projection259 which utilize thermal fusion bonding260, high temperature 
sintering261, and photo-crosslinking262, respectively. The specific 3D-printing 
technology selected impacts the choice of material used for the scaffolds. The 
relatively low cost of FDM machines over the past decade has enabled the 
widespread use of the technology for bone tissue engineering in convenient 
desktop formats263. FDM allows for sufficient resolution needed for structural and 
pore designs, and many materials suitable for FDM result in scaffolds which are 
bioactive and have similar stiffness as native bone27.  
Researchers have used a number of thermoplastic polymers to 3D-print 
tissue engineering scaffolds, including poly--capro-lactone (PCL26,102,264, poly(l-
lactic acid) (PLLA), and poly-vinyl-alchohol (PVA)265.  PCL is the most commonly 
used thermoplastic polymer for AM of bone scaffolds due to its prior FDA approval, 
excellent biocompatibility, and slow biodegradation via hydrolysis235,238,266. The low 
melting point of PCL (60°C) makes it an ideal thermoplastic ideal for benchtop 
FDM, and it maintains strong crystallization and moderate mechanical properties 
after manufacturing, particularly in compression69,233. However, synthetic PCL 
scaffolds are not inherently osteoinductive267,268. Several groups have 
functionalized PCL by incorporating various forms of calcium phosphate into the 
scaffolds257. The three most commonly used calcium phosphate mineral additives 
are tricalcium phosphates (TCP)240,269,270, hydroxyapatite crystals (HA)102,271–274, 
and decellularized bone matrix (DCB)27. These all vary in form and function: TCP 
contains readily available calcium and phosphates for bone production and 
degrade semi-rapidly (6 weeks) via hydrolysis into ions and via osteoclast 
resorption275–278. HA is the naturally occurring crystal form of bone mineral and is 
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similar to TCP except for a denser crystalline structure and increased mechanical 
properties. DCB is obtained from native (xenogenic and allogenic) bone sources 
and may include an organic protein phase such as collagen. However, a clinically 
available form of DCB, Bio-Oss, provides millimeter sized granules of bovine 
trabecular bone with the organic phase largely removed, However, doping PCL 
with any of these different mineral additives might impact the mechanical 
properties and present additional challenges with fabrication271.  
Previously, our group has demonstrated enhanced bone healing with DCB 
blended into a PCL scaffold, hypothesizing that the inclusion of collagen aided in 
cell attachment and migration27. We presently hypothesize that the collagen 
present in DCB in addition to the mineral phase may make DCB a better additive 
than TCP or HA. Despite the previous investigations into 3D-printed scaffolds 
incorporating HA102,272 and TCP240,269,270 hybrids, those various study outcomes 
cannot be compared with the effect PCL-DCB27 since the methods of printing, the 
synthetic material, and the printing protocols may be different. In this study, we 
seek to directly compare the printability and bioactivity of PCL-DCB approach with 
PCL-TCP, PCL-HA, and PCL-BO, which do not have the organic phase of native 
bone.  The objectives of this study are (1) to evaluate the relative manufacturability 
of bone scaffolds containing different bone-forming dopants in a biocompatible 
thermoplastic using fused-deposition manufacturing, (2) to compare the material 
properties of the resulting bone scaffolds, and (3) to determine the osteoinductivity 
of the scaffolds in vitro. 
96 
Materials and Methods 
Supplies 
All materials were obtained from Sigma unless otherwise stated. Calf knees 
were obtained from Green Village Packing Co in Green Village NJ.   
Materials 
Powdered polycaprolactone (PCL 43k-50k MW; Polysciences 25090) was 
combined with β-Tricalcium Phosphate (TCP; Sigma Aldrich 49963), 
Hydroxyapatite (HA, Aldrich 289396), Bio-Oss (BO) small granules (Geistlich 
20111), or decellularized bovine bone extracellular matrix (DCB).  TCP and HA 
were unaltered and used in their powder forms. BO granules were pulverized using 
a SPEX SamplePrep 6770 cryo-mill (SPEX SamplePrep, Metuchen, NJ) at a 
frequency of 10 cycles per second for 15 minutes to obtain particles. Bovine DCB 
was obtained by isolating trabecular bone from calf knees. The bone was 
decellularized using a protocol as described previously27. Briefly, bovine trabecular 
bone fragments were blasted with water to remove as much cellular debris as 
possible. The bone fragments were then placed in a series of four detergent 
washes of 0.1% EDTA for 1 h, 0.1% EDTA/10 mM Tris for 12 h, 0.5% SDS/10 mM 
Tris for 24 h, and 50 u/mL DNase, 1 u/mL RNase, and 0.1% EDTA/10 mM Tris for 
5 h. Following the washes, the bone was rinsed with PBS and lyophilized. The 
decellularized bone fragments were cryomilled with a Spex 6870 Freezer Mill to 
form a powder.   
3D-Printing of Scaffolds using Fused Deposition Modeling  
Materials were mixed 30% w/w with PCL by sifting through a stainless steel 
400 µm mesh three times. Scaffolds were manufactured using an in-house 
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pneumatic fused-deposition system mounted to a CNC machine with a nozzle 
diameter of 460 µm26. Briefly, a powdered mixture of material is loaded into the 
nozzle chamber, heated to a set temperature in order to bring the polymer to a 
liquid phase, and then a pneumatic pressure is applied to the top of the liquid to 
force it out the extrusion die at the bottom of the chamber. Scaffolds for cell studies 
were prepared using rectilinear patterns with 60% void volume and two layers in 
height (0.640mm) and punched to 4mm in diameter. Solid 1 cm2 sheets that were 
also two layers in height were printed for surface analysis, and solid and 60% void 
1 cm3 cubes were printed for mechanical testing. Print temperatures, pressures, 
and extrusion head speeds were varied empirically for each composition in order 
to maximize print quality. Extrusion head speed was determined by measuring the 
length of material extruded for 5 minutes; temperature and pressure were raised 
within the range of the system until the material extruded at a steady rate. Prior to 
seeding cells, scaffolds were treated with 1M NaOH for 1h to increase 
hydrophilicity, washed with PBS, soaked in 100% EtOH for 1h to sterilize, and 
immersed in 100% FBS at 37 °C for 1h to facilitate protein adsorption to the surface 
of the scaffold prior to seeding. Scaffolds were imaged under computed 
tomography (CT) using a Gamma Medica X-SPECT small animal system (Gamma 
Medica, Salem, NH). Imaging was performed at 80 kV peak voltage and 600 µA 
current. Reconstruction was done with voxel size of 70 µm. 
Differential Scanning Calorimetry 
The melting point and degree of crystallinity was determined via differential 
scanning calorimetry (Perkin Elmer DSC 8000). Powder mixes of each group (5 ± 
1 mg) and printed constructs (15 ± 5 mg) were measured at a scan rate of 3 °C/min 
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from 10 °C to 120 °C in flowing nitrogen gas (n=4). The melting point was 
determined at the maximum of the melting endotherm. The degree of crystallinity 
(Xc) in the PCL was calculated assuming proportionality to the reported heat of 
fusion (∆𝐻𝑐) of 139.5 J/g for 100% crystalline PCL
233. Heat of fusion in the samples 
(∆𝐻𝑓) was determined using the peak area calculation feature of the Pyris 
software. Only the net weight of the PCL was considered in calculating the degree 
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Assessment of Print Dimensions and Quality 
The strut and pore dimensions of two-layer porous scaffolds were analyzed 
post-hoc using the ImageJ plugin OrientationJ (NIH, Bethesda MD). Print quality 
was also computed comparing two-layer porous scaffolds pixel-by-pixel to a 
computer-generated ideal lattice. The percentage of pixels that matched between 
the two images was taken as a measure of print quality.  
Mechanical Testing 
Solid and porous cubes were subjected to unconfined compression using a 
MTS Criterion Model 43 (Eden Prairie, MN) with a 5 kN load cell. Solid specimens 
were assumed to have isometric mechanical properties, and compressive strain 
was applied along the print axis (z-axis) at 4 mm/min to determine the compressive 
modulus of the bulk material (n=3). Porous cubes were similarly measured to 
determine scaffold properties.  
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Raman Spectroscopy 
To determine the molecular constituents of the hybrid material and confirm 
the presence of both the mineral and collagen phases of the DCB particles, Raman 
spectroscopy was utilized as previously described279. Briefly, Raman scattering 
spectra were measured in backscattering geometry using a Horiba Jobin-Yvon 
T64000 spectrometer equipped with an Olympus microscope. A 514.5 nm line of 
Ar+-Kr+ laser was used for excitation. The laser power was kept below 1 mW to 
avoid overheating of the sample. Spectra of printed sheets containing 30% dopant 
were recorded and spectra of each of the pure materials were recorded as 
controls. For recording spectra of BO and DCB samples, samples were 
photobleached for 30 min to reduce luminescence background.  
Scanning Electron Microscopy 
Scanning electron microscopy (SEM) was performed to assess the 
morphology of the particle additives and manufactured sheets. Particles and solid 
manufactured sheets were mounted on carbon tape and sputter coated with 30 nm 
of Au/Pd using a Denton Vacuum Desk III to make the samples conductive for 
imaging. Samples were imaged with a LEO/Zeiss Field-Emission SEM using the 
InLens detector and an accelerating voltage of 1 kV.  
Cell Seeding 
Adipose-derived stem cells (ASCs) were obtained under Institutional 
Review Board approved protocols with patient consent. Briefly, lipoaspirate was 
digested with 1 mg/mL collagenase I (Worthington Biochemical Corporation, 
Lakewood, NJ) for 1 hour at 37 °C. The released cells were centrifuged to obtain 
the stromal vascular fraction pellet and plated. Adherent cells were termed ASCs 
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and expanded for the current study. Expansion conditions consisted of Dulbecco’s 
Modified Eagle Medium (DMEM; Life Technologies, Frederick, MD) with 4.5 g/L 
glucose, 10% v/v fetal bovine serum (FBS; Atlanta Biologicals, Flowery Branch, 
GA), 100 U/mL penicillin and 100 μg/mL streptomycin (P/S; Cellgro), and 1 ng/mL 
basic fibroblast growth factor (PeproTech, Rocky Hill, NJ). ASCs were cultured in 
standard conditions on tissue culture plastic at 37 °C with media changes every 
third day and seeded into the scaffolds at passage two in a suspension of 
fibrinogen-thrombin at 20,000 cells/µL. Fibrinogen concentration was 10 mg/mL 
and thrombin concentration was 10 U/mL. The volume ratio was 4:1 
fibrinogen:thrombin for a final fibrinogen concentration of 8 mg/mL.  Control media 
(DMEM with 4.5 g/L glucose, 10% v/v FBS, P/S) was used for in vitro control 
groups, while groups osteo-induced for osteoblastic differentiation used induction 
media (DMEM with 1 g/L glucose, 10% v/v FBS, P/S, 10 mM β-glycerol phosphate 
and 50 µM ascorbic acid-2-phosphate)  
Biochemical Assays 
Scaffolds were cultured for 3 weeks in control or induction conditions (n = 3 
or 4 per assay). DNA quantities were assessed using the Quant-It PicoGreen 
dsDNA assay (Invitrogen, Carlsbad, CA) according to manufacturer instructions. 
Total calcium was measured by agitating scaffolds in 0.5N hydrochloric acid for 24 
hours then measuring the calcium in solution using a Stanbio LiquiColor calcium 
assay (Stanbio, Boerne, TX) to determine calcium content. Calcium content was 
normalized to the amount of cellular DNA. Mineralized calcium was detected using 
Alizarin Red S (Sigma A5533) staining and detected using bright-field microscopy.   
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Gene Expression 
After the culture periods, scaffolds were digested with TRIzol (Life 
Technologies) and isolated mRNA was used to produce cDNA. cDNA was subject 
to real-time polymerase chain reaction (RT-PCR) for osteogenic genes Col1a1, 
Runx2, osteopontin (OP), osteocalcin (OCN), and osteonectin (ON) as previously 
described243. The primers used are presented in Table 6-1. For analysis, the delta-
delta Ct method was used in which β-actin served as the housekeeping gene, and 
gene expression was normalized to that of cells cultured in PCL scaffolds under 
control conditions at Day 21. 
Table 6-1. PCR Primers 
Gene Name Direction Sequence 
Osteopontin F TTGCAGCCTTCTCAGCCAA 
 R GGAGGCAAAAGCAAATCACTG 
Runx-2 F GTCTCACTGCCTCTCACTTG 
  R CACACATCTCCTCCCTTCTG 
Osteonectin F TCGGCATCAAGCAGAAGGATA 
 R CCAGGCAGAACAACAAACCAT 
Osteocalcin F GTGACGAGTTGGCTGACC 
 R TGGAGAGGAGCAGAACTGG 
Collagen 1 F GAGAGGAAGGAAAGCGAGGAG 
 R GGGACCAGCAACACCATCT 
 β-Actin F AGTTGCGTTACACCCTTTCTTG 
 R TCACCTTCACCGTTCCAGTTT 
 
Statistical Analysis  
Statistical analysis was conducted using GraphPad Prism Software 
(GraphPad Software Inc.). One-way ANOVA nonparametric tests and Tukey's 
comparison posttest was sued to compare means for print quality, mechanical 
testing, and Ca/DNA. One-way ANOVA with a Dunnett's posttest to the control 
PCL group for each gene was used for qRT-PCR. P < 0.05 was considered 
significant.  Data were calculated as the means ± SD.  
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Results  
Particle Size Characterization & Printability 
All scaffolds were manufactured using the 3D-printing process. Particles 
were all within a similar size range (20 – 50 µm), and had an irregular rough 
appearance except for HA, whose smooth spherical appearance is likely due to 
fabrication via crystallization in solution (Figure 6-1). Two-layer sheets (solid and 
porous) were manufactured reproducibly after empirically determining pressure 
and temperature parameters. However, porous and solid cubes required long 
manufacturing times (several hours), and the printing process with the mineral 
dopants was subject to clogging of the nozzle. Dopant particles were non-
homogenously arrayed on the surface of HA, BO, and DCB constructs, while they 
were absent in TCP and highly present in BO (Figure 6-1, 6-2). The inclusion of 
the various dopants decreased the printability of the scaffolds, requiring an 
increase in print temperature and pressure in addition to a reduced print speed 
(~35% of speed of pure PCL prints; Table 6-2). The DCB and BO material mixes 
were more difficult to extrude than TCP or HA for the longer print times (> 1 hour).  
 
 
Table 6-2. Manufacturing Settings for Pneumatic 3D-Printing 
 Temperature (°C) Pressure (psi) 
Extrusion Head 
Speed (mm/min) 
Pure PCL 80 85 70.09 
30% TCP 100 85 32.50 
30% HA 100 90 25.69 
30% BO 115 90 3.00 - 26.00 





Figure 6-1. Morphological Assessment.  
SEM images show morphology and size range (~20 – 50 µm) of mineral 
particles (left column) and surface topography of the 3D-printed 




Figure 6-2. SEM of Scaffold Fiber Cross-Sections 
 
Differential scanning calorimetry of the material mixes before (in powder 
form) and after printing revealed printing pure PCL scaffolds were highly crystalline 
(96% print vs 50% powder) and the various dopants decreased the crystallinity of 
the polymer phase to 40 – 46% (Table 6-3, Figure 6-3). The dopants did not 
drastically affect the melting (Tm) temperature from pure PCL: the Tm of pure 
printed PCL was 62.5 ± 0.5 °C while Tm of the printed materials of for all dopants 
prints was 60.6 ± 1.0 °C. The glass transition temperature, Tg, of all prints was 36 
± 1.0 °C. However, the printing process did decrease all Tm by 0.5-2 °C relative to 
the Tm of pure powdered PCL and similarly increase all Tg by 1.0-2.5 °C, 
highlighting a minor effect of thermal history upon the behavior of the material. This 
minor effect did not impact the printing process, as the temperature setting was 
40-60°C greater than the measured melt temperatures.  
Table 6-3. Percent Crystalline of Material 
 Powder Print 
PCL 51 ± 2 % 96 ± 3 % 
TCP 55 ± 2 % 46 ± 5 % 
HA 60 ± 2 % 45 ± 2 % 
BO 47 ± 2 % 40 ± 5 % 
DCB 50 ± 1 % 45±2 % 
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Figure 6-3. Melting Curves of Composite Mixtures.  
The cycle moves from 10*C up to 100 through peak 1 (Melting Curve), 
then down through peak 2 (Crystallization) and up again through a 
second heating scan which has a lesser melting curve (3) because it has 
crystallized more perfectly in the machine than in the print bed. For 
interpretation please see ref 233. (A) Thermally green samples of particle 
mixtures: PCL only, PCL + TCP, PCL + HA, PCL + BO, and PCL + DCB. 
(B) Samples of printed materials: PCL, PCL-TCP, PCL-HA, PCL-BO, 
and PCL-DCB. (C) Zoomed in image of curves for print samples of PCL-




The mineral dopants caused the scaffolds to become radio-opaque (Figure 
6-4A) in CT imaging. Alizarin red staining revealed a strong calcium presence in 
BO and DCB (Figure 6-4B). Expansion of the material after extrusion through the 
nozzle-die was evident in measurements of strut widths in all of the material 
combinations (Figure 6-4C) except for HA (460 µm, PCL = 501 µm, BO = 513, 
TCP = 546 µm, DCB = 614 µm). This expansion caused pore area to be reduced 
from its theoretical value in all cases, resulting in decreased void area fraction 
measured at 39% in HA, 37% in PCL, 35% in BO, 31% in TCP, and 25% in DCB 
(Figure 6-4D). All pores were greater than 500,000 µm2, and struts were all greater 
than 400 µm, with overlapping struts accounting for 26% of the scaffold area. Print 
quality measurements compared the output layout of the scaffolds to the input 
design and demonstrated a decrease of 17% in PCL, 20% in HA, 28% in TCP and 
DCB, and 30% in BO (Figure 6-4E). Inspection of the radio-opacity of the materials 
along a centerline in a cross-section of a strut in CT images confirmed the 
increased strut diameter. Hounsfield intensities revealed a lower mineral density 
in DCB compared to HA and TCP, which were similarly intense but also slightly 



















Figure 6-4. Determination of Print Quality.  
(A) CT images of 3D-printed PCL scaffolds containing TCP, HA, BO, 
and DCB confirming the presence of mineral. (PCL only scaffolds were 
not visible via CT). (B) Stereomicroscope images of scaffolds stained 
with alizarin red. (C) Width of struts in each composite scaffold. Gray 
line represents theoretical width of 460 m. (D) Cross-sectional area of 
void regions in scaffolds. Gray line represents theoretical design void 
area (40%). (E) Print quality: measure of how actual printed scaffolds 
compare with a theoretical ideal. PCL and PCL-HA are statistically 
higher than other groups (& p< 0.05; n=3). (F) Trace of radiographic 
intensity through the core of an individual strut (gray = design parameter 
of 460um).  
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Mechanical Properties  
Porous and solid cuboidal scaffolds were subjected to unconfined 
compression along their print axis (Figure 6-5A) until reaching either 80% strain 
or 4.5 kN. Comparison of the scaffolds before (Figure 6-5B) and after (Figure 6-
5C) illustrates the equidirectional and permanent (plastic) deformation of the 
scaffold along the xy-plane. Compressive moduli of the scaffolds were obtained by 
measuring the slope of the stress-strain curve in the linear region between 2 and 
4% strain (Figure 6-5D) for porous scaffolds and solid blocks of manufactured 
material. Bulk PCL-TCP and PCL-DCB scaffolds had stiffness of 253 MPa and 241 
MPa, compared to PCL (266 MPA). PCL-HA had a statistically higher modulus of 
338 MPa (Figure 6-5E). Compressive moduli of porous scaffolds were all 
significantly reduced from the bulk values. The moduli of the various scaffolds were 
HA (83 MPa), PCL (51 MPa), TCP (37 MPa), and then DCB (32 MPa) (Figure 6-
5E).  
Raman Spectroscopy  
Raman spectroscopy revealed the C-H bands characteristic for PCL (peaks 
1 – 4) in all of the materials (Figure 6-6). Phosphate bands associated with the 
mineral (peaks 5 – 7) were observed in the prints containing PCL, HA, BO, and 
DCB indicating that mineral deposits were present on the surface of the materials. 
Amide bands that are indicative of the presence of collagen were observable in 
DCB and to a lesser extent in BO (Figure 6-6). Spectra of the pure dopant powders 










Figure 6-5. Mechanical Testing.  
(A) Schematic of applied force along print axis (z-axis). (B) Top-down 
view of scaffold along print axis before applying strain. (C) Top-down 
and side vies of scaffold after 60% strain. (D) Representative stress-
strain curves. (E) Compressive moduli of scaffolds. Modulus of PCL-HA 







Figure 6-6. Raman Spectroscopy.  
Raman spectra of printed materials showing characteristic peaks for 
PCL (1: 1110 cm-1 skeletal stretching; 2: 1300 cm-1 ωCH2; 3: 1450 cm-
1 δCH2; 4: 1720 cm-1 C=O) and bone (5: 430 cm-1 4v2 PO43-; 6: 590 cm-
1 v4PO43-; 7: 960 cm-1 v1PO43-; 8: 1340 cm-1 Amide III; 9: 1660 cm-1 







Figure 6-7 Raman Spectra of Pure Dopants.  
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Cell Seeding & Growth  
The numbers of ASCs in the scaffolds after 3 weeks were generally higher 
in the control cultures relative to the osteo-induced cultures for the same materials. 
In the control cultures, cell numbers were significantly lower in PCL scaffolds 
relative to the other scaffold groups. The cell numbers in the PCL-TCP, PCL-HA, 
PCL-BO, and PCL-DCB were all statistically identical (Figure 6-8A). Cell numbers 
in the osteo-induced cultures were unchanged among the different biomaterial 
scaffolds (Figure 6-8A). For each scaffold composite, the amount of calcium/DNA 
deposited was greater in the osteo-induced groups compared to their controls. In 
the control groups, the amount of Ca/DNA was statistically higher in PCL-TCP 
(34.6±2.6 ng/ng), PCL-BO (60.0±21.7 ng/ng), and PCL-DCB (64.2±3.2 ng/ng) 
relative to PCL (5.6±5.2 ng/ng) and PCL-HA (17.5±2.4 ng/ng) (n=3). This trend 
was similar in the osteo-induced groups, with the greatest Ca/DNA in DCB and the 
least in HA and PCL (Figure 6-8B).  
 
Figure 6-8. DNA and Calcium Content of ASC-seeded Scaffolds.  
(A) Total DNA harvested from scaffold after 21 days of in vitro culture. 
(B) Calcium content normalized to the amount of DNA after 21 days of 
in vitro culture.  * statistically different from all other groups (p < 0.05); & 
groups are similar to each other but statistically different from all other 
groups (p < 0.05 ; n=3).  
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Gene Expression  
PCR analysis of the cell-laden constructs was performed on day 21. There 
were no clear trends in the expression of Runx2.  Under control conditions, Runx2 
expression was only roughly 17-fold higher in PCL-HA relative to PCL only. After 
21 days of osteo-induction, Runx2 expression was elevated in PCL (13.1±3.5 fold; 
p = 0.0003) and PCL-DCB (7.2±3.5 fold; p = 0.0489) relative to control PCL (Figure 
6-9). Similarly, there were no clear trends for osteocalcin expression: all of the 
scaffold groups were statistically similar to the control PCL under control or osteo-
induced conditions (Figure 6-9). Osteopontin was upregulated roughly 4- to 5-fold 
in PCL-HA and PCL-TCP scaffolds in control conditions. Osteopontin expression 
increased 5- to 10-fold in all biochemically osteo-induced cultures though statistical 
significance was only observed with PCL-HA and PCL-DCB. In control cultures, 
the Osteonectin expression increased in PCL-TCP (3.6±1.8 fold; p = 0.5423), PCL-
BO (8.8±2.2 fold; p = 0.0040), and PCL-DCB (10.1±0.95 fold; p = 0.0011). The 
expression increased 10- to 5000-fold in all osteo-induced groups relative to the 
PCL control. Collagen 1 expression in control cultures showed a strong 
dependence on scaffold composition. Collagen I expression increased in PCL-
TCP (4.6±0.87 fold; p = 0.9421), PCL-BO (18.5±8.2 fold; p = 0.0197), and PCL-
DCB (19.8±1.6 fold; p = 0.0078), but not in PCL-HA (0.48±0.11 fold; p = 0.9959). 
With the addition of soluble osteo-inductive factors, expression levels increased in 
all groups relative to the PCL cultures in control conditions: PCL (11.7±9.2 fold; p 
= 0.9704), PCL-TCP (74.7±32.6 fold; p = 0.0094), PCL-HA (4.6±1.7 fold; p = 
0.9970), PCL-BO (14.8±6.8 fold; p = 0.04920), and PCL-DCB (12.5±6.5 fold; p = 
0.0480) (Figure 6-9).  
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Figure 6-9. Expression of Osteogenic Genes in ASCs.  
qRT-PCR assessment of Runx2, osteocalcin, osteopontin, osteonectin, 
and collagen I after 21 days of culture. Gene expression normalized to 
ASCs cultured in PCL with Control medium. *p < 0.05 ; **p < 0.01; ***p 
< 0.001.  
 
 
Figure 6-10. In Vivo Evaluation of Dopant Scaffolds at 12 Weeks.  
Representative results. Left:  CT of scaffolds after 12-weeks of healing. 
Right: Mason’s trichrome staining of cross-sections of the defects. White 








Current commercially available bone substitutes include allografts and their 
derivatives (e.g. demineralized bone matrix), xenograft derivatives (e.g. Bio-Oss), 
collagen-derivatives, synthetic materials (e.g. TCP and HA), and combination 
products (e.g. collagen sponges with bone morphogenetic protein-2). Yet, none of 
these approaches is capable of producing adequate treatment of critical-sized 
defects that require the regeneration of delicate anatomic structures. 3D-printing 
has emerged as a promising strategy for producing scaffolds with an array of small 
features from a multitude of synthetic materials. In fact, several groups have 
demonstrated the potential for 3D-printing scaffolds from polymeric 
materials236,280,281. To enhance the bioactivity of 3D-printed, polymer-based 
scaffolds, they are often functionalized with mineral deposits including TCP275, 
HA272,277, and DCB282. In fact, a previous study from our group demonstrated that 
incorporating bovine DCB into 3D-printed PCL was sufficient to induce 
upregulation of bone-specific markers in ASCs27. We hypothesized that the 
presence of collagen in bovine DCB rendered it a more effective dopant than either 
HA or TCP, which are the two most commonly investigated materials in the field.  
To test this hypothesis, it was important to directly compare 3D-printed PCL-DCB 
with PCL-HA and PCL-TCP manufactured using similar protocols. Since the 
mineral phases of TCP and HA differ from that within native bone, we also included 
Bio-Oss in our analysis.  Bio-Oss is a commercially available bovine bone 
substitute which is available as granules (Geistlich Pharma AG, Wolhusen, 
Switzerland). It is processed from bovine bone and is treated to remove the organic 
or protein phase from material, resulting in a structure enriched in inorganic 
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mineral. An identical 3D-printing procedure was used to create PCL-TCP, PCL-
HA, PCL-BO, and PCL-DCB. The weight ratios were kept constant in all groups.   
While the osteo-inductivity of HA and TCP blends have been previously 
compared271, this study provides the first comparison of PCL-TCP, PCL-HA, PCL-
BO, and PCL-DCB with direct PCL for material and biological properties. 
This study directly compared the printability of common mineral 
components. Particles for each material were readily available or easily 
manufactured into an appropriate particle size for mixing with PCL and extruding 
through a small diameter nozzle (20-50µm particle diameter / 460µm nozzle 
diameter). Despite this size ratio, the pulverized materials (BO, DCB) sometimes 
clogged the nozzle during printing suggesting that the particles may clump during 
the process. The viscosity of the PCL melts increased with the addition of the 
mineral dopants resulting in reduced linear print rates. Previous work studying a 
range of DCB concentrations in PCL demonstrated a reduced printability with 
increased dopant concentration27, therefore 30% w/w was selected for this study 
to ensure that all groups would be manufacturable. While increasing the 
concentration of dopants also increased the osteoinductive effect and cell 
adhesion, it reduced the overall strength of the scaffold—we expect those trends 
would be replicated in the materials used in this study. Our print temperature and 
pressures are less than other reported values102,264, despite being well above the 
measured melt temperatures of the polymer phase. Design parameters were 
chosen according to previous optimization of our 3D-printed scaffolds for bone 
formation: 60% porosity, 800µm pore size, and strut thickness 460 µm26. Porosity 
was chosen at 60% to enable space for tissue formation and to arrive at a design 
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with sufficiently large pores, as the porosity and strut size directly determine the 
pore size in our 3D-printing system. Large, 1000 µm sized pores have been 
previously shown to be enhance ASC-driven bone formation greater than smaller 
pores283. Strut thickness was chosen to impart sufficient strength to the material.  
Variation in the print features was present in all material blends and did not 
correlate with any obvious feature of the various dopants. Despite the variation in 
print features, the mechanical and porous design goals were preserved. Increased 
strut width and reduced pore area is likely due both to swelling of the polymer after 
extruding through the die, which a normal feature of thermopolymer extrusion. The 
variations of material speed might be due to the varying amount of material in the 
print nozzle during a print, or a change in the printing environment (such as 
humidity or temperature) during a print, as the print times were long (between 30-
60 minutes for a two-layer sheet and 2-6 hours for a porous cube).  
We employed differential scanning calorimetry and found that the percent 
crystallinity of the PCL constructs reduced significantly when doped with the 
mineral particles. The particles likely inhibited the crystal growth of the material 
during the cooling phase as physical barriers284. In spite of this, the mechanical 
properties of the composite scaffolds did not exhibit drastic changes. Compressive 
mechanics of the materials were well suited to bone scaffolds, with compressive 
moduli around 250-300 MPa for bulk and 32-83 MPa for porous.  This exceeds 
some of the values typically reported for trabecular bone (compressive modulus 
0.5-14.6 MPa)285. Our results are similar with other reports of compressive moduli 
in bulk and porous PCL236,286–288. The reduction in compressive moduli in the 
porous scaffold is related to the decrease in solid material in columnar contact 
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along the direction of force (26% in porous vs solid, while porous moduli were 
reduced to 20% of solid). Doping with HA particles increased the mechanical 
stability of the solid and porous scaffolds. This is consistent with other studies, 
which have found that the inclusion of HA particles within bulk PCL material phase 
hardened the material and increased the elastic modulus274. They ascribed this 
result to the greater hardness of HA relative to PCL289,290. However, the 
mechanism by which strengthening occurs is unclear, particularly as all other 
dopants resulted in slightly lower (though not statistically significant) compressive 
moduli than that of pure PCL scaffolds. 
SEM images appeared to reveal sparse distribution of particles along the 
surfaced of the 3D-printed struts (Figure 6-1) with a greater amount within the 
center (Figure 6-2). However, the amounts of material on the surfaces were 
sufficient to be detected by Raman spectroscopy (Figure 6-6). See reference291 
for a complete list of bone wavelet assignments and reference284 for PCL 
assignments. The presence of material on the surface is important for increasing 
cell adhesion and contact-based signaling (such as ECM-integrins). The presence 
of mineral in the inner regions of the struts may be advantageous for long-term 
accessibility of the particles as they become more exposed as the PCL degrades. 
This arrangement may be particularly useful for TCP, which degrades relatively 
quickly. This distribution of particles throughout the struts was corroborated by the 
CT data. The CT images revealed mineral distribution through the strut. There was 
a distinct increase in opacity at the center of the strut relative to the edges, 
however, this profile may be due to the 3D-cylindrical profile of the struts.  
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Even though ASCs were suspended in fibrin hydrogels in the pore spaces 
of the scaffolds, their proliferation and calcium deposition were influenced by the 
presence of mineral in the scaffold struts. For example, cell proliferation in control 
medium conditions was significantly higher in the mineral-containing scaffolds 
relative to PCL only scaffolds. While the mechanistic reason for this is unknown, it 
is possible that the release of ions from the various calcium phosphates could be 
influencing these increases in proliferation292. Alternatively, ASCs might be 
responding to changes in topography at the surfaces of the struts. In general, when 
biochemical osteo-induction was used, proliferation was lower possibly due to the 
low-glucose environment. Interestingly, mineralization detected using alizarin red 
stains within the scaffolds was apparent not only at the surface of the scaffold in 
the control groups, where cells would have direct contact and binding with the 
particles present on the surface—but also throughout the bulk of the fibrin gel. This 
suggests that the effects of the bioactive scaffolds are not limited only to direct 
physical interactions between the cells and the biomaterials. The expression of 
Runx2, osteocalcin, and osteopontin data did not exhibit clear trends. However, 
upregulation of collagen 1 and osteonectin was clearly observed in the PCL-BO 
and PCL-DCB groups relative to PCL only when ASCs were cultured in control 
and osteo-induced medium. These are both key secreted matrix proteins with roles 
in mineral formation. These data correlate with the increased Ca/DNA in the PCL-
BO and PCL-DCB groups.  This correlation suggests that the natural apatite 
structure present in DCB and BO may be more effective at osteo-induction than 
either of the synthetic TCP or HA minerals. It is also possible that the osteo-
inductive signals are enhanced by the presence of the collagenous phase. While 
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Bio-Oss has been treated to remove the organic phase, the Raman spectroscopy 
data did reveal a small amide peak (# 9) that was also clearly evident in PCL-DCB 
but not in the PCL, PCL-TCP, or PCL-HA spectra.  However, it may also be that 
fewer of the TCP and HA particles were present on the surface of the struts and, 
hence, less potent. 
While the mineral dopant changes the bioactive and mechanical properties 
of PCL, we do not expect that the biocompatibility, degradation, or physiochemical 
properties will be reduced to invalidate PCL as the primary material choice for the 
scaffold. The biocompatibility and biodegradation of PCL293, TCP257, HA, and Bio-
Oss294 are well understood individually. PCL undergoes slow degradation via 
hydrolysis of the ester group239, while calcium phosphates undergo slight ionic 
dissolution in combination with resorption by osteoclasts295. Yeo et al have shown 
that inclusion of TCP in PCL scaffolds produces a slightly acidic environment 
during degradation in vitro269. While we have not investigated the degradation and 
biocompatibility properties of these scaffolds  directly, our previous in vivo work 
with 3D-printed PCL-DCB scaffolds did not give rise to any adverse inflammation 
events and the scaffolds were not visibly degraded after 12 weeks27.  
While this data confirmed clear advantages for using PCL-BO and PCL-
DCB, further work is required to improve the printability, speed, and potential for 
scale-up of the mineral-polymer scaffolds. This might be addressed through the 
use of a filament-based system, as used in Albrecht et al296. Additionally, the use 
of a photo-crosslinker to polymerize the PCL297 might be used in a digital light 
projection manufacturing system to improve the resolution and complexity of the 
scaffolds, in addition to enabling low-temperature production that might permit the 
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inclusion or retention of existing growth factors within an ECM or other GF-binding 
ingredient. The in vitro response of these materials combined with a more versatile 
manufacturing system will be further evaluated in vivo in a critical-sized or 
anatomically complex defect model.  
Conclusion 
We successfully 3D-printed several composite PCL-mineral scaffolds and 
compared their relative abilities to drive osteo-induction in ASCs. In this 3D-printing 
system, PCL-BO and PCL-DCB exhibited greater ability for osteoinduction than 
synthetic materials such as PCL-HA or PCL-TCP. PCL-DCB and PCL-BO blends 
induced significant increases in mineral deposition and upregulation of collagen 
and osteonectin relative to PCL only scaffolds. The PCL-TCP and PCL-HA 
scaffolds also showed some enhanced osteo-inductivity, though not to the same 
extent. This greater induction might be due to the presence of a collagen phase 
(as measured by Raman spectra), the structure of the apatite, or greater presence 
of the BO and DCB particles on the surface of the struts following the printing 
process. These results indicate that doping 3D-printed PCL scaffolds with DCB or 
BO might better support bone healing in vivo in comparison to TCP- or HA-doped 
grafts.    
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CHAPTER 6§§  
PREASSEMBLY TIME MODULATES THE VASCULOGENIC POTENTIAL  
OF ADIPOSE-DERIVED STEM CELLS IN PSUEDO-IMPLANT  
AND IMPLANT CONDITIONS  
 
Summary 
Pre-vascularization of tissue engineered grafts is a promising strategy to 
facilitate improved viability of transplanted cells following in vivo implantation. In 
this process, endothelial cells form a primitive capillary-like vascular network that 
can anastomose with blood vessels from the host. Adipose-derived stem cells 
(ASCs) are a commonly used cell population for tissue engineering and contain a 
subpopulation of endothelial cells capable of assembling into robust vascular 
networks when cultured in 3D fibrin hydrogels. However, their initial vascular 
assembly is significantly impaired in hypoxic conditions (2% O2). Previously our 
group found that a six-day period of normoxia (20% O2) produced stable vascular 
networks. When these structures were transferred to hypoxic conditions, the 
vessels remained patent and continued to grow. In this study, we explored the 
minimum period of normoxic pre-treatment required to enable the formation of 
stable vascular networks and the in vivo response. To test this minimum time, we 
pre-assembled ASC-vessels in normoxia for 0, 2, 4, or 6 days and then 
transplanted the grafts into hypoxic environments for six days. We assessed total 
vascular length, pericyte coverage, cell proliferation, apoptosis rates, and ECM 
production. There was a steady progression in vascular assembly over the 6 days 
                                            
§§ Adapted from Nyberg, E., & Grayson, W. (2018). Assessing the Minimum Time-Period of 
Normoxic Preincubation for Stable Adipose Stromal Cell-Derived Vascular Networks. Cellular and 
Molecular Bioengineering, 1-11. 
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of culture. However, our data showed four days as the minimum period of time 
required for stable vascular assembly to occur. We compared the major 
differences in cell behavior and network structure at Day 2 and Day 4. There were 
no differences in proliferation or apoptosis, however, the Day 4 time-point was 
associated with a significant increase in pericyte coverage (46.1±2.6%) compared 
to Day 2 (24.3±5.3%). Pharmacologic inhibition of pericyte coverage during vessel 
assembly resulted in a similar reduction in vessel length. These data suggest 
oxygen tension may be a mediator of endothelial cell-pericyte interactions during 
vascular assembly.  
Introduction 
Tissue engineered implants have the potential to treat a number of large 
volumetric musculoskeletal disorders and defects298 but are severely limited in 
scale by a lack of a perfused blood vessel networks299. The inclusion of functional 
vascular networks within tissue engineered constructs is a promising strategy 
when scaling from mouse- to human-sized applications in order to provide the 
oxygen, nutrients, and waste removal needed by tissues300. Neovascularization is 
a slow process with rates less than 1 mm/week301 and cellular constructs with 
thicknesses greater than 400 µm become rapidly necrotic due to the diffusion 
limitation of oxygen302. Hence, the inability to provide sufficient vascularization has 
limited the clinical use of tissue engineered implants. Several approaches to create 
tissue engineered scaffolds with functional vascular networks have been reported. 
These include 3D-printing channels for vessel ingrowth303, releasing angiogenic 
growth factors from the scaffold212, and periods of in vitro culture to ‘pre-
vascularize’ the construct before implantation304,305.  
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Pre-vascularization is a highly promising strategy in which endothelial cells 
(ECs) are stimulated to form nascent capillary-like vascular network structures that 
can anastomose with the host vasculature. In order to form stable networks, ECs 
are typically co-cultured with fibroblasts306, mesenchymal stem cells307,308, or 
pericytes309, which act as perivascular cells and stabilize the vascular networks. 
Recently, adipose-derived stem cells (ASCs) from human lipoaspirate tissues 
have been shown to be a suitable source of ECs and perivascular cells. The 
vascular potential of ASCs arises, due to a sub-population of endothelial cells 
(ECs) at early passages310,311 as well as their limited ability to differentiate into 
ECs312,313. ASCs also include a pericyte or pericyte-like population314 and pericytes 
have potential to modulate the effect of angiogenic therapies315. When cultured in 
fibrin hydrogels, the EC sub-population within ASCs exhibit the potential to form 
extensive, interconnected vascular network structures131,316 that survive in vivo 
implantation316.  
The capacity of ECs and ASCs to assemble into vascular networks is highly 
oxygen-dependent. Specifically, hypoxic conditions (<5% O2) inhibit the self-
assembly of vascular networks. Hypoxia (5% O2) prevented the self-assembly of 
vascular networks in a co-culture of human endothelial colony forming cells and 
multipotent stromal cells317. Griffith and George have shown that in addition to 
inhibiting self-assembly, challenging constructs with hypoxia after a period of 
preassembly leads to the degradation of capillary networks318.  More recently, it 
has been shown that hypoxia inhibits de novo assembly of ASC-derived vascular 
networks246. These reports run counter to the predominant narrative of hypoxia as 
a pro-angiogenic stimulus. In fact, while hypoxia drives new blood vessel formation 
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via angiogenesis (and is a key mechanism underlying tumor vascularization), low 
oxygen tension is a known inhibitor of vascular assembly. Interestingly, while 
hypoxia inhibits the de novo vascular assembly of ASCs and their EC sub-
populations, transferring pre-assembled ASC-vessels into hypoxic environments 
stimulated their growth246. Prevascularization strategies therefore require 
understanding the impact of oxygen on the kinetics of assembly and stabilization.  
In this study, we aimed to determine the minimum amount of normoxic (20% 
O2) preassembly time that is needed for ASC-vascular networks to stabilize so that 
they when transferred to hypoxic (2% O2) conditions, the vessels would continue 
to elongate. To assess this, ASCs were cultured in fibrin hydrogels and allowed to 
pre-assemble into vascular network structures for 0, 2, 4, or 6 days. At the end of 
each of these pre-incubation periods, we split the cultures into two and transferred 
one group to continued normoxic cultures and the other group to hypoxic (2% O2) 
culture conditions for a further 6 days (Figure 7-1). We assessed geometric and 
cellular properties of the networks to establish the underlying mechanism 
mediating the switch in behavior of endothelial cells to hypoxic environments. 
These studies suggest that the interactions between endothelial cells and pericyte-
like populations are strongly oxygen-and time-dependent. Further understanding 






Figure 7-1: Schematic of the Psuedo-Implantation Study.  
Gels of ASC aggregates were allowed to preassemble for 0, 2, 4, or 6 
days in normoxia with regular feedings before moving into a psuedo-
implant condition for 6 days.  
 
Materials and Methods 
ASC Isolation and Culture 
Human subcutaneous adipose tissue was obtained in the form of 
lipoaspirate from 3 female Caucasian donors undergoing elective surgery and with 
written informed consent under the approval of the Johns Hopkins Medicine 
Institutional Review Board. ASCs were isolated as previously described246,319. 
Briefly, tissue was digested with collagenase (1 mg/mL; Worthington Biochemical 
Corp.) to isolate the stromal vascular fraction of cells. These cells were plated onto 
tissue culture plastic and were termed “passage 0 ASC” when they reached 80-
90% confluence. ASCs were used at passage 2 for all experiments. Growth 
medium consisted of: high glucose DMEM (Gibco) with 10% fetal bovine serum 
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(FBS; Atlanta Biologicals), 1% penicillin/streptomycin (Gibco), and 1 ng/mL basic 
fibroblast growth factor (FGF-2; PeproTech).  
Cell Aggregation via Suspension Culture 
Cells were trypsinized and resuspended at a concentration of 250,000 
cells/mL in growth medium containing 0.24% (w/v) methylcellulose (Sigma). The 
cell suspension was pipetted into 10-cm Petri dishes coated with 2% (w/v) agarose 
to minimize cellular adherence to the dish. After overnight suspension culture, 
cellular aggregates were collected with a pipette, and then centrifuged before 
encapsulation procedures. 
Aggregate Encapsulation and Culture 
Pre-assembly culture: Cell aggregates were suspended in fibrinogen (8 
mg/mL final; Sigma) and thrombin (2 U/mL final; Sigma) at a final cell concentration 
of 2 x 104 cells/μL. Fibrin gels were formed by pipetting 12 μL of gel solution into 
4-mm diameter wells and incubating at 37ºC for 30 min to allow complete gelation 
before adding medium. Each gel sample was fed with 1 mL of culture medium 
containing: Endothelial Basal Medium-2 (EBM-2, Lonza), 10% FBS, and 1% 
penicillin/streptomycin. The media was not supplemented with growth factors 
beyond those naturally present in serum. To assess the effect of preassembly on 
future hypoxic cultures, freshly encapsulated cells were cultured in normoxia (20% 
O2) for 0, 2, 4, or 6 days with the medial changed every other day to create different 
degrees of vascular networks.   
Pseudo-implantation culture: On the last day of preassembly, the samples 
were fed once more and then cultured in either normoxia or hypoxia (2% O2) for 
an additional 6 days with no media changes (Figure 7-1). Normoxic samples were 
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maintained in a 37ºC incubator with 5% CO2, 95% ambient air. Hypoxic samples 
were placed in a modular incubator chamber (Billups-Rothenberg) that was flushed 
every day with pre-mixed gas (2% O2 / 5% CO2 / N2 balance) and placed in a 37ºC 
incubator. 
Proliferation Labelling 
Cells were incubated with bromodeoxyuridine (BrdU, Sigma) to detect 
proliferating cells. Briefly, 10 μM BrdU was pipetted into existing culture medium 
(i.e. medium was not changed), and samples were quickly returned to their 
appropriate oxygen environment (less than 5 minutes of normoxic exposure) for a 
20-hour incubation. Samples were then washed with PBS and fixed with 3.7% 
formaldehyde. 
Whole-mount Immunostaining 
Whole-mount immunostaining of fibrin gels was performed as previously 
described131. Briefly, samples were fixed with 3.7% formaldehyde for 3 hours at 
4ºC, washed with PBS, and blocked with 5% normal goat serum / 0.2% Triton X-
100 / PBS for 3 hours at 4ºC. Antibodies were incubated overnight at 4ºC, followed 
by three 1-hour washes in PBS with 0.1% Tween. Primary antibodies included: 
mouse anti-human CD31 (4 μg/mL, Sigma), mouse anti-human collagen IV (20 
µg/mL, Santa Cruz Biotech), and Cy3-conjugated mouse anti-alpha smooth 
muscle actin (αSMA; 7 μg/mL, Sigma). Secondary antibodies used included: 
DyLight 488-conjugated goat anti-mouse (3.75µg/mL, Jackson ImmunoResearch), 
cy3-conjugated donkey anti-mouse (7 µg/mL, Jackson ImmunoResearch), biotin-
conjugated goat-anti mouse (5.5 µg/mL, Jackson ImmunoResearch) and 
fluorescein-conjugated streptavidin (4.5 µg/mL, Jackson ImmunoResearch). Prior 
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to secondary labelling for incorporated BrdU, samples were stained for all other 
antigens and post-fixed with 3.7% formaldehyde for 30 min to preserve the stain. 
Samples were then denatured with 2N HCl / 0.5% Triton X-100 for 45 minutes at 
room temperature, washed, re-blocked, and then incubated with AlexaFluor 647-
conjugated mouse anti-BrdU (4 μg/mL, Invitrogen) overnight at 4ºC. Cell nuclei 
were counterstained with 4’-6-diamidino-2-phenylindole (DAPI; Sigma). 
Apoptosis Staining 
The APO-BrdU TUNEL assay kit (Invitrogen) was used following 
manufacturer protocol before staining for other antigens. Briefly, samples were 
fixed in 70% ethanol at -20ºC for one week, rinsed in wash buffer for 20m twice, 
incubated with DNA-labelling solution for 4h in a shaking water bath, washed with 
rinse buffer twice for 20m at 4ºC, and stained with Alexa Flour 488-conjugated 
mouse anti-BrdU overnight at 4ºC. Samples were co-stained with DAPI.  
Imaging and Analysis 
Immunostained gels were mounted on glass slides and imaged using a 
Zeiss LSM 510 confocal microscope (5x and 20x objectives). Confocal z-stacks 
were z-projected and thresholded for quantification. AngioQuant320 software was 
used to quantify total vessel length (sum of the lengths of all vessel branches within 
a gel). Matlab (Mathworks) was used for all other image analysis. Pericyte 
coverage was defined as αSMA+ area within at least 5 μm of the abluminal face 
of vessel networks. Briefly, vessel networks were selected in the CD31 channel of 
thresholded image composites. Selections were enlarged by 5 μm at all edges and 
applied to the αSMA channel. αSMA+ area fraction within the selected area was 
measured and displayed as “Percent SMA Coverage”. BrdU+ nuclei were counted 
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and counts from the whole gel indicate overall proliferation within the culture 
(displayed as “# BRDU/CD31 (#/mm2)”. To assess proliferation within the vessels 
only, CD31+ vessel area was selected and applied to the BrdU channel prior to 
counting within the selected area. This count was normalized to the CD31+ vessel 
area to account for differences in vessel density and is displayed as “#BRDU in 
CD31”.  
Animal Studies  
All studies were approved by the Johns Hopkins University IACUC. Male 
nude immunocompromised mice (fox1n1, Charles River) were used at 8 weeks of 
age. To locate cells after implantation, cells were prepared and seeded as above 
into porous 3D-printed polycaprolactone (4mmx8mmx2mm, 70% porous) 
scaffolds. Four subcutaneous pockets were created on the dorsum of each mouse 
via blunt dissection.  After one week, constructs were recovered en bloc with the 
surrounding skin and imaged on a Zeiss Discovery V8 stereoscope.  
Statistical Analysis 
Quantitative data are expressed as mean ± standard error. Statistical 
analyses were performed using GraphPad Prism 5 software. Statistical 
significance was determined by one-way ANOVA with Tukey’s post-test and is 




Figure 7-2. Assessing Vascular Length.  
A. ASCs grown in fibrin hydrogels for 6 days sprouted into vascular 
network structures that stained positively for CD31. At 0, 2, 4, and 6 days 
ASCs were transferred to either normoxic or hypoxic pseudo-
implantation conditions for a subsequent 6 days. B. Measurements of 
total vessel length. Gray lines indicate preimplantation length. * = p < 




Preassembly-Mediated Vascular Assembly  
ASC aggregates underwent vascular morphogenesis and developed a 
highly-branched vascular morphology when cultured in the fibrin hydrogel for 6 
days in normoxic conditions (Figure 7-2A). The ASCs used in this study are 
isolated via plastic adherence and contain a minute population of CD31-positive 
cells246,310, which we understand to be the building block of the vascular network, 
rather than ASCs differentiating into ECs. The vascular lengths at 2, 4, and 6 days 
were 30.9±7.7mm, 43.6±10.9mm, and 61.2±15.3mm, respectively (Figure 7-2B). 
With 0 days pre-assembly, subsequent culture in either normoxia or hypoxia for 6 
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days without media changes (pseudo-implantation model) resulted in no visible 
vascular assembly, demonstrating the nutrient-starving nature of the pseudo-
implant condition alone is sufficient to impair vascular assembly.  However, with 
two days of preassembly, ASCs in the normoxic pseudo-implant condition 
assembled into preliminary branching structures with significantly greater vessel 
length (67.2±16.8mm) than the hypoxic pseudo-implant (38.4±9.6mm). After four 
days of preassembly, transplantation of the vascular structures into either 
normoxic or hypoxic pseudo-implantation conditions for 6 days resulted in 
continued vascular development and the formation of interconnected networks 
(72.3±17.8mm vs. 75.4±18.5mm, respectively). Similarly, with a full six days of 
preassembly ASC vascular networks continued to branch and develop into highly 
interconnected and dense vascular networks after pseudo-implantation in 
normoxia (77.4±19.3mm) and hypoxia (92.8±23.2mm). Hence, with 0 or 2 of 
preassembly in a favorable, normoxic environment, transfer to hypoxic 
microenvironments had detrimental effects on vascular morphogenesis. However, 
following 4 or 6 days of pre-assembly, transfer to hypoxic microenvironments 
appeared to be supportive of subsequent vascular assembly. Thus, we observed 
a time-dependent change in the effect of hypoxia on ASC-derived vascular 




Figure 7-3. Proliferation Analysis.  
A. BRDU staining overlaid with CD31. B. Total number of BrdU+ nuclei 
within CD31 in each gel. C. Number of BrdU+ nuclei normalized to the 
area of CD31 in each gel. * = p < 0.05, ** = p < 0.005, *** = p < 0.0005, 
n = 5, Scale bar = 100µm.  
 
Endothelial Cell Proliferation 
Endothelial cell proliferation was assessed by monitoring the incorporation 
of the thymidine analog BrdU into CD31+ cells during mitosis over the final 20h of 
culture (Figure 7-3). Proliferation predominantly occurred within CD31+ areas. We 
hypothesized that endothelial cells might be in a more proliferative state with 
increasing amounts of preassembly. While this hypothesis is supported by the 
large increase in number of BrdU+ nuclei within CD31+ regions at six days of 
preassembly, only a slight increase was observed between two and four days of 
preassembly (Figure 7-3B, day 2 and 4: 22.8±9.2 and 32.7±4.6, day 6: 99.3±49).  
However, this trend is not present when the number of BrdU+ nuclei was 
normalized to the CD31+ area (Figure 7-3C). The spike in #BrdU/CD31 at two 
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days of preassembly (2295.9±276.2 #/mm2) is due in part to the very small area 
fraction of the gel that is CD31+ at that time, resulting in division by a very small 
number. After pseudo-implantation, proliferation is greater in normoxic than 
hypoxic groups with zero (hypoxic 870.0±381.1, normoxic 1201.7±340.1 #/mm2) 
and two days of preassembly (hypoxic 270.0.0±38.8, normoxic 995.1±143.1 
#/mm2), and then switches to be increased in hypoxic groups with four (hypoxic 
1038.6±226.6, normoxic 594.4±132.7 #/mm2) and six days of preassembly 
(hypoxic 1304.7±341.6, normoxic 437.9±68.0 #/mm2). These results are similar to 
our total vessel length analysis, indicating that cultures with four or more days of 
pre-assembly entering a more proliferative state after exposure to hypoxia.  
Apoptosis Analysis 
To determine if cells were undergoing apoptosis at an increased rate in 
hypoxia—as opposed to proliferating at an increased rate—a TUNEL assay was 
used to label the nicked ends of nuclear DNA as it was reduced into 200bp 
fragments by the apoptotic cascade (Figure 7-4). There was an increase in the 
number of apoptotic cells during the preassembly period (days 2, 4, 6: 52.5±4.2 to 
129.0±20.3 to 228.2±10.1), and in the normoxic groups after the pseudo-
implantation period relative to parallel hypoxic conditions (228.0±68.7 to 
1120.0±333.6 with 4-day preassembly; 688.5±55.9 to 1164.0±293.9 with 6 days 
preassembly). Therefore, it is more likely that cells are simply not proliferating in 
hypoxic conditions instead of undergoing apoptosis.  
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Figure 7-4. Quantification of Apoptotic Cells.  
A. TUNEL staining of apoptotic cells in the fibrin hydrogel. TUNEL = 
green, DAPI = blue. B. Quantification of apoptotic cells during 
preassembly and post-pseudo implantation * = p < 0.05, n = 4, Scale bar 
= 400µm. 
 
Pericyte and Collagen IV Coverage Analysis   
Pericyte coverage of vessels was analyzed by staining for αSMA fibers co-
localized within 5µm of CD31+ areas (Figure 7-5 and 7-6). Pericyte coverage was 
significantly increased from two to four days of preassembly (24.3±5.3% to 
46.1±2.6%; p < 0.005). αSMA coverage in normoxic groups post-pseudo 
implantation with 4 and 6 days of preassembly was greater than parallel hypoxic 
groups. In fact, despite the hypoxic groups increasing total vascular length with 
time, they demonstrate decreasing αSMA coverage post-psuedo-implantation 
from two to four to six days of preassembly (51.9±7.2% to 25.2±4.8% to 9.8±1.9%). 
This decrease in αSMA coverage might be due to pericytes migrating away from 
their classical position on the abluminal wall of a tubule to facilitate greater growth 
in hypoxia321.  
Therefore, we hypothesized that a more mature vascular structure with 
greater pericyte coverage was surviving and thriving in the hypoxic environment 
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and tested by using a pharmaceutical inhibitor of pericyte coverage. Additionally, 
one of the functions of the pericytes is to deposit collagen IV into a basement 
membrane which can provide supportive signaling to endothelial cells during 
hypoxia322. Pericytes were inhibited with AG1295 and the vascular assembly was 
contrasted with co-localization of collagen IV. AG1295 significantly inhibited 
vascular assembly at days four and six of preassembly relative to untreated 
controls (Figure 7-7A, day 4: 6.22±0.55 to 2.57±0.26; day 6: 7.73±0.55 to 
3.57±0.52 mm/mm2) and almost totally eliminated collagen IV deposition 
throughout the construct (Figure 7-7B, day 6: 20.7±2.80% to 2.2±0.13%, p < 0.05). 
Within CD31+ regions, AG1295 significantly reduced collagen IV deposition at all 
timepoints (Figure 7-7C, p < 0.005).  
 
Figure 7-5. Analysis of Pericyte Coverage.  
A. Constructs at days 2 and 4 of preassembly stained for pericytes 
(aSMA, red) and endothelial cells (CD31, green). B. Quantification of 
αSMA+ coverage of CD31+ vessels during vascular assembly of ASCs 
during preassembly and following transfer to pseudo-implant conditions.  
** = p < 0.005, n = 5, Scale bar = 100µm.  
137 
 
Figure 7-6 Schematic of Pericyte Coverage Calculation.  
First the CD31 channel was isolated and the resulting vessels dilated 
5µm. The SMA channel was then isolated and trimmed to the area of 
dilated vessels, and the trimmed area of SMA relative to the dilated 






Figure 7-7. Assessment of Vascular Structure Following AG1295 Inhibition.  
A. Vascular density of CD31+ networks. B. Total area fraction of Col IV 
in the gel. C. Area fraction of CD31 positive for Col IV. * = p < 0.05, ** = 




After one week of implantation in the subcutaneous environment, cell-laden 
constructs were recovered and imaged. Constructs without preassembly show 
poor vascularity, while constructs with four and six days of preassembly have 
visible vasculature (Figure 7-8).  
 
 
Figure 7-8. Gross Pictures of Subcutaneous Implants.  
Cells with varying amounts of preassembly were implanted into mice for 
one week subcutaneously. Porous 3D-printed scaffolds were used as a 




The hypoxic microenvironments within volumetric tissue defects provide 
serious challenges to cell-based regenerative strategies. Hypoxia impairs cell 
survival and hypoxia vascular assembly of transplanted ECs used to rapidly 
vascularize engineered grafts246,317,318. The data in the current study confirm that 
hypoxia is inhibitory to the earliest stages of vascular assembly. To overcome this 
limitation in the therapeutic application of ASCs, one solution is to preassemble 
the vascular networks before implantation. A preassembly period allows for a 
number of organizational and construction steps in vascular assembly to take 
place in a metabolically favorable environment. However, preassembly 
approaches have regulatory and manufacturing drawbacks. In this study, we 
modeled preassembly using a culture period with abundant nutrients and oxygen. 
Additionally, we investigated several parameters of vascular assembly during the 
preassembly period to characterize the tissue features that would support further 
growth in hypoxia. The data herein suggest that at minimum, four days of normoxic 
and nutrient-rich conditions are required before implantation into a hypoxic or 
ischemic environment. Such a period allows for a sufficient amount of pericyte and 
collagen IV coverage to develop and supports the growth and proliferation of 
endothelial cells in a future hypoxic and nutrient-starved environment.  
We found that pericyte-like cells in ASC cultures are essential stabilizers of 
vascular structures. Inhibition of pericyte-like cell recruitment via blocked PDGF-
BB signaling closely mimics inhibition of vascular assembly in hypoxia.  This 
suggests that hypoxia delays the contributions of pericyte-like cells during vascular 
assembly. Previous work identified pericyte-like ASCs as an important component 
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of ASC-vascular assembly  (via heterotypic cell assembly)310. Pericytes have well 
defined functions in microvascular systems controlling EC proliferation, sprouting, 
and stabilization323 via factor signaling, regulation of the basement membrane 
ECM, and cell-cell contact signaling via Notch pathways324,325. Indeed, pericyte-
EC interactions are required for proper basement membrane ECM formation with 
fibronectin, laminin, vitronectin and collagen IV proteins, which together tune 
vascular tube formation via EC integrin interactions322,326. Further, EC integrin 
sensing of vitronectin drives expression of the antiapoptotic protein Bcl-w and 
autocrine expression of VEGF-A327,328.   
Hypoxia inhibits vascular assembly of individual ECs but promotes 
angiogenesis of ASC-vessels that have at least four days of preassembly.  In 
general, hypoxia at physiologic (20 mmHg in bone vs 160 mmHg in atmospheric 
air) or slightly lower levels causes an increased amount of EC proliferation and 
angiogenesis329. However, EC-vasculature also regresses via apoptosis in 
response to severe hypoxia (1% or less)330,331 in contrast to the positive angiogenic 
effects of less severe hypoxia. The idea of a sufficient amount of preassembly is 
required for hypoxic function supplants the idea that exposure to hypoxia supports 
vascular growth, via increased expression of VEGF and increased tubule 
formation332. These hypoxic vascular-boosting effects have traditionally been 
observed with vascular explants or other structures that have already been 
assembled, and not with individual ECs.   
These findings suggest that direct implantation of a vascular population may 
not be sufficient to provide assembled vasculature to the construct before the 
development of anoxia and associated necrosis. However, this four day period of 
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assembly might be achievable in vivo using approaches that can deliver oxygen 
and other nutrients during the first four days of implantation333. One such approach 
utilizes oxygen-releasing materials in 3D-printed bone scaffolds, and can sustain 
delivery periods up to 48 hours long334.  
While the time-scale of vasculogenesis in fibrin hydrogels depends on the 
cell types and growth media, the assembly of a robust vascular network can 
commonly be observed in as little as six days in a number of systems322,335,336.  
Chen et al. compared vascular fibrin constructs with and without one week of 
preassembly in vivo and found that preassembly accelerated anastomosis with 
host vasculature, increased proliferation of implanted cells, and increased 
production of ECM, confirming that a period of preassembly is critical to in vivo use 
of vascular hydrogels 336. However, it is important to limit the amount of 
preassembly as vessels may regress without perfusion and other physiological 
maturation cues337. Additionally, there are potential benefits to limiting culture time 
as studies have shown that culture on tissue culture plastic could induce cell fate 
plasticity338,339. Perfusion of vascular networks drives their maturation and 
remodeling340,341 and was not included in the current study. The increased 
apoptotic rate observed in normoxia might be due to natural pruning/regression as 
they have matured without a hypoxic or fluid shear stress signal. Remodeling is 
further driven by the transport demands of the surrounding tissue exceeding the 
ability of diffusion329.  
The distance between individual ECs impacts the paracrine gradient and 
might have an impact on the rate of vascular assembly. Previous experience310 
revealed higher seeding densities lead to a more rapid assembly of vascular 
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networks, perhaps due to the close positioning of ECs to each other at high 
seeding densities. MacGabhann et al demonstrated local gradients of VEGF have 
an effect on vascular assembly in skeletal muscle over distances as short as 
10µm128. Other groups342,343 have modeled tip cell interaction by pairing 
computational and experimental models, but highlight that there are additional 
complicating factors beyond tip distance and VEGF gradients (such as Notch and 
EC-PC signaling) which add complexity to the system. This gradient-sensing and 
-directed vascular growth is increasingly important as systems become more 
complicated with anatomic geometries and physical barriers to vascular networks, 
avascular border regions between implant scaffold and host vasculature, and 
approaches where the cell density is limited.  
ECs are highly sensitive to changes in oxygen levels through the hypoxia 
induced factor (HIF) family of transcription factors, metabolism, hypoxia-regulated 
microRNAs, causing upregulation of vascular endothelial growth factor (VEGF) 
and its receptors329. VEGF is a potent mitogenic for ECs, which supports network 
assembly via angiogenesis or vasculogenesis344. While we did not measure 
variable production of growth factors as a function of preassembly here, previous 
studies found VEGFA production by ASC-vessels was only upregulated in severe 
(0.2% O2) hypoxia after normoxic preassembly for 6 days246. Such induction of 
VEGFA expression might be useful in large scale applications, where despite 
vascular preassembly, anastomosis and blood flow to interior regions might be 
delayed, result in network regression, and the associated VEGFA aiding those 
regions in undergoing revascularization.  
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Conclusion 
This study sought to elucidate the processes active during ASC-vascular 
assembly that might support the beneficial response of ASC-vasculature 
morphogenesis in hypoxia. It builds upon previous work that de novo assembly of 
ASC-vasculature is inhibited in hypoxia. In ASC-fibrin constructs with less than 4 
days of preassembly, hypoxia drove disassembly of vascular structures. However, 
with a minimum of 4 days preassembly before exposure to hypoxia resulted in 
robust vasculature network formation, whereupon hypoxia drove increased 
network formation. The main difference observed between 2 and 4 days of 
preassembly was a significant amount of pericyte coverage, and inhibition of that 
coverage similarly inhibited vascular formation. This suggests the interactions 






COMPARISON OF STROMAL VASCULAR FRACTION AND PASSAGED 
ADIPOSE-DERIVED STROMAL/STEM CELLS AS POINT-OF-CARE AGENTS 
FOR BONE REGENERATION 
Summary 
Large craniofacial bone defects remain a clinical challenge due to their 
complex shapes and large volumes. Stem cell-based technologies that deliver 
osteogenic stem cells have shown remarkable regenerative potential but are 
hampered by the need for extensive in vitro manipulation prior to implantation. To 
address this, we explored the bone forming potential of the clinically-relevant 
stromal vascular fraction (SVF) cells obtained from human lipoaspirate. SVF cells 
can be isolated for acute use in the operating room and contain a sub-population 
of adipose-derived stem cells (ASCs) that can develop mineralized tissue. ASCs 
can be purified from the more heterogeneous population of SVF cells via 
secondary and tertiary culture on tissue culture plastic. In this study, the relative 
potential for using SVF cells or passaged ASCs to induce robust bone regeneration 
was compared.  Isogenic SVF and ASCs were suspended in fibrin hydrogels and 
seeded in 3D-printed osteoinductive scaffolds of decellularized bone matrix and 
polycaprolactone. In vitro, both cell populations successfully mineralized the 
scaffold, demonstrating the robust bone formation properties of SVF. In murine 
critical-sized cranial defects, ASC-loaded scaffolds had greater (but not statistically 
significant) bone volume and bone coverage area than SVF-loaded scaffolds. 
However, both cell-laden interventions resulted in significantly greater bone 
                                            
*** Adapted from Nyberg, E., Farris, A., O'Sullivan, A., Rodriguez, R., & Grayson, W. L. (2019). 
Comparison of SVF and Passaged ASCs as Point-of-Care Agents for Bone Regeneration. Tissue 
Engineering Part A, (ja). 
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healing than contralateral acellular controls. In conclusion, we observed 
substantial in vitro mineralization and robust in vivo bone regeneration in tissue 
engineered bone grafts using both SVF and passaged ASCs. 
Introduction 
Annually, there are over 200,000 bone replacements for reconstruction of 
craniomaxillofacial (CMF) bones in the United States1. Reconstructive surgeries 
are performed following trauma, congenital malformation, or cancerous re-
sectioning. While bone is a self-healing organ, critical-sized (non-healing345) CMF 
bone defects are challenging to treat due to their geometric complexity and the 
volume of viable bone needed. Compared with other bony defects, massive loss 
of CMF bone structure is more likely to cause disfigurement and psychosocial 
pathologies250,346. The current standard of care is the free fibular bone graft, which 
poorly replicates the mechanics and anatomy of defects, is resorbed at high 
rates16, exhibits a slow rate of conduction from the surrounding bone 
(~1cm/month)347, and may be negatively impacted by other comorbidities that 
impair bone healing, such as radiation osteonecrosis348. Alternatively, stem cell-
mediated bone regeneration349 using tissue engineering strategies has significant 
potential for regenerating massive CMF defects. 
Adipose-derived stem cells (ASCs) have been considered as a potent 
cellular agent for tissue engineering and regeneration: they are readily available in 
patients, their isolation causes limited morbidity, they possess multipotency for 
bone and cartilage, and they are potent agents of neovascularization26,245. 
Compared to the bone marrow mesenchymal stem cells (MSCs) however, ASCs 
reportedly have lower relative osteogenic potency350,351. Consequently, additional 
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processing steps are required to promote osteogenic differentiation and thus for 
them to function as skeletal progenitor stem cells352. Accordingly, most reported 
strategies are limited by the need for extensive in vitro manipulation of the ASCs 
to generate an osteogenic phenotype prior to implantation. ASCs are derived from 
the adherent sub-population of the stromal vascular fraction (SVF) of cells from 
lipoaspirate. They are a less heterogenous population of cells than SVF311,353. In 
particular, the sub-population of endothelial cells is reduced in ASC cultures. Prior 
studies have demonstrated that bone forming cells and endothelial cells together 
elicit greater bone formation responses than alone354,355. Therefore, the inherent 
heterogeneity of SVF might be advantageous to bone regeneration.   
SVF is a potential alternative cell source for bone regeneration to ASCs that 
may be used intraoperatively356–358. Prior uses of SVF in small-animal models and 
in human clinical trials24 have yielded mixed results. Güven et al. compared SVF 
seeded for five days in a perfusion bioreactor before ectopic implantation in rats 
with isogenic ASCs and bone marrow stem cells (MSCs) that had been similarly 
prepared. They found SVF-seeded constructs had faster tissue in-growth, 
increased vasculature, and bone formation compared to ASCs and MSCs359. Rhee 
et al. used syngeneic rat SVF in a cranial model which increased regeneration from 
13% in acellular controls to 58% in SVF groups360. Finally, Prins et al. used 
autologous SVF in maxillary elevation surgery in humans and found very slight 
improvements in bone volume and area when SVF was included compared to 
acellular contralateral treatments361.  
There are several case reports of SVF/ASCs used to treat volumetric CMF 
defects in human. First, Lendeckel et al. reported on SVF in combination with 
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milled iliac bone, resorbable microporous sheets, and fibrin glue with excellent 
results 3 months post-operatively362. Mesimäki et al. used ASCs, bone 
morphogenic protein-2, and beta-tricalcium phosphate to develop an ectopic bone 
flap to successfully create a neomaxilla with good results 1 year postoperatively363. 
Sándor et al. used autologous cultured ASCs as an adjuvant to implants/bone 
granules in a variety of craniofacial defects. They found acceptable hard-tissue 
graft function in mandibular and midface locations. However, cranial defects 
showed unexpected resorption rates364 and the six-year follow-up was 
unsatisfactory365.  SVF treatments have not demonstrated a robust amount of bone 
formation in humans, nor have they improved bone healing compared to standard-
of-care or acellular treatments.  
In this study, we explored the potential of human SVF to enable robust bone 
regeneration in vitro as well as within orthotopic in vivo murine calvarial defect 
implantation models. The SVF was obtained from human donors and immediately 
combined with 3D-printed osteoinductive scaffolds232,366 in the absence of growth 
factors to mimic an intraoperative procedure. Further, we sought to determine 
whether the bone regeneration potential of the SVF was comparable to that of 
isogenic ASC populations similarly seeded in 3D-printed scaffolds. We performed 
similar study in scaffolds of larger volumes and implanted intramuscularly to 
evaluate the angiogenic characteristics of SVF and ASCs. To our knowledge, this 
is the first study to directly compare the osteogenic and angiogenic potential of 
intraoperative SVF with isogenic ASCs. 
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Materials and Methods 
Study Design 
SVF was isolated from human lipoaspirate and cultured to obtain isogenic 
ASCs. Flow cytometry characterization was performed on all cell populations. The 
bone forming potential of the cells was then assessed in 3D-printed scaffolds in 
vitro and orthotopically in vivo. The vascular potential of the cells was also 
examined in vivo using an intramuscular model. In vitro results were the average 
of all six donors, while only one donor was used for in vivo studies. The study 
design is summarized in Figure 7-1.  
 
Figure 7-1. Schematic of study design  
Cells were sourced from human donors undergoing elective cosmetic 
liposuction. Freshly isolated cells (SVF) and isogenic cultured cells 
(ASCs) were used in all the experiments. Cells were evaluated with flow 
cytometry and used for in vitro differentiation and in vivo tissue formation 
assays. 
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Cell Isolation and Culture 
Human subcutaneous adipose tissue was obtained in the form of 
lipoaspirate from six female Caucasian donors undergoing elective surgery, with 
written informed consent, and with Institutional Review Board approval (#846242-
1). ASCs were isolated as previously described246,319. Briefly, tissue was digested 
with collagenase type 1 (1 mg/mL; Worthington Biochemical Corp.) to isolate the 
stromal vascular fraction of cells. Cells were filtered through a 100µm filter and 
termed "SVF." SVF was directly seeded into scaffolds or used for flow cytometry. 
Cells not used as SVF were plated onto tissue culture plastic and were termed 
“passage 0 ASC.” Cells were passaged with trypsin when they reached 80-90% 
confluence, termed "passage 1 ASCs". Upon reaching 80-90% confluence, these 
cells were lifted with trypsin and used as "passage 2 ASCs" for all experiments 
with ASCs groups. Growth medium consisted of: high glucose DMEM (Gibco) with 
10% fetal bovine serum (FBS; Atlanta Biologicals), 1% penicillin/streptomycin 
(Gibco), and 1 ng/mL basic fibroblast growth factor (FGF-2; PeproTech).  
Flow Cytometry  
Cell surface markers were analyzed using flow cytometry to determine cell 
phenotype: mesenchymal (CD73), endothelial (CD31), stem/progenitor (CD34), 
and hematopoietic (CD45). Briefly, SVF cells were resuspended and passaged 
ASCs were detached and resuspended in phosphate buffered saline (PBS) 
containing 2% fetal bovine serum. Cells were then incubated with monoclonal 
antibodies conjugated to fluorescein isothiocyanate, phycoerythrin, or PerCP-
Cy5.5 for 30 minutes at 4°C and cell surface markers were analyzed on a Sony 
SH800 cell sorter. All markers were acquired from BD Biosciences (Table 7-1).  
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Table 7-1. Flow Cytometry Antibodies 
 Isotype Clone Stain Manufacturer Catalog # 
CD34 Mouse IgG1 κ 8G12 PerCP-Cy5.5 BD Biosciences 347203 
CD45 Mouse IgG1 κ HI30 PerCP-Cy5.5 BD Biosciences 564106 
CD31 Mouse IgG1 κ WM59 FITC BD Biosciences 555445 
CD73 Mouse IgG1 κ AD2 PE BD Biosciences 561014 
 
Preparation of DCB 
All materials were obtained from Sigma unless otherwise stated. Calf knees 
were obtained from Green Village Packing Co (Green Village, NJ). Decellularized 
bovine bone extracellular matrix (DCB) was obtained by isolating trabecular bone 
from calf knees. The bone was decellularized using a protocol as described 
previously27. Briefly, trabecular bone fragments were blasted with water to remove 
as much cellular debris as possible. The bone fragments were then placed in a 
series of four detergent washes of 0.1% EDTA for 1 h, 0.1% EDTA/10 mM Tris for 
12 h, 0.5% SDS/10 mM Tris for 24 h, and 50 u/mL DNase, 1 u/mL RNase, and 
0.1% EDTA/10 mM Tris for 5 h. Following the washes, the bone was rinsed with 
PBS and lyophilized. The decellularized bone fragments were pulverized using a 
SPEX SamplePrep 6770 cryo-mill (SPEX SamplePrep, Metuchen, NJ) at a 
frequency of 10 cycles per second for 45 minutes to obtain powdered bone.   
3D-Printing of Scaffolds 
Cryo-milled decellularized bone powder was mixed 30% w/w with powdered 
polycaprolactone (PCL; 43k-50k MW; Polysciences 25090) by sifting through a 
stainless steel 400 µm mesh three times. PCL-DCB scaffolds were manufactured 
using an in-house pneumatic fused-deposition system mounted to a CNC machine 
with a nozzle diameter of 460 µm26. Briefly, a powdered mixture of PCL-DCB was 
loaded into the nozzle chamber and heated to 100°C in order to bring the polymer 
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to a liquid phase. Pneumatic pressure was then applied to expel the liquefied 
mixture out a 460µm brass extrusion die at the bottom of the chamber. Scaffolds 
for cell studies27,232,366 were prepared using rectilinear patterns with 60% void 
volume and two layers in height (0.640mm) and punched to 4mm in diameter.  
Intramuscular PCL-DCB scaffolds were printed in the same pattern and cut to 6mm 
× 4mm × 4mm (length × width × height). Intramuscular scaffolds are larger to 
provide 3-dimensional depth to assess vascular formation.  Prior to seeding cells, 
scaffolds were treated with 1M NaOH for 1h to increase hydrophilicity, washed with 
PBS, soaked in 100% EtOH for 1h to sterilize, and immersed in 100% FBS at 37 
°C for 1h to facilitate protein adsorption to the surface of the scaffold. 
Scaffold Seeding  
Cells were suspended in fibrinogen (8 mg/mL final; Sigma) and then mixed 
with thrombin (2 U/mL final; Sigma) for a final cell concentration of 2 x 104 cells/μL 
gel. Constructs were seeded by pipetting 12 μL of gel and cell solution into 4-mm 
diameter scaffolds and incubating at 37 ºC for 30 min to allow complete gelation 
before the addition of medium. Twice the gel volume (24 µL) was used for 
intramuscular scaffolds to account for the larger porous volume of the scaffold.  For 
in vitro culture, Control Medium (CM) scaffolds were fed with 0.5 mL of low glucose 
DMEM (Gibco) supplemented with 10% FBS and 1% penicillin/streptomycin. 
Osteogenic Medium (OM) scaffolds were fed with 0.5 mL of control media 
supplemented with 10 mM β-glycerol phosphate and 50 µM ascorbic acid-2-
phosphate. Media was exchanged every other day. For in vivo studies, scaffolds 
were incubated for 10 hours in 0.5 mL of low glucose DMEM (Gibco) supplemented 
with 10% FBS and 1% penicillin/streptomycin before implantation.    
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Gene Expression 
After the culture periods, scaffolds were digested with TRIzol (Life 
Technologies) and isolated mRNA was used to produce cDNA. cDNA was subject 
to real-time polymerase chain reaction (RT-PCR) for osteogenic genes COL1A1, 
RUNX2, osteopontin (OP), osteocalcin (OCN), and osteonectin (ON) as previously 
described243. The primers used are presented in Table 7-2. For analysis, the delta-
delta Ct method was used in which β-actin served as the housekeeping gene, and 
gene expression was normalized to that of SVF cells at the time of isolation. 
Table 7-2. PCR Primers 
Gene Direction Sequence 
Osteopontin F TTGCAGCCTTCTCAGCCAA 
 R GGAGGCAAAAGCAAATCACTG 
Runx-2 F GTCTCACTGCCTCTCACTTG 
  R CACACATCTCCTCCCTTCTG 
Osteonectin F TCGGCATCAAGCAGAAGGATA 
 R CCAGGCAGAACAACAAACCAT 
Osteocalcin F GTGACGAGTTGGCTGACC 
 R TGGAGAGGAGCAGAACTGG 
Collagen 1 F GAGAGGAAGGAAAGCGAGGAG 
 R GGGACCAGCAACACCATCT 
 β-Actin F AGTTGCGTTACACCCTTTCTTG 
 R TCACCTTCACCGTTCCAGTTT 
 
Biochemical Assays 
Scaffolds were cultured for 3 weeks in control or osteogenic conditions (n = 
4 per assay). Calcium and DNA were measured as previously described366. Briefly, 
cellular DNA quantities were assessed using the Quant-It PicoGreen dsDNA assay 
(Invitrogen, Carlsbad, CA) according to manufacturer instructions. Total DNA at 21 
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days and the fold change from day 0 total DNA are reported. Total calcium was 
measured by agitating scaffolds in 0.5N hydrochloric acid for 24 hours and then 
measuring the calcium in solution using a Stanbio LiquiColor calcium assay 
(Stanbio, Boerne, TX) to determine calcium content. Samples were mixed with the 
color reagent 1:100 and the absorbance was read on a plate reader at 550nm 
according to assay instructions. Samples were reduced by the absorbance from 
wells without sample and interpreted as a fraction of the absorbance of the 
standard (10 mg/dL). PCL-DCB scaffolds were also reduced by the amount of 
calcium retrieved from acellular scaffolds, resulting in 'deposited calcium'. Calcium 
content was normalized to the amount of cellular DNA. Mineralized calcium was 
detected using Alizarin Red S (Sigma A5533) staining and detected using bright-
field microscopy.   
Animal Studies  
In conducting research using animals, the investigator(s) adhered to the 
laws of the United States and regulations of the Department of Agriculture. All 
studies were approved by the Johns Hopkins University Institutional Animal Care 
and Use Committee (Protocol Number M016M468). Male nude 
immunocompromised mice (fox1n1, Charles River) were used at 8 weeks of age.   
Assessing Bone Regeneration in Cranial Defects 
To determine the effect of cells and scaffolds in vivo, the critically-sized 
murine calvarial defect model was used as previously described243,367,368. Briefly, 
a 4-mm circular knife (Medicon, Tuttiligen, Germany) was used to excise a 4-mm 
disk of calvaria between the coronal and lambdoid sutures and 1 mm lateral to the 
sagittal suture. Constructs consisting of SVF or ASCs seeded in fibrin inside DCB-
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PCL scaffolds were press-fit into the resulting defect. A total of 14 mice were 
operated, 7 for SVF and 7 for ASCs, with n = 3 at 6 weeks and n = 4 at 12 weeks. 
The contralateral sides of each animal were also operated and treated with 
acellular control scaffolds. Post-mortem imaging of defects with computed 
tomography (CT) used a nanoScan PET/CT (Mediso, Budapest). Imaging was 
performed at 35 kV peak voltage and 800 μA current (0.48mAs). Reconstruction 
was done with a voxel size of 40 μm. Scans were conducted at 6- and 12-weeks 
post-implantation. Samples were fixed in 3.7% formalin overnight for histological 
analysis. 
Assessing Vascular Potential in Intramuscular Implantation 
Blunt dissection was used to create pockets in the hamstring portion of each 
leg369. Scaffolds were placed into the pockets and the tissue was sutured closed. 
Each animal received an SVF or ASC-loaded scaffold and a contralateral acellular 
control. After 10 days (n = 3) or 6 weeks (n = 4), mice were sacrificed and MicroFil-
MV® (Flow Tech Inc, Carver MA)370, a radiopaque polymer, was perfused through 
the vasculature. MicroFil-MV was mixed at 20:8:1 (dilutent:compound:curing 
agent) and perfused intracardially at 250 µL/min following perfusion of heparinized 
saline (5 U / mL). Samples were dissected out and fixed in 3.7% formalin overnight. 
Finally, µCT (Bruker SkyScan 1275, 10µm resolution, 65keV with 1mm aluminum 
filter, 0.3° rotation between images) was used to determine the extent of scaffold 
vascularization in implanted scaffolds. Analysis was done in Mimics (Materialise, 
Belgium). First, the vasculature and the scaffold were identified by thresholding. 
Second, the vasculature was manually segmented from the scaffold based on the 
different morphologies of scaffold and vasculature. Finally, the segmented 
155 
vasculature was cropped to the boundaries of the scaffold, and the volume of 
cropped vasculature within the scaffold was reported.  
Histology 
Samples were decalcified in 14% EDTA for 14 days and then trimmed to 
the cranial region. Samples were then embedded in 2% w/v agarose gel, 
dehydrated, and placed in chloroform overnight to remove the PCL phase. They 
were then washed three times with hot paraffin to remove residual chloroform and 
cast into paraffin wax blocks. Blocks were sectioned at 7µm using a microtome 
(Leica). Masson’s trichrome staining was performed according to manufacturer 
specifications (Sigma HT15).  Stained sections were imaged at 5x and 20x 
magnification on an upright microscope (Zeiss) and stitched371 in ImageJ 
(Bethesda MD). 
Statistical Analysis 
Quantitative data are expressed as the mean ± standard error. Statistical 
analyses were performed using GraphPad Prism 5 software. Statistical 
significance was determined by one-way ANOVA with Tukey’s post-test and is 





Cells were collected from six donors; the donor demographics and cellular 
yields are summarized in Table 7-3. Cell populations were analyzed using flow 
cytometry and markers for endothelial cells, hematopoietic cells, and stem cells 
(Figure 7-2A). There was little donor-to-donor variability in the number of cells 
positive for each cell surface marker. The percentages are presented as the 
average ± standard deviation of the six donors. There was a greater presence of 
endothelial cells (CD31+) in the SVF population (12.9 ± 0.82%) compared to the 
ASC population (1.3 ± 0.13%). Likewise, we observed a decline in hematopoietic 
cells (CD45+) in the SVF (15.6 ± 1.6%) compared to ASCs (0.60 ± 0.065%). We 
observed a decrease in CD34 (SVF = 68.2 ± 2.54%; ASCs = 8.116 ± 0.63%) and 
increase in CD73 from SVF to ASCs (SVF = 17.6 ± 1.25%; ASCs = 95.7 ± 1.43%) 
(Figure 7-2B).  
 
Table 7-3. Donor Profiles and Cellular Yield 
Donor Age Race Sex BMI Location(s) 
Yield (cells / mL 
of clean fat) 
1 54 Caucasian F 25 Flank / Scapular 63,750 
2 37 Caucasian F 23.9 Flank / Inner Thigh 120,000 
3 54 Caucasian F 28.6 Flank / Scapular 700,000 
4 43 Caucasian F 20.8 Flank / Abdomen 145,000 
5 32 African Am F 25.8 Flank 676,000 






Figure 7-2. Flow Cytometric Analysis of Cell Populations.  
(A) Representative flow cytometry histograms for endothelial (CD31), 
hematopoietic (CD45), and stem cell (CD34, CD73) markers before and 
after culture. (B) Surface marker profiles averaged for all 6 donors. Data 
shown as average ± standard deviation.  
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In Vitro Mineral Deposition 
DNA and calcium contents as well as gene expression in the PCL-DCB 
scaffolds were measured after 21 days (Figure 7-3). There were greater cell 
numbers in osteogenic (OM) vs. control (CM) media and SVF scaffolds had less 
total DNA than those seeded with ASCs (Figure 7-3A. OM: SVF = 704.2 ± 72.6ng; 
ASCs = 944.7 ± 9.0ng; p < 0.005. CM: SVF = 433.8 ± 18.6ng; ASCs = 757.3 ± 
15.2ng; p < 0.005.). SVF scaffolds had greater proliferation than ASCs in OM 
(Figure 7-3B. SVF = 1.5 ± 0.15-fold, ASCs = 1.3 ± 0.012-fold). In vitro cell cultures 
were used to test whether SVF had the potential to mineralize PCL-DCB scaffolds 
to a similar extent as passaged ASCs. In vitro culture over three weeks revealed 
that both SVF and ASCs mineralized scaffolds. While, SVF and ASCs grown on 
PCL-DCB scaffolds had similar total mineralization (Figure 7-3C. OM: SVF = 59.0 
± 3.3 µg Ca+2; ASCs = 56.2 ± 3.2 µg Ca+2 n.s.), SVF had a greater mineralization 
per cell (Figure 7-3D. DCB-OM: SVF = 75.6 ± 4.3 ng Ca+2/ng DNA; ASCs = 61.0 
± 3.8 ng Ca+2/ng DNA; p<0.005).  To confirm that the DCB in the scaffolds was 
osteoinductive, we measured DNA and calcium in PCL only scaffolds (Figure 7-4. 
PCL-OM: SVF = 51.2 ± 3.2 ng Ca+2/ng DNA; ASCs = 45.3 ± 3.6 ng Ca+2/ng DNA; 
SVF vs ASCs p<0.005, PCL vs PCL-DCB p>0.05). Both SVF and ASCs responded 
to osteoinductive cues in the PCL-DCB scaffolds. The cells also responded to the 
PCL-DCB scaffolds by upregulating key bone forming genes independent of media 
condition. While RUNX2, OCN, and OPN were significantly more upregulated in 
ASCs in OM, COL1A1 was more significantly upregulated in SVF groups 
regardless of media condition (Figure 7-3E;F. OM: SVF = 11.3 ± 0.41; ASCs = 1.4 







Figure 7-3. In vitro mineralization of SVF and ASCs in PCL-DCB scaffolds   
SVF and ASCs from 6 donors were cultured in osteoinductive (OM) and 
control (CM) media in PCL-DCB scaffolds over 21 days.  
(A) Total DNA content. (B) DNA normalized to day 0 amounts. (C) 
Deposited calcium in the scaffolds. (D) Deposited calcium normalized to 
total DNA. (E, F) Bone gene expression of one donor at 21 days, on 
PCL-DCB scaffolds.  
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Figure 7-4 In Vitro Osteoinduction of DCB Scaffolds.  
(A) Scaffolds were stained with alizarin red after three weeks of culture. 
+ = osteoinductive media (OM), – = control media (CM). Dark red 
staining is distributed throughout the induced groups, and the DCB- 
group is slightly darker than the PCL- group. (B) Total DNA in PCL or 
PCL-DCB scaffolds after 21 days. (C) Total calcium recovered from PCL 
or PCL-DCB scaffolds after 21 days. (D) Total DNA normalized to day 0 
amounts. (E) Total calcium normalized total DNA at day 21.  
 
Bony Healing 
To test the ability of these cells to regenerate bone in an orthotopic 
environment, SVF and ASCs were loaded onto PCL-DCB scaffolds and implanted 
into critical-sized cranial defects in mice (Figure 7-5A, 7-6). The inclusion of cells 
led to an increased amount of bone volume when compared to contralateral 
acellular defects. At twelve weeks after surgery, SVF (Figure 7-5B, paired SVF = 
4.72 ± 0.10 mm3 and Acellular = 4.10 ± 0.12 mm3; p < 0.005) and ASCs (Figure 
7-5C, paired ASCs = 5.07 ± 0.24 mm3 and Acellular = 4.11 ± 0.14 mm3; p < 0.05) 
both had significantly more bone volume.  
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At six and twelve weeks, acellular scaffolds had open pore spaces with 
slight amounts of bone formation along the border of the defect (Figures 7-5, 7-6, 
7-7). Acellular groups had less than 40% of the porous space filled (Figure 7-5C, 
6-weeks = 46 ± 5%; 12-weeks = 34 ± 10%). SVF groups had increased amounts 
of bone filling the pore spaces (Figure 7-5C, 6-weeks = 73 ± 6%; 12-weeks = 78 
± 7%), and bone volume increased between weeks six and twelve (Figure 7-5D, 
BV-PV at 6-weeks = 0.32 ± 0.052 mm3; 12-weeks = 0.62 ± 0.04 mm3, p < 0.05). 
ASCs filled the most pore volume with bone (Figure 7-5C, 6-weeks = 83 ± 11%; 
12-weeks = 100 ± 18%).  
 
Figure 7-5. In Vivo Bone Forming Potential.  
(A) microCT reconstructions of 4mm diameter cranial defects (red 
outline) (B) Pair-wise comparison of bone volume per animal. Each 
connected pair indicates a single animal containing two defects (cellular 
and acellular). (C) Percentage of porous space filled with bone. Bone 
volume reduced by the initial scaffold volume and normalized to the 
porous volume: (Bone Volume-Scaffold Volume) / Pore Volume. (D) 
Bone volume within defect reduced by contralateral acellular defect 
bone volume. (E) Area coverage of defect area. Measured in ImageJ as 
(number of non-black pixels) / (total number of pixels) in the 4mm-






Figure 7-6. Complete Set of Orthotopic Defects.   
CT reconstructions of defects. Each mouse has contralateral acellular 

















Figure 7-8. Cross-sectional CT Views of a Cranial Defect.   
The CT is thresholded and a 3D-pobject is created with the resulting 
bone signal (upper left). Cross sections from that object along the red 
lines are shown on the right. The red X indicated the border of the host 
bone, and the scaffold is visible between the Xs as thin and darker grey.  
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Figure 7-9. Histology Staining of Murine Cranial Defects.  
Mason’s Trichrome Staining on cross sections of samples at 6 (top row) 
and 12 weeks (bottom row). Scaffold struts indicated by empty white 
space, dense collagen as blue. Red lines indicate boundaries of the 
defect, and green boxes are the zoomed in section. Scale bars 5x = 
500µm, 20x = 100µm. 
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Histology  
The osteogenic performance of implanted scaffolds at 6 and 12-week post-
surgery was evaluated using Mason’s Trichrome stain. Cell-laden scaffolds (both 
SVF and ASC) showed greater amounts of dense collagen formation, as indicated 
by the dark blue coloring around scaffold struts, when compared to the acellular 
scaffolds, which showed more open red-colored fibrotic tissue around the struts 
(Figure 7-9). Scaffolds with ASCs showed denser collagen formation, particularly 
between scaffold struts, at 6 and 12 weeks; although, by 12 weeks, SVF scaffolds 
also had dense collagen indicative of bone matrix deposition between struts. In 
ASCs, the new boney matrix also appeared integrated into host bone on both sides 
of the defect. By 12 weeks, the defect was filled with new tissue in both SVF and 
ASC scaffolds, with a high concentration of collagen around scaffolds struts and 
bridges of collagen in between them. By contrast, acellular scaffolds showed very 
little dense collagen present anywhere in the defect. 
Vascular Infiltration 
To observe the ability of cells to promote an angiogenic response, larger 
constructs were implanted in the hindlimbs of mice (Figure 7-10A). MicroFil 
perfusion was used to examine the extent of vascularization at 10-days and 6-
weeks (Figure 7-10B). At 10 days, there was minimal vascular infiltration in the 
acellular and ASC groups (Figure 7-10C, 0.30 ± 0.058 mm3 and 0.19 ± 0.044 mm3 
respectively), and some infiltration into the SVF group (Figure 7-10C, 0.65 ± 0.068 
mm3, p < 0.05 vs acellular and ASCs). At 6 weeks, cellular groups were both 
significantly greater than the acellular groups (Figure 7-10C, ~3-fold, SVF = 1.71± 
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0.10 mm3, ASCs = 1.47 ± 0.22 mm3, acellular = 0.45 ± 0.045 mm3, p < 0.05) and 
the SVF group was similar to the ASCs group.  
 
 
Figure 7-10. Intramuscular Implantation and Microfil Perfusion  
Top: (A) Example CT showing scaffold implant (red box) in relation to 
leg. (B) microCT reconstructions of scaffolds implanted intramuscularly, 
with the vasculature filled with radiopaque microFil.  (C) Total vascular 
volume within scaffold. Bottom: Example of the methodology of trimming 
the vascular volume (red, left) to the scaffold boundaries (middle, 
particles in white), and the resulting vascular volume of interest (right).   
 
Discussion 
The inability to effectively regenerate bone within critical-sized craniofacial 
defects is a present clinical challenge and overcoming this limitation using tissue 
engineering strategies would significantly advance current treatment modalities. 
One approach would be to harvest SVF, combine it with 3D-printed osteoinductive 
scaffolds, and within the same surgical procedure, implant it into the bone defect 
to stimulate regeneration. This approach offers a number of advantages compared 
to traditional tissue engineering methods where cells (e.g. ASCs) are culture 
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expanded and maintained in the scaffold ex vivo for a period of time prior to 
implanting into the defect site. Specifically, it would reduce the required number of 
operations for the patient, eliminate the cost and practical limitations associated 
with manipulating the cells ex vivo, and leverage the regulatory feasibility of an 
intraoperative vs multi-operative procedure. This study addresses two potential 
limitations of this strategy, which is (i) whether minimally-processed SVF delivered 
to a critical-sized bone defect within an osteoinductive scaffold in a manner that 
mimics a clinical intraoperative procedure could promote robust bone 
regeneration, and (ii) determining whether the bone-formation by SVF is as 
effective as that obtained from culture expanded ASCs. 
To assess the feasibility of the SVF-based bone regeneration, we first 
characterized the isolated cells. While there was donor-to-donor variability in cell 
yield, the trends of osteoinduction and proliferation remained the same across 
donors, and we were able to isolate large quantities of cells that would be suitable 
for acute clinical use. Potential intervention for a defect of 4 - 10cc would require 
on the order of 107 -108 cells if seeded at concentrations ranging from 1 to 25 × 
106 cells/mL. This corresponds to 250 mL of lipoaspirate. For this study, we 
obtained over 500 mL from each donor of average BMI of 25.  Cell marker 
distributions were also consistent across donors. The values in our study also 
correlated with those reported previously by other groups, which describe 
decreases in endothelial (CD31), hematopoietic (CD45),  and CD34 sub-
populations and a concomitant increase in mesenchymal (CD73) sub-
populations311,353,372.  
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As reported in a recent review, several groups are working to implement 
SVF or ASCs in clinical trials for bone regeneration24. Yet, the ability of SVF or 
ASCs to directly differentiate into osteoblasts and produce bone in vivo remains 
contested. A recent study reported that despite the ability of ASCs to deposit 
mineral and turn on bone-forming genes in vitro, they were unable to 
spontaneously form ectopic bone351 even though promoted a robust angiogenic 
response and exhibit trophic function373. Hence, demonstrating bone regeneration 
capacity in a critical-sized defect remains a crucial hurdle in the clinical translation. 
While others have used autologous rodent SVF360 in bone healing, we believe this 
is the first reported case of non-pre-differentiated human SVF significantly 
contributing to new bone volume in small animals. As such, this work corroborates 
other studies which have shown SVF used in humans is safe and effective in 
promoting bone regeneration361.  
This current study applied the SVF to the calvarial defect with minimal 
manipulation to simulate a clinically applicable intervention for bony regeneration 
that did not rely upon ex vivo culture or ‘priming’ of the cells prior to implantation. 
While the ASCs were cultured for two passages, they were also implanted in the 
defect site without prior in vitro osteogenic differentiation, yet both cell types 
promoted mineral deposition that was significantly greater than the acellular 
controls. The amount of bone formation formed by the SVF was lower than that 
formed by ASCs though the difference was not statistically significant. The reason 
for this is not clear: While, this result could potentially correlate with the relatively 
lower number of mesenchymal (CD73+; believed to be osteogenic progenitors) 
sub-populations present in SVF than ASCs, if this were true, the same trend should 
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have been observed in vitro. Yet, both SVF and ASCs exhibited similar osteogenic 
potential in vitro.  In our prior studies, we have shown that human cells are present 
at the site of new bone formation243 though we have not validated in either study 
that the cells responsible for new bone formation are human. Alternatively, it is 
possible that the cells act on endogenous cells to affect bone formation. Recent 
work has shown that transplanted mesenchymal stem cells act on surrounding 
host cells with trophic, paracrine, and immunomodulatory functions115,374,375.  In 
future studies, we will use cells transduced with bone-forming gene reporter labels 
to probe the direct contribution of transplanted cells. This study is limited by the 
xenogenic nature of evaluating human cells in immunocompromised mice and also 
by the nature of the size and scale difference between murine and human bones.  
These experiments highlight the strength of a 3D-printed bioactive material-
based approach to mediate bone regeneration. 3D-printing technologies are 
powerful tools to facilitate patient-specific approaches376. Regenerative 
approaches that utilize 3D-printed scaffolds may avoid the stress-shielding, 
loosening, and implant extrusion that cause permanent plastic, metal, and ceramic 
implants to fail377,378. We have previously reported that 3D-printed PCL-DCB 
scaffolds enhanced the expression of bone-related genes (RUNX1, COL1A1, 
OCN) in ASCs366 and regenerated bone in murine calvarial defects27 in a dose-
dependent manner, i.e. the higher the concentration of DCB in the 3D-printed 
scaffolds, the greater the amount of mineral deposition in vitro and in vivo bone 
formation366. We have also shown that embedded DCB in 3D-printed PCL 
scaffolds was a more potent osteoinductive stimulus than other clinically-used 
bone replacement materials such as tricalcium phosphate and hydroxyapatite232. 
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In this study, SVF and culture-expanded ASCs were encapsulated in 3D-printed 
PCL-DCB scaffolds and implanted orthotopically in vivo without prior osteogenic 
differentiation and still gave rise to significant amounts of new bone formation. 
Several groups have demonstrated that pre-differentiation of ASCs to osteoblasts 
results in substantial bone formation350,359,379,380. Moving that differentiation 
process to the implanted-scaffold environment eliminates in vitro preparation time 
and enables the osteoinductive signals to act, additionally, on endogenous cells.  
It should also be noted that the addition of exogenous growth factors induces 
robust bone regeneration203,381,382 but the limitation is that they are provided at 
supra-physiological levels, which is not the case with the PCL-DCB 3D-printed 
scaffold system. Even the acellular scaffolds induced some bone healing, showing 
the robustness of the PCL-DCB-based scaffold approach.  
The study also evaluated the relative angiogenic potential of SVF and 
ASCs. The formation of healthy regenerated bone in large, critical-sized defects in 
humans would rely on well-established vascular networks. To assess the vascular 
response induced by the cells, we used an ectopic model that enabled us to test 
scaffolds of larger volumes. Scaffolds were filled with fibrin hydrogel which 
promoted vascular ingrowth even in acellular scaffolds and we assessed 
specifically the perfused vascular networks by using MicroFil-MV. Both SVF and 
ASCs exhibited roughly three-times greater vascular responses than acellular 
scaffolds at six weeks. This later time point was chosen to investigate sustained 
vascular networks. At the early time-point (10 days), only SVF-seeded scaffolds 
showed increased vasculature compared to the acellular controls. This early 
vascular presence correlated with the greater presence of endothelial cells in the 
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SVF, suggesting those endothelial cells might assemble into vasculature and 
patently anastomose with the host. In this study, we did not investigate the 
contributions of blood vessels of human or mouse origin. It may also be due to a 
higher secretion of pro-angiogenic factors by SVF compared to ASCs383. This early 
vascular response in our system might enable more of the implanted cells to 
survive implantation conditions and contribute to subsequent mineralization. Thus, 
the robust vascular formation and bone formation observed in this study using SVF 
and ASCs may be correlated.  
Conclusion 
The data from this study demonstrated that SVF isolated from lipoaspirate 
and used in vivo with minimal processing could promote substantial bone healing. 
The SVF-seeded scaffolds filled 80% of the void volume of scaffolds in critical-
sized murine calvarial defects. In an ectopic intramuscular model, the SVF also 
induced a robust angiogenic response that was sustained at 6 weeks post-
implantation. We compared both the bone healing and angiogenic responses with 
that obtained from isogenic, passage 2 ASCs. We found that the SVF and ASCs 
behaved comparably. The ASCs stimulated new bone formation that filled up to 
100% of the pore volume of the scaffolds and exhibited similar levels of 
vascularization at 6 weeks. Altogether, the study supports the potential 
intraoperative use of SVF combined with bone scaffolds for the treatment of 





Figure 7-11 Isolation and Use of Stromal Vascular Cells.  
Flow chart shows how fat tissue contains a stem cell niche in the 
perivascular space. Isolated fat tissue can be in a number of forms. The 
resulting SVF contains a high percentage of ECs, which is mostly lost 
during culture. Cells are mixed with hydrogel (fibrin/thrombin) and 
injected into a scaffold. The cells work to form blood vessels (ASCs 




CHAPTER 8  
3D-PRINTING SCAFFOLDS WITH CONTROLLED HETEROGENEOUS 
POROUS AND MECHANICAL PROPERTIES 
Summary 
3D-printing is a powerful manufacturing tool which can create precise 
microscale architectures across macroscale geometries from various materials. 
Within biomedical research, 3D-printing has been used to fabricate rigid scaffolds 
for cell and tissue engineering constructs, where the precise microarchitecture has 
direct effects on behavior and function of the construct. While 3D-printing hardware 
has become low-cost due to modelling and rapid prototyping applications, there is 
no common paradigm or platform for the controlled design and manufacture of 3D-
printed constructs for tissue engineering. Specifically, controlling the tissue 
engineering features of pore size, porosity, and pore arrangement is difficult in 
currently available software. We have developed a MATLAB approach 
(scafSLICR) to design and manufacture tissue engineered scaffolds with precise 
microarchitecture and with simple options to enable spatially patterning pore 
properties. Using scafSLICR, we designed, manufactured, and characterized 
tissue engineering scaffolds in ABS with a variety of pore sizes, porosities, and 
gradients thereof with a high degree of accuracy. We found that transitions 
between different porous regions maintained an open, connected porous network 
without compromising mechanical integrity. Further, we demonstrate the 
usefulness of scafSLICR in patterning different porous designs throughout large 
anatomic shapes and in preparing craniofacial tissue engineering bone scaffolds.  
Finally, scafSLICR is distributed as open source MATLAB scripts and as in a 
stand-alone graphical interface.  
174 
 Introduction 
3D-printing has grown into a widely available technology since the patents 
surrounding the core technology expired in 2009384. As a result of this 
technological expansion, a large number of low-cost hardware systems and 
printable materials have become commercially available385,386. A growing number 
of tissue engineering studies have utilized such 3D-printing techniques to fabricate 
scaffolds for tissue regeneration26,102,255–258. The specific 3D-printing technology 
selected impacts the choice of material and available microarchitectures that can 
be used for the scaffold387. One prominent technique, fused deposition 
manufacturing (FDM)27, utilizes thermal fusion bonding260 to additively join fibers 
of thermoplastic polymer into porous and solid 3D-shapes. The relatively low cost 
of FDM machines over the past decade has enabled the widespread use of the 
technology for tissue engineering in convenient desktop formats263. Additionally, 
FDM allows for sufficient resolution needed for structural and pore designs, out of 
many relevant materials27.  
Thus far, much of the work using FDM to produce constructs for tissue 
engineering has focused on developing suitable biomaterials for 3D-printing386. 
Such work has led to a wide array of biomaterials which may be used in FDM with 
a variety of mechanical and biological properties388. The resulting constructs 
function as cell scaffolds and have the potential be directly manufactured in precise 
anatomic shapes. However, the scaffold material is not the sole contributor to the 
success of the scaffold.  
Scaffolds for tissue engineering necessarily contain highly-defined porous 
networks, which are essential for cell seeding and nutrient diffusion throughout the 
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scaffold. These networks also allow room for cells to effect tissue formation. The 
interplay between scaffold mechanics, porous volumes for cell and tissue growth, 
and the diffusion of nutrients throughout presents a challenging paradox in 
determining the optimal microarchitectural design for a scaffold. Principally, it is 
necessary to provide sufficient material to promote strong mechanical properties 
while also creating sufficient connected porous space to allow for cell seeding, 
growth, and nutrient transport.  
The fiber deposition process of FDM can be used to control the scaffold 
mechanics and porous network properties. FDM works by passing a thermoplastic 
filament through a small-diameter hot element which moves in x, y, and z 
directions. Extruded molten material (termed a fiber) rapidly cools and sets in the 
position it was deposited, fusing with any adjoining fiber portions. By operating in 
a layer-by-layer manner, the print can be constructed via many xy-print layers 
assembled in the z-print direction. Spacing between fibers in the xy-plane creates 
a porous space, which can be designed to connect between different print layers 
and result in a connected porous network.  
The interconnectivity, size, and extent of the porous network directly and 
indirectly influence cell behavior26,283,389,390. Patterns of these porous properties 
across 3D-printed objects could result in complex tissues with spatial specificity 
that have thus far only been achieved via directly printing cells in different spatial 
patterns102. 
An ongoing tissue engineering design goal is the ability to create patterns 
of porous properties throughout 3D-space in anatomic shapes. Spatially controlling 
pore properties would also enable the spatial control of mechanical properties, as 
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porosity and mechanical strength are closely linked. The most common method of 
creating patterns of porous properties is modifying the fiber-fiber spacing between 
z-levels, which results in different pore sizes at different heights in the print. For 
example, Sobral et al. designed a gradient of pore sizes by systemically increasing 
or decreasing fiber-fiber spacing in each print layer391. Additionally, Woodfield et 
al. 3D-printed cartilage constructs with a gradient of pore sizes in the z-direction392.  
These fiber-spacing approaches are constant across an xy-plane and limit 
designs to changes in spacing in the z-direction. While such an approach is 
applicable in small-scale prints, it does not easily transfer to human-scale complex 
anatomic shapes. One group, Di Luca et al., has demonstrated fiber-fiber spacing 
across the xy-plane, resulting in a step gradient across the plane393–395. Therefore, 
fiber-fiber spacing could be controlled in xy, and z directions simultaneously, 
enabling designs with different pore sizes across 3D-space. Thus far, this 
approach has only been shown in a small scale, cuboid scaffold with a three-
pattern linear gradient. Implementation of such gradients in the x-y plane across a 
variety of large, more complex geometries remains an unmet challenge for bone 
tissue engineering. 
Additionally, specific control over pore architecture is desirable. Fiber height 
is often mismatched from desired pore sizes, and cross-hatching fiber patterns on 
alternating print layers result in pore diameters that are determined by the versatile 
fiber-fiber spacing in the z-direction but limited by fiber height in the xy-direction. 
Varying the fiber height can change the height of the pores in the xy-plane, but this 
approach must be implemented across the entire print plane which prevents in-
plane patterning. Further, fiber height is limited by the range of nozzle hardware. 
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However, repeating the same print pattern without changing the fiber location could 
result in stacked, taller fibers and therefore pores, as shown by Moroni396 and 
Xu397. Struts designed from congruent, stacked fibers could be used to make pore 
microarchitectures isotropic and vary pore size in all three spatial dimensions.  
The process of transforming a 3D-design into the xy-layers of hot element 
paths is termed slicing. The slicing process determines the fiber laydown pattern, 
and the resulting porous and mechanical properties and microarchitectures of the 
print. Slicing is often achieved using a slicing software, which operates on a 3D-
shape and “slices” it into individual z-level layers. Traditional slicing software 
systems create a solid wall or shell around the exterior surface of the shape with 
a single, infilling, truss pattern applied to the interior bulk of the shape.  
By intention, these software systems facilitate the manufacture of models 
and prototypes with solid shells and compartmentalizing, internal trusses. These 
resulting designs are not useful for tissue engineering constructs as they do not 
contain interconnected pore networks. Research groups have been limited by the 
set of functionalities in broadly-used hobbyist software (such as Slic3r398 or 
Cura399) or in the proprietary software delivered with the bioprinter – which has 
restricted the availability of useful tissue engineering designs.  
To overcome the limitations of the available slicing software, research 
groups have prepared custom porous designs through 'brute force' design. They 
manually design each pore and strut in CAD programs and then pass the CAD file 
to a traditional slicing program, which best approximates fiber placement across 
the design256,400. This design process is labor and computationally intensive and 
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disconnects the design process from the design space of the 3D-printer, which can 
cause infidelities in the final product. 
Alternatively, custom slicing software can enable the creation of gradients 
or custom porous structures. For example, the Atala group at Wake Forest 
University developed an integrated tissue-organ printer and custom software 
integrated into the system for design and manufacture of constructs. While they 
published the source code, it is unique to their hardware and does not appear to 
allow for the design of gradients102. Trachtenberg et al. developed a Python and 
Pronterface system to generate GCODE that can vary the fiber-fiber spacing on 
different print levels on a custom-built 3D-printer401. However, these programs are 
specialized to each design and manufacturing system and are not easily replicable 
or adaptable. 
Therefore, currently available slicing programs do not allow precise control 
over porous patterns and microarchitectural features needed for tissue 
engineering scaffolds. Here, we present an approach to designing 3D-printed 
scaffolds with patterns of porous and mechanical properties. The goals of this 
approach are to (i) achieve isotropic pore architectures appropriate for tissue 
engineering, (ii) create manufacturable designs with patterns of pore properties 
throughout 3D-space, and (iii) provide this approach as a tool that researchers can 
use when 3D-printing tissue engineering scaffolds. Additionally, we demonstrate 
that the resulting approach allows the independent patterning of pore size and 
porosity.  
The goals of this approach are to (i) develop a software which can design 
and implement patterns of pore properties throughout 3D space which contain 
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isotropic, fully connected pores relevant to tissue engineering, (ii) validate the 
printability and mechanical integrity of such designs, and (iii) provide this software 
as a tool that researchers can use when 3D-printing tissue engineering scaffolds. 
Additionally, we demonstrate that the resulting approach allows the independent 
patterning of pore size and porosity across a variety of anatomic shapes relevant 
to craniofacial bone regeneration.  
Methods  
3D-Printing on Lulzbot 
The methods in this paper were developed on a Lulzbot Taz 5 3D-Printer 
(Aleph Objects, Loveland, CO), which is representative of the many low-cost 
desktop 3D-printers that are broadly in use by researchers. The printer uses gears 
to drive a solid polymer filament through a melt chamber and narrow extruder 
nozzle. The nozzle is moved in the x and y directions as it deposits material in a 
single z level before proceeding in a layer-by-layer fashion until the build is 
complete. The cooling and solidification rate of the extruded polymer is critical for 
determining print quality, and it is controlled by adjusting air fans and the heat of 
the print surface.  
Most importantly, the Lulzbot uses the Marlin operating system to process 
the standard RepRap flavor of GCODE instructions to control the robotic behavior 
of the system. The machine responds to commands to deposit a fiber of material 
(extruder diameter) at a given temperature (extruder temperature), at a given rate 
(extrusion rate), and move in x-y space (tool paths, extruder movement speed). 
Additionally, the print surface can be heated to prevent warping (bed temperature) 
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and the print can be cooled by turning the fan on at various print heights (fan speed, 
fan start height) (Table 8-1). 




The temperature of the print surface 
Extruder  
The assembly containing gears which drive 
filament into the melt chamber, the melt chamber, 
and the die element.  
Extruder 
Diameter 
The diameter of the die element where molten 








The temperature of the die element and melt 
chamber where the material undergoes solid to 
molten transition.   
Extrusion Rate 
The rate at which the gears driving filament into 
the melt chamber turn (mm / min).   
Fan Speed 
The relative speed of the fan (0 – 100%) blowing 
from the extruder onto the deposited fibers 
Fan Start 
Height 
The print height at which the fan powers on 
Fiber 
a single extruded strand of polymer from the 
extruder 
Fiber width determined by extruder nozzle diameter 
Layer-by-layer 
Additive manufacturing approach whereby the 
object is manufactured by sequentially depositing 
layers of planar thin sections 
Pore size  Width and height of square pore 
Porosity 
void volume fraction of scaffold (referring to 
macro-porosity not porosity within the actual fiber) 
Slicing 
Transforming a 3D-object into sequential, thin, 
planar sections, and creating tool-paths for each 
planar section.  
Strut solid trusses made up of adjacent, touching fibers 
Strut width  determined by number of fibers in a single strut 
Toolpaths lines that the extruder follows in x-y plane 
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Scaffolds in this paper were printed using ABS plastic filament (IC3D, 
Columbus, OH) with the following printer settings. A 0.5mm diameter extruder was 
used with the extruder temperature set to 240°C and bed temperature set to 
110°C. The layer height was set to 0.2mm and fans were turned on to 50% speed 
after the first layer was deposited. The federate was set to 1200 mm/min and a 1% 
over-extrusion factor was applied throughout the entire scaffold. 
 
 
Figure 8-1: Overview of scafSLICR Approach.  
User inputs a labelled 3D shaped and the pore properties for each label 
(green boxes). The program then generates support structure between 
the shape and the print bed (blue/red shape) and tool path templates for 
each pore pattern (blue boxes). The slicing process convolves these tool 
path templates with each x-y level of the shape according to the label 
(gray box).  The result of this convolution is then translated into a set 
GCODE instructions or into a predicted porous model of the shape 
(yellow boxes). These outputs can be manufactured on a 3D-printer or 
used for in silico modeling (orange boxes).  
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Scaffold Design with MATLAB Script 
The code was written to enable the feature-driven design of tissue 
engineering scaffolds. The key features of porosity and pore size are used to 
create a 3D-template, which is then applied to the desired areas of the scaffold 
shape (Figure 8-1). Pores are designed as isotropic square pores. Porosity is 
tuned by both the pore width and the strut width (Equation 8-1). The strut width 
can be increased by placing multiple fibers directly adjacent to each other (fiber-
fiber spacing = 0mm) and pore width is controlled by the strut-strut distance. By 
repeating the same strut pattern on consecutive layers, the strut height can be 
increased to equal the pore width and result in square pores. Squares are 
computationally easy to implement on cubic voxels at low resolutions.  Further, 
linear fibers and struts have a higher manufacturing fidelity than curved equivalents 
because of the drawing action of the extruder head as it moves.  
𝑝𝑜𝑟𝑜𝑠𝑖𝑡𝑦 =
𝑝𝑜𝑟𝑒 𝑤𝑖𝑑𝑡ℎ
𝑝𝑜𝑟𝑒 𝑤𝑖𝑑𝑡ℎ + 𝑠𝑡𝑟𝑢𝑡 𝑤𝑖𝑑𝑡ℎ
𝑒𝑞𝑛 8 − 1 
The inputs to the code are 3D-shape, pore sizes, and porosities. The 
possible combinations of pore sizes and associated porosities are dependent on 
the thickness of the struts and are available as design options. The shape can be 
easily adapted from CT scans, STL files, or other 3D-data. The pore size and 
porosity can be inferred from the initial biologic data (e.g. CT density), 
mathematically defined in a variety of gradients, or any desired pattern that can be 
applied to a 3D-matrix.  
The scafSLICR function generates templates of toolpaths in both x and y 
directions based on these parameters and convolves them with the shape matrix. 
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Additionally, it generates support material between the input shape and the print 
bed surface. The function includes the options to improve print quality by pausing, 
back-tracking, or retracting material at the end of each fiber to prevent dragging 
strands across pore spaces.  
The program outputs include common GCODE instructions that are 
conserved across many common FDM (tested on the RepRap Marlin system402) 
printers and 3D rendering of expected design (as STL and volumetric data). For 
ease-of-use the function was incorporated into a graphical user interface 
(Appendix A). It uses 3D-plotting403 and STL import404 scripts from the Mathworks 
repository.  
scafSLICR is freely distributed in supplements and appendices to this 
chapter.  
Scaffold Manufacturing  
Scaffolds were manufactured to assess print quality of different porous 
patterns (homogenous scaffolds), the transition between different patterns (hybrid 
scaffolds), and gradients of patterns in three dimensions (gradient scaffolds). 
Homogenous and hybrid scaffolds were 20x20x10 mm and gradient scaffolds were 




Table 8-2: Pore features of homogenous, biphasic, and gradient scaffolds. 













0.2 28% 0.2 → 0.5 28% → 25% 0.2 28% 
0.5 25% 0.5 → 0.8 25% → 28% 0.35 26% 
0.8 
28% 0.2 → 0.8 28% → 28% 0.5 50% 
45% 0.8 → 0.8 28% → 45% 0.65 56% 
62% 0.8 → 0.8 45% → 62% 0.8 62% 
 0.8 → 0.8 28% → 62%  
 
Print Quality Assessment 
Design features were measured in manufactured scaffolds and evaluated 
for accuracy to the input values. scafSLICR was used to design and print scaffolds 
(20x20x10mm) with a variety of combinations of pore size and porosity, along with 
a solid ABS cube. The porosity of printed porous scaffolds was determined by 
mass measurements compared to solid prints of the same dimensions (Equation 
8-2).   
𝑃𝑜𝑟𝑜𝑠𝑖𝑡𝑦𝑚𝑎𝑠𝑠 = 1 −
𝑚𝑎𝑠𝑠𝑝𝑜𝑟𝑜𝑢𝑠
𝑚𝑎𝑠𝑠𝑠𝑜𝑙𝑖𝑑
𝑒𝑞𝑛 8 − 2 
Scaffolds were imaged on a stereoscope (Zeiss Z8). Images were taken of top and 
side views at 2x magnification. Pore size and strut width were measured separately 
for top and side views. Pore size was analyzed using the DiameterJ plug-in for 
FIJI405,406 by measuring the area of each pore of the binarized image. The size of 
pore was then reported as the square root of the pore area. All of the pores were 
measured in each scaffold and each scaffold design was printed in triplicate. Strut 
widths were measured by hand in FIJI using the original stereoscope image. 
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Between 59 and 69 struts were measured over three scaffolds per group. For pore 
size and strut width the ratio of measured value to predicted value was report +/- 
standard deviation. 
Mechanical Testing 
Scaffolds were tested to assess base mechanical properties of 
homogenous and hybrid scaffolds. Scaffolds measuring 20x20x10mm were 
loaded into an MTS Criterion Model 43 (Eden Prairie, MN) with a 5 kN load cell 
and subjected to unconfined uniaxial compression. The scaffolds were 
compressed perpendicular to the print axis at a rate of 1.27mm/min. The 
compressive modulus was determined from the linear region of the stress-strain 
curve (n=3).  
Analysis of Porous Boundaries 
In order to assess the connectivity of pores between regions of different 
porous microarchitectures, the total connected area was analyzed in MATLAB. 
The area of each connecting pore was measured and transformed into width by 
assuming the pores were square. The porous area fraction of the boundary surface 
was found by summing the individual pore areas and dividing by the surface area 




Large portions of the craniofacial skeleton were selected to serve as 
anatomic test shapes. STLs or DICOMs of the shapes were exported from MIMICs 
(Materialise, Plymouth, MI) and imported into scafSCLICR. The shapes were 
divided into regions arranged linearly along the length of the shape (zygoma), or 
according to shape thickness (orbital bones), or according to depth 
(hemimandible). Different porous patterns appropriate for tissue engineering were 




scafSLICR was used on a standard desktop to generate the designs in this 
study (Appendix A, Examples 1-9). The largest shape (orbital bone) took six 
minutes to slice and generate the GCODE file, which is similar to the computing 
time when using Slic3r. Designed scaffolds were manufactured using the output 
GCODE without complications. Isotropic, regular, cubic pores were visible from 
top-down and side-on views of the scaffold (Figure 8-2A). Support material was 





Figure 8-2: Available Design Space.  
(A) Stereoscope pictures (1x, 5x) of scaffolds produced with scafSLICR 
demonstrating isometric pores. (B) Modulating the width of struts can 
produce a range of discrete porosities that are manufacturable at a given 
pore diameter for 0.5mm nozzle. 
 
Available Design Space 
Based on the diameter of the printer nozzle in use, the strut width can be 
modulated by depositing adjacent fibers (Figure 8-2A), thus a variety of strut 
widths may be achieved that are integer multiples of the printer nozzle diameter. 
This allows the decoupling of pore diameter and overall porosity. By modulating 
the strut width, a multitude of porosities may be achieved for a given pore diameter 
(and vice versa) as shown in Figure 8-2B. Pore diameters ranging from 0.2mm to 
1.0mm were successfully printed using the 0.5mm nozzle on the Lulzbot Taz5 
printer. Within this range of pore diameter, many different porosities may be 
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achieved by varying the strut width. For example, for a pore diameter of 500µm, 
eight different porosities may be achieved between 11% and 50% by increasing 
the strut width from 0.5mm to 4mm.  
The maximum porosity is determined by the pore size and printer nozzle 
diameter. The maximum porosity for pore diameters ranging from 0.2mm to 1.0mm 
are summarized in Table 8-3. For a 0.5mm nozzle diameter, porosities may be 
achieved between 29% and 67%, and the porosity may be further increased to 
74% by using a printer nozzle with a diameter of 0.35mm. 
 
 
Table 8-3. Maximum Porosity Across a Range of Pore Diameters   
Pore Size 
Upper Porosity Limit 
(0.5mm nozzle) 
Upper Porosity Limit 
(0.35mm nozzle) 
0.2mm 29% 36% 
0.3mm 38% 46% 
0.4mm 44% 53% 
0.5mm 50% 59% 
0.6mm 55% 63% 
0.7mm 58% 67% 
0.8mm 62% 70% 
0.9mm 64% 72% 
1.0mm 67% 74% 
 
 
Similarly, a specific porosity may be achieved using multiple different pore 
diameters. A porosity of 28.57% can be achieved at 0.2, 0.4, 0.6, 0.8, and 1.0mm 
pores by modulating the strut width between 0.5mm and 2.5mm (Figure 8-2B).  
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Print Quality/Validation of Predicted Designs 
This study used five combinations of pore size and porosity that represented 
useful porous patterns for tissue engineering (summarized in Table 8-2). These 
designs were printed and used to validate that the predicted designs from 
scafSLICR could be successfully manufactured with a high degree of fidelity. 
Printed scaffolds are shown with their respective design previews in Figure 8-3A. 
Manufactured scaffolds matched predicted designs to a high degree in both the 
top and side views. There was slight over-deposition of material, with pore sizes 
consistently below the predicted value irrespective of the actual pore diameter 
(Figure 8-3B). Pore diameter ranged from 76% to 93% of the expected value while 
the strut width varied from 3.5% under deposition to 13% over deposition. 
The measured gravimetric porosity (Figure 8-3D) is strongly correlated to 
the specified porosity of input design. The deviation of measured porosity from 
input porosity is due to the dimensions of the printed scaffold not being exact 
multiples of the characteristic distances of the individual microarchitectures (pore 




Figure 8-3: Homogenous Scaffolds.  
(A) Side-by-side comparison of scaffold preview (top row) and printed 
ABS scaffold (bottom row) for different patterns of pore size and 
porosity. (B, C) Assessments of print fidelity of pore diameter and strut 
width to design from top and side views. (D) Observed gravimetric 




Homogenous scaffolds were compressed to find the effective compressive 
modulus (Figure 8-3E). Primarily, the effective compressive modulus decreased 
with increased porosity. Increasing the porosity from a solid cube to 28% porosity 
with 200µm pores resulted in a 44% decrease in compressive modulus. Further 
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increasing the porosity to 62% with 800µm pores resulted in an 84% decrease in 
compressive modulus relative to the solid cube. Despite the clear inverse 
relationship between porosity and compressive modulus, the three designs with 
near 25% porosity had different compressive moduli, demonstrating that the 
mechanics also vary with the specific microarchitecture (pore size and strut size). 
Increasing pore size also resulted in decreased modulus with scaffolds containing 
200, 500, and 800µm pores with near 28% porosity having a compressive modulus 
of 503, 486, 327.5 MPa, respectively. 
Hybrid scaffolds were also tested for mechanics in compression normal to 
the plane of transition between microarchitectures (Figure 8-4B&D). The modulus 
of the hybrid scaffold was compared to the modulus of the more porous (softer) 
design and less porous (stiffer) design. In all cases, the hybrid scaffolds had moduli 
between those of the two constitutive homogenous designs. This result indicates 
that the transition between microarchitectures did not weaken the mechanics of 
the scaffold.  
Pore Interconnectivity Between Regions 
The porous interconnectivity between different microarchitectures was 
analyzed in predicted designs (Figure 8-4C). Because the nature of the interface 
depends on the position, extent, and curvature of the interface surface, pattern-to-
pattern interconnectivity could not easily be physically measured and was instead 
measured in in silico designs of the presented examples. All interface designs 
included connected pores. A portion of the connected pores were often reduced in 
individual area, but together represent a large area fraction of connected porous 
space (10-30% of boundary area) per interface.    
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Figure 8-4: Hybrid Scaffolds.  
(A) 3D previews of scaffold designs featuring a more porous half and 
less porous half which meet at a center boundary. (B) Schematic 
showing application of force and alignment of scaffold (C) Pore 
connectivity of transition plane: measured pore areas, number of pores, 
and area fraction of boundary plane that is connected pore space. (D) 
Compressive modulus of each transition scaffold compared to 
homogenous scaffolds composed of one of the pore diameter-porosity 
combinations found in the transition scaffold. 
 
Examples of Gradients of Pores and Porosity  
Gradient patterns of different porous microarchitectures were applied to 
cubes (Figure 8-5). First, we demonstrate the ability of scafSLICR to prepare 
gradients. It readily applied gradients in the print (z) direction (Figure 8-5A) or 
across the print layer (xy plane) (Figure 8-5B). Further, a 3D gradient was applied 
which graded the porous microarchitectures from the exterior to interior of the cube 
(Figure 8-5C). The cubes were larger than homogenous or hybrid scaffolds in 
order to accommodate the characteristic sizes (twice the sum of the pore and strut 
width) of the five patterns. The designs were 3D-printed without complication.  
193 
 
Figure 8-5: Gradients in Cubic Scaffolds.  
Pictures of cross-sections of 2x2x2 cm3 ABS scaffolds (left) and design 
(right). (A) Graded in z. (B) Graded in x. (C) Graded in xy. (D) Graded 





Examples of Anatomic Shapes 
Portions of the craniofacial skeleton were used to test shape complexity, 
pattern complexity, and scale. The zygomatic bone (Figure 8-6A) was printed with 
regular regions from left to right, arranged so the less porous design was at the 
narrow portion of the bone and the more porous was at the wider portion of the 
bone. The gradient of increasing pore sizes is visible to the naked eye.  
The hemi-mandible (Figure 8-6B) was graded into shells based on depth 
from the surface of the shape. A more porous pattern was applied to the outer 
shell, versus a more solid pattern along the inner core. This shell design could 
allow for cell ingrowth into the scaffold along the surface with some added stability 
from the inner core. There is good porous connection between the outer two shells, 
Figure 5: Gradients in cubic scaffolds. Pictures of cross-sections of 2x2x2 cm3 ABS scaffolds (left)
and design (right). (A) Graded in z. (B) Graded in x. (C) Graded in xy. (D) Graded in xyz.
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however the inner core was nearly solid and did not have many pores for 
connectivity.  
3D-printing thin structures is difficult, more so when the structure is 
manufactured with a porous pattern. The orbital bone shape (Figure 8-6C) has 
characteristically thin bones across the orbital floor. To print these faithfully, the 
shape was divided into regions based on the average thickness, which allowed the 
thin regions to be assigned a less porous, more stable pattern. Thicker, more 
stable regions were assigned more porous patterns. The arrangement of the 
patterns resulted in curved and interwoven boundaries throughout the shape. 
These boundaries maintained 10% and 20% area pore-connectivity for the three 
most porous patterns while the less porous designs had much lower connectivity 
(1.4% and 4.1% area fraction) concurrent with their decreased porosity and pore 
size. 
These large, curved shapes show step/staircase artifacts (particularly in the 
zygoma example) because there are multiple print levels for a single level of input 
voxels (input voxel edge = 0.600mm, slicing voxel edge = 0.100mm, printing layer 
height = 0.200mm). This staircase artifact could be resolved by smoothing the 



















Figure 8-6: Anatomic Scaffolds.  
Anatomic shapes from the craniofacial skeleton were labelled with 
different design regions, sliced with scafSLICR, and 3D-printed in ABS. 
(A) Zygomatic arch patterned linearly left-to-right. (B) Hemi-mandible 
patterned with shells from exterior to interior. (C) Orbital midface 





This work develops and implements an approach for the design and 
manufacture of 3D-printed scaffolds for tissue engineering applications. 
scafSLICR provides the ability to easily leverage the available design and 
manufacturing space available in additive manufacturing. In particular, the broad 
subset of porous microarchitectures can be dependably mixed together in patterns 
with mechanical integrity and porous interconnectivity.  
The cubic cross-hatch pore pattern used in scafSLICR has been used 
broadly throughout tissue engineering applications of 3D-printing. This structure is 
further varied here by changing both fiber-fiber spacing and the width and height 
of struts via adjacent and stacked fibers. scafSLICR operates across the design 
space of the hardware (nozzle diameter) to create porous micropatterns according 
to desired features (pore size, porosity). This design approach permits multiple 
porosities with the same pore size and multiple pore sizes with the same porosity. 
The availability of this breadth in the design space is important because porosity 
is most directly attuned with print mechanics and pore size with biologic function. 
Thus, by decoupling the pore size and overall porosity, one could change one of 
the properties throughout the scaffold without sacrificing the other.  
Different strut patterns beyond the classic cross-hatched rectangular 
patterns are possible. By off-setting the print direction to different angles or curves, 
the base pattern can be drastically alternated by z-layer and xy-location to create 
more complex patterns. Changing the base design from regular cubic cross-
hatched struts to another with different offset angles or arching fibers would 
increase the design space further, and perhaps influence mechanics and porosity 
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in beneficial ways. For example, Moroni et al. manufactured scaffolds with 0-45-
90 degree patterns of strut offset in order to closely match scaffold mechanics to 
the cartilage microenvironment396. Additionally, Szojka et al. 3D-printed scaffolds 
with alternating layers of parallel fibers with layers of radial ring fiber pattern407. 
Such changes could be implemented into scafSLICR by changing the template 
creation sub-routine.  
The design limits of the microarchitectures of this study are well suited to 
bone tissue engineering. There are well established constraints for bone tissue 
engineering scaffolds with regards to porosity, pore size, and mechanics. Porosity 
should be greater than 30% to provide space for tissue growth and 
regeneration408–410. Pores should range between 100µm and 1mm408,411,412. 
Mechanical moduli needed to mimic bone vary from 14MPa of trabecular bone to 
2GPa of cortical bone27,408,413,414. 
Scaling the manufacture of unique porous architectures to large shapes has 
been a challenge in the field, limiting the 3D-printing of anatomically shaped 
scaffolds. Many studies establish their techniques at scales less than 2cm in 
regular cubes and cylinders, which poorly reflects the challenges tissue 
engineering seeks to address. The complex geometric nature (curves, gaps, 
peaks, and small walls and divots) of anatomic shapes challenges the 3D-printing 
processes developed for cubes and cylinders. Moreover, when developing a 
slicing system for tissue engineering scaffolds, it is essential that the system can 
readily adapt to a variety of complex anatomic shapes. scafSLICR easily scaled to 
large prints, with regional heterogeneity that did not compromise porous or 
mechanical interconnectivity.   
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One of the major weaknesses of this study is the choice of material. While 
it is bioinert, ABS was used because of the manufacturing simplicity, speed, and 
cost. The mechanical assessments were used to validate that porosity influenced 
mechanics and were not to intended to demonstrate appropriateness for bone 
scaffold implantation. Towards that end, our research group has used scafSLICR 
to design and manufacture scaffolds in polycaprolactone and bioactive variations 
thereof (data not shown).  
Direct assessment of interior pores and transitions between different 
patterns is difficult. We assessed the boundary and the connected pores at the 
boundary in the sliced design and expect it to be similar to the manufactured case 
because the exterior print features are of high fidelity. Cracking or cutting the 
scaffolds were too imprecise to directly examine the boundary plane. Computer 
tomography scans are one potential method to directly assess the porosity at 
boundary surfaces. Scans could be registered with the sliced design matrix which 
would enable further validation of manufacturing quality.  
One strength of the programmatic nature of the MATLAB script is the rapid 
generation of GCODEs that vary tunable properties such as extrusion speed and 
temperature. Example 9 (Appendix A) demonstrates a higher throughput test of 
the parameter space by generating designs that vary in pore size and print speed.  
While the examples demonstrate the applicability of 3D-printing for bone 
tissue engineering, many other tissue engineering applications require porous 
scaffolds with known pore structures and mechanics.   
The outputs of scafSLICR enable design validation in silico before proceeding to 
manufacturing or implantation. The manufactured scaffolds in this study precisely 
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matched the porous designs. These digital porous models of the scaffolds could 
be used to assess properties such as mechanics, diffusion, or degradation. Such 
properties are difficult to directly measure, particularly in complex anatomic 
shapes. The ability to validate such critical attributes are within desired ranges 
before manufacturing or implantation provides a low-cost means to assure implant 
functionality.  
Despite the validation of print quality and print accuracy, scafSLICR is not 
validated at the level needed for medical software. It would need additional 
dimensional and resolution tests to demonstrate reliability with many complex 
shapes, design transitions, and materials. Importantly, the software validation can 
be compromised by the resolution and calibration of the specific 3D-printer and its 
ability to properly execute the GCODE.  
At a base-level, scafSLICR operates on a volumetric 3D-matrix. This matrix 
approach can be memory intensive (design matrix variables sometimes reach 
5GB) but allows for the inclusion of more spatial specific information across the 
3D-shape. Additionally, the 3D-matrix has direct correlation to the DICOM format 
used to obtain patient-specific anatomic shapes and allows for minimal 
manipulation of that data along the design and manufacturing process. In contrast, 
many slicing software systems operate on the common STL format, which only 
includes information on the surface topography and therefore slice based on 2D 




This work developed an approach to designing and manufacturing 3D-
printing scaffolds for tissue engineering, with direct control over scaffold features. 
It was successfully implemented in MATLAB (or the open-source OCTAVE) and is 
available at Mathworks Repository as modifiable source code and as a user-
friendly graphical user interface. Scaffolds manufactured with the approach were 
validated with sliced designs. Complex designs of graded pore patterns were 
demonstrated in regular cubes and complex anatomic shapes at scale. scafSLICR 
provides both an approach to designing tissue engineering scaffolds with 
controlled, heterogeneous complexity and scale as well as a readily available tool 
for tissue engineers to use in designing and manufacturing scaffolds across a 






Figure 8-7 Limitations of Hobbyist 3D-printing Software.  
Hobby modelling software creates structures with a thin exterior shell 
and supporting interior struts, which sub-divides the construct into 
isolated regions. Adapting this software to create scaffolds results in 
poorly controlled pore designs that are nearly totally occluded from the 




Figure 8-9 Design Paradigm for 3D-Printing Tissue Engineering Scaffolds.  
The common approach to studying 3D-printed scaffolds has 
manipulated the hardware properties (blue boxes) because the available 
software did not enable the precise control of fiber deposition. By 
controlling fiber deposition, we could control pore and strut parameters 
exactly (red box), resulting in an improvement to the characteristic cross-







CHAPTER 9  
OPTIMIZED DESIGN TO PATTERN POROUS AND MECHANICAL 





Regenerative CMF implants function as a temporary structure to position 
and pattern cells for tissue formation as well as a replacement for the mechanical 
function of the absent bone volume. Therefore, the designs of 3D-printed CMF 
implants must meet mechanical and regenerative design requirements. These 
design requirements are in conflict—for bone regeneration, implants must be both 
porous and mechanically strong. This work uses optimization algorithms in an 
approach to design 3D-printed craniofacial bone implants with both pores and 
mechanical strength. The algorithm is constrained to be, on the average, 50% 
porous and works to minimize deformation caused by physiologic load by 
patterning different regions of 30%, 50% and 70% porous microarchitectures 
throughout the design domain on the implant shape. Optimized implant designs 
were created and manufactured (3D-Printed) for a variety of craniofacial bones. 
Finite element modeling showed reductions in design deformation across 
zygomatic, cranial, and mandible implants. Reductions were greater in large 
implants (> 4mL, 20-30% vs unoptimized design) than small implants (< 2mL, 8 to 
12% vs unoptimized design).  The approach was also successfully used to design 




Annually, there are over 200,000 bone replacement procedures for the 
reconstruction of craniofacial bones1, which repair bone losses caused by trauma, 
congenital malformation, or cancerous re-sectioning. Compared with other skeletal 
defects, defects of the craniofacial bones are likely to cause disfigurement and 
psychosocial pathologies250,346. While bone has some self-healing capacity, bone 
replacement is required because these boney defects can be large in size and 
slow or impossible to heal. Additionally, craniofacial bone defects are challenging 
to treat due to their geometric complexity, large volume, and incident  
mechanical forces.  
These craniofacial defects have unsatisfying treatment options. The current 
gold standard of care is autologous bone grafting, which poorly replicates the 
mechanic and anatomic features of the predecessor bone and is resorbed at high 
rates16. Additionally, autologous bone grafts cause donor site morbidity and are 
limited in supply. Due to the low availability of bone grafts, permanent plastic, 
metal, and ceramic implants have become common. However, these artificial 
implants suffer from stress-shielding, loosening, implant extrusion, and infection 
rates—all conditions which lead to implant failure377,378.  
Over the past decade, there have been design improvements to reduce 
these failure rates. To reduce stress-shielding, the material preference changed 
from medical steel to PEEK which more closely matches that of the bone415.   
Infection rates were associated with the poor vascularity of implants, thus pores 
were added through the implants to permit blood vessel growth across the 
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implant416. Despite these improvements, cranial implants still fail relatively often 
and there remains a need for improved craniofacial bone replacement technology. 
3D-printed implants have emerged as a promising alternative treatment. 
Importantly, 3D-printing has the ability to manufacture implants in patient-specific 
shapes, enabling improved restoration of the original anatomy and aesthetic. In 
addition to the macro-scale anatomic shape, specific micro-scale architectures can 
be controlled and manufactured in the 3D-printing process. Different 
microarchitectures influence the mechanics and permeability417 of the implant as 
well as the biologic functions of cells283. The small-batch nature of 3D-printing also 
leverages the burgeoning field of biomaterials, where the material can be 
functionalized with bone forming signals232, biodegradation418, immune 
modulation419, or metabolites such as oxygen333. Together, these 
microarchitectures and biomaterials can impart a regenerative capacity to 3D-
printing implants, especially when combined with a drug420 or stem cell therapy421. 
Particularly our research group has developed 3D-printed bone scaffolds using 
fused deposition manufacturing26,232. When combined with stem cells these 
scaffolds lead to promising bone regeneration outcomes in mouse studies421.  
The design requirements of 3D-printed implants are in conflict as the 
technologies are translated to human scale. Implants intended to replace 
craniofacial bone have essential design criteria pertaining to mechanical support, 
anatomic shape, cell infiltration/seeding and growth, and fluid 
permeability/metabolite transport.  
• Anatomic shape: Bones of the craniofacial skeleton are highly curved, often 
thin/narrow projections, contain sinuses, or interact with teeth. Because 
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normative shape and defect shape vary from patient to patient, each implant 
design has different values for the design criteria, and each implant design is 
necessarily individualized.  
• Mechanics: The craniofacial bones provide vital support for mastication, 
respiration, and central nervous system protection (Figure 9-1). The forces 
from the loading regimens are conducted throughout the whole craniofacial 
skeleton as each bone buttresses others28,422. The base mechanical strength 
of 3D-printed biomaterials—especially when they are in porous patterns—is 
often less than that of native bone (3D-printed polycaprolactone232 porous 50 
MPa, solid 250 MPa vs trabecular bone423 0.1 to 2 GPa vs cortical bone423 15-
25 GPa).   
• Pores: The broad and sometimes wall-like function of the facial bones can 
separate the outside layer of soft tissue from steady vascular input. This lack 
of vascular influx can lead to tissue thinning, detachment, and resilient 
infection. Additionally, if the intention of the implant is to be regenerative, the 
pores function as a space for tissue formation and growth to occur. Implant 
porosity is the only way to for cells to dwell and function within the implant, and 
generally, regenerative implants should be between 50 and 70 percent porous 
with large pore from 100um to 1mm in width424.  Pore microarchitecture also 
impacts overall implant mechanics: increase of porosity directly decreases the 
mechanical strength of the implant. The inclusion of pores also reduces the 
manufacturability of small or thin features, especially when the pore size is on 





Figure 9-1 Forces on Craniofacial Skeleton.  
A.  Muscle attachments across the craniofacial skeleton create forces 
and loads on the bones. Adapted from Smith, Visible Body 2014. B. 
Buttress lines show how the forces are transferred from bone to bone 
across the craniofacial skeleton. Adapted from Janovic, Annals of 
Anatomy 2013.  
 
In combination, these desired mechanical, porous, and shape features of 
3D-printed implant conflict with each other.    
Porous heterogeneity could be used to solve the conflict between porous 
spaces and mechanical stability: portions could be less porous (mechanically 
stronger) to withstand forces, while other parts could be more porous 
(mechanically weaker) to provide space for vascular infiltration and tissue 
regeneration. Generic gradients and stock patterns could be used to automatically 
design implants with heterogenous porosity. While these patterns could improve 
the implant design, they are not optimal and poorly individualized. Optimization 
algorithms can be directly integrated within the design process.  
Topology optimization algorithms have been used to design solid implants 
for the midface skeleton in response to geometric and loading constraints425,426. 
More similar to the work herein, Hollister et al. have used topology optimization 
algorithms to design porous bone implants for spine427 and mandible428. This work 
Mastication: Many muscle attachments 
in complex patterns in context of airway 
and d n e facial features
Forces from impact and
masticat on are distributed 
across buttr sses of the face
Smith, Visible Body 2014. Janovic, Annals of Anatomy 2013
A B
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uses an optimization algorithm to determine the optimum heterogenous pattern of 
porous microarchitectures that resist deformation from physiologic loads on 
individual, anatomic-shaped implants.  
Approach 
Designing a Patient-Specific Shape 
In most cases, the normative anatomy to replace the missing bone can be 
obtained from pre-injury scans or simple reflection of the contralateral side (Figure 
9-2). This shape can provide geometric constraints with regards to the outside 
surface of the bone and the joining with the remaining surrounding bone. However, 
craniofacial bones have thin walls surrounding a sinus cavity, and 3D-printed 
(especially porous patterned) implants do not work well with these thin walls or 
narrow standalone features. Further, the thin walls would not provide ample design 
space/domain for the optimization to occur. Thus, to enable 3D-printing and to 
increase the overall strength of the implant, the design shape is a solid version of 
the intended bone, with sinus and cavities filled in. 
Fixation hardware can be added in the form of plates and screws at the time 
of surgery or included as a part design shape. Herein, designs include solid fixation 
plates that can be screwed into the surrounding bone and hold the implant in place. 
The possible fixation points can be identified from the edge of the defect with 
surgeon input. Generally, the buttress lines of the craniofacial skeleton which 
intersect with the implant are preferred locations for implant fixation.  
CT scans were imported into MIMICs (Materialise, Belgium) where the 
contralateral bone was selected, the wrap function was used to remove sinus 
cavities, and the resulting 3D-object was exported as an STL file. The STL file was 
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opened in SolidWorks (Dassault Systèmes, France), reflected across the 
midsagittal plane, and saved as a new STL file. The reflected STL file was imported 
into MIMICs and positioned into the defect space. The overlap of reflected and 
remaining host bone was removed, resulting in a smooth and precise joining 
between host bone and implant. STL of plate fixation was imported into MIMICs 
and placed along the buttress lines where the implant met the skeleton. Finally, 
the whole implant and fixation design was exported as color-coded DICOM sets 




Figure 9-2 Flow Chart of Anatomic Shape and Physiologic Forces.  
A CT scan reveals the defect shape and a contralateral uninjured 
anatomic shape. The uninjured shape is reflected and attached with 
fixation tabs along buttress lines. Finally, physiologic forces are applied 
to the shape.  
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Approximating Physiological Loads  
Implants need to endure the forces acting on the craniofacial skeleton. 
Herein, the loads on the craniofacial skeleton are generalized into three conditions: 
mastication, resting weight, and impact. Mastication forces are distributed across 
the craniofacial skeleton with the different muscles involved, and the buttressing 
action which conducts those forces. On teeth, mastication is approximately 20N, 
and varies by food type and chewing pattern429. The resting weight of the head on 
a persons' hand, pillow, or other position is substantial (a human head weighs 
approximately 5kg or a resting force of 50N).  Examples of impact forces to the 
face include falling and hitting the head, a punch or other blunt trauma to the head. 
In the MATLAB implementation, static forces can be input as point loads or 
dispersed loads and the resulting deformation is calculated. Because it is difficult 
obtain exact measures of expected force, simplifications are used as inputs, with 
the goal of reducing compliance for such general loads. Therefore, the location, 
angle and relative scale of the forces is sufficient for the optimization to produce 
useful designs. The resulting optimized designs can be failure-rated to find the 
yield or deformation force for each type of load to provide user assurance of 
function.  
3D-Printing Material and Microarchitectures  
Solid material and three different porous patterns were considered as 
microarchitecture options to be assigned throughout the shape (Figure 9-3). An 
800-micron width was chosen as a uniform pore width in each of the porous 
designs in order to keep the designs similar in pattern and biologic influence. 
Polycaprolactone was selected as the material because of printability, 
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biocompatibility, biodegradation, and common use throughout the literature241. The 
effective compressive moduli of the different pattern choices were measured. This 
measurement does not fully recapitulate a mechanical modulus and Poisson's 
ratio.  
There are regions of craniofacial skeleton that are below the print resolution 
of the printer. Further, each of the porous pattern options has a different minimum 
characteristic pattern width (determined by the strut and pore dimension), which 
influences the minimum permittable region in the optimization algorithm. 
Therefore, thin or narrow structures are automatically identified. Those that are 
below the solid domain resolution are dilated to meet that resolution (e.g. 350µm 
to 1mm) and those regions less than the porous options minimum pattern width 
were moved from the design domain to the solid material domain. These 
adjustments ensure the manufacturability of the shape as well as the inclusion of 





Figure 9-3 Flow Chart of 3D-Printing Constraints.  
The 3D-printing patterns used in this work. To ensure manufacturability, 
portions of the design thinner than the manufacturable size are dilated 
to the minimum manufacturable size. The adjusted design and solid 
domains are passed into the optimizer.  
 
 
Optimization Algorithm  
Using topology optimization algorithms adapted for the constraints (shape, 
pore microarchitectures, porosity) of craniofacial bone implants, designs were 
optimized to minimize the compliance of the scaffold at static physiologic loads. 
The algorithm models compliance according to Hooke's law. This finite element 
model uses the moduli and incident force to approximate each element's 
displacement, and the corresponding global compliance. The moduli are modeled 
using the simplified isotropic material with penalization430 (SIMP) approach to 
create penalized intermediate moduli values of the moduli (Figure 9-4). This 
penalization creates derivatives towards the design options. The sensitivities are 
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also calculated for each element's compliance with respect to changes in porous 
pattern choice. The combined sensitivities are used to shift elements to new design 
(porous microarchitectures) values according to optimality criteria, within a certain 
step size. Finally, a filtering step prevents the appearance of checker box patterns 
and allows implementation of a minimum region size431. The total of the changes 




Figure 9-4: Flow Chart of Optimization Algorithm.  
The compliance is calculated using penalized moduli and the 
sensitivities of it are filtered and then used select new designs with 
greater or weaker moduli. The new design is then used to calculate the 
compliance for the next iteration. If the improvements in compliance 
converge, the final design is output.   
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Algorithm Implementation in MATLAB 
The algorithm was implemented in MATLAB (MathWorks, Natick, 
Massachusetts) by combining the code from a 3-dimensional optimization 
approach Liu and Tovar432 and a multi-material 2D optimization approach from Zuo 
and Saitou433. It maintains the ordered simplified isotropic material with 
penalization interpolation from the multi-material approach. The finite element 
model uses nodes, as implemented Tovar et al, across the combination of the 
design domain and the solid domain.  
The optimization software was run on a desktop computer with a quadcore 3.4 
GHz processer and 32 GB of memory. The shapes ranged from 3,000 to 100,000 
elements, which required twenty to forty minutes to prepare the mesh and between 
one and fifteen minutes for each iteration of the optimization algorithm. Because 
the shapes are non-regular, we developed a graphical user interface to easily 
assign loading and fixation locations. Code and an example are provided in 
Appendix B.   
 
3D-Printing Methods 
The resulting optimized design was passed to a custom MATLAB slicing 
algorithm (Chapter 8) which prepared a GCODE file with different microporous 
architectures patterned throughout the shape according to the design. The 
GCODE file was 3D-printed on a Lulzbot Taz 5 3D-Printer (Aleph Objects, Ohio) 





In addition to a patient defect, different facial bones were isolated and 
designed as implants. The optimization ran on a desktop computer. Generally, the 
optimized designs had connections of low porosity-high strength pattern between 
fixation and loading points. Compliance of the designs decreased from the 
homogenous starting condition in every case.  
The available designs fed to the optimization all contained 800µm pores, 
with porosities of 28%, 45%, and 62%. The normalized moduli of those designs 
(compared to solid material) were 0.39, 0.26, and 0.12. The total porosity of the 
design region was constrained to 50%. Screw holes were fixed in 3D-space.  
Case 1: Zygomatic Arch 
The portion of the zygomatic arch was isolated; it was 2.7cm in length and 
had a volume of 1.5mL. As fixation, a single screw plate was designed on the 
posterior, narrow edge and a double screw plate was added on the anterior, 
maxillary edge. The design was constrained by buttress planes at the edge 
surfaces which connected to the zygoma and maxillary bones. The load was input 
to mimic the masseter attachment along the transverse frontal edge of the implant 
(Figure 9-5).  
As a result of the optimization, there was a beam-like continuity of denser 
patterns along the region of muscle attachment and connected to the fixation 
points. The displacement of the implant was reduced by 11% from an unoptimized, 
homogenous porous design to the optimized design.  
The 3D-printed model closely matched the expected design. The individual 
zones of different patterns were grossly evident and contained 2 – 10 pores per 
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zone. The dimensions were accurate to the design. However, there were artifacts 
from the support structure used along the frontal surface of the print, resulting in a 





Figure 9-5 Optimization of a Zygomatic Shape.  
(A) The input to the optimization algorithm: shape (blue), fixation points 
(red), force (yellow), and buttress planes (green). (B & C) The resulting 
optimized design with different microarchitectures: solid (red), 72% solid 
/ 28% porous (yellow), 55% solid / 45% porous (teal), and 38% solid / 
62% porous (blue). (D) The design with the corresponding pores 
microarchitectures patterned throughout. (E) Views of the 3D-printed 











Figure 9-6 Optimization of Portion of Mandible 
(A) The input to the optimization algorithm: shape (blue), fixation points 
(red), force (yellow), and buttress planes (green). (B & C) The resulting 
optimized design with different microarchitectures: solid (red), 72% solid 
/ 28% porous (yellow), 55% solid / 45% porous (teal), and 38% solid / 
62% porous (blue). (D) The design with the corresponding pores 
microarchitectures patterned throughout. (E) Views of the print during 
the printing process with 20% and 60% of the print complete. These 
views highlight the different regions of porous patterns within the design. 





Case 2: Mandibular Ramus 
A hemimandible (approximately from the mental foramen to 1cm from the 
temporomandibular joint) was selected (Figure 9-6). It was approximately 5.2cm 
in length, 2.7cm in thickness, and had a volume of 13.6mL. Double screw plates 
were added to the design to attach the implant to the body of the mandible 
anteriorly and the ramus of the mandible at the joint, posteriorly. The load was 
applied along inner angle. 
 The optimization patterned denser patterns along the interior of the implant 
shape and along the mastication surface, connecting to the fixation points. The 
displacement of the implant was reduced by 22% from the unoptimized control 
case.  
The 3D-printed model matched the design as expected. However, rotations 
applied to the optimized design matrix and contraction (from cooling) during the 
printing process skewed the final output shape and increased the angle of the 
implant between the two fixation points. The different porous regions were clearly 
visible and correlated with the optimized design. The fixation tabs were very 
strongly integrated into the body of the print.  
Case 3: Cranium  
A section of the frontal cranial bone was selected (Figure 9-7). It was 16.2 
mL in volume and approximately 6.5 cm x 2.1 cm x 7.5 mm in size. Double screw 
plates were added on every adjoining edge and the load was applied in an 
orthogonal direction to the center of the implant.  The optimization pattern had 
denser patterns in the middle of the implant connecting to the fixation tabs, with 
the less dense patterns along the outer portions of the implant that were in contact 
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with the hose bone. The displacement of the implant was reduced by 25% from 
the unoptimized control case. The 3D-printed model very closely matched the 
design, and the different porous patterns were grossly observed and matched the 
optimized design.  
Case 4: Patient Case  
Designs were created for a patient case (Figure 9-8). The anterior cranial 
scaffold was 47.0 mL in volume and had a size of 7.89cm x 9.6cm x 9.6mm. The 
optimization resulted in a design with a 45% reduction in displacement compared 
to the homogenous control design. The posterior cranial scaffold was 62.0 mL in 
volume and had a size of 11.0cm x 8.0cm x 1.2cm. After optimization, the design 
had a 44% reduction in displacement.  
The 3D-prints of the patient case implants were less curved than the design, 
which is likely due to warping of the plastic as the print cooled. The anterior case 
used tabs for fixation, while the posterior case used a lip design to hold the 










Figure 9-7: Optimization of a Portion of the Frontal Bone.  
(A) The input to the optimization algorithm: shape (blue), fixation points 
(red), force (yellow), and buttress planes (green). (B & C) The resulting 
optimized design with different microarchitectures: solid (red), 72% solid 
/ 28% porous (yellow), 55% solid / 45% porous (teal), and 38% solid / 
62% porous (blue). (D) The design with the corresponding pores 
microarchitectures patterned throughout. (E) Mid-print view of the 
implant shows the different porous regions in the interior of the scaffold. 
(F) Views of the 3D-printed optimized design from the inside (left) and 

















Figure 9-8: Optimization of a Patient Case.  
(A & B) Shape design of scaffolds to replace bone in a patient with two 
cranial bone defects. The red shape uses tabs to fixate the implant to 
the remaining skeleton, and the blue shape uses a lip structure to hold 
the implant in place. (C & D) The optimized designs for each case were 
3D-printed and demonstrate the different pore patterns across the shape 








The design of regenerative CMF implants is difficult due to their conflicting 
design goals. The goal of this study was to design implants with improved 
mechanical function and with porosities appropriate for regeneration. We tested 
the hypothesis that heterogeneous mixtures of microarchitectures could be 
designed according to the fixation and physiologic forces on the implant, and that 
such designs deform less than homogenous patterns. While the optimized designs 
were stronger than the homogenous designs, the degree of improvement was 
dependent on sufficient volume for the optimization algorithm to create useful 
designs— the improvements of the large scaffolds (cranial, mandible) were twice 
that of the smaller zygomatic design.  
The design process for patient specific implants herein is dependent on a 
normative contralateral side. Cases where there is no normative anatomy to reflect 
could rely on modeling of the normative shape from the remaining portions of the 
skull434.  
By making thin features solid and non-porous there is a risk of the implant 
degrading without any bone formation occurring there, which could lead to implant 
failure. This risk could be alleviated by leveraging true multi-material 3D-printing 
and placing a permanent implant material in that region.  
 The optimization has a requisite porosity limit (50%), and regions of stiffer 
material are spatially patterned throughout the shape to reduce deformation 
caused by input loads. The entire shape must have some material placed there, 
and to meet the requisite porosity, there is a limited amount of higher stiffness 
regions that can be patterned. None of the optimized designed eliminated 
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deformation with that available design space. The optimization goal and major 
constraint could be switched: the mechanics could be constrained to non-
deformative designs and the objective goal could be maximization of porosity.  
Because the model operated on cubic elements, the resolution of the model 
impacts the resulting design. Generally, the designs from the CT scan are down-
sampled to enable the MATLAB scripts to operate on the desktop computer. These 
down-sampled resolutions (1-2mm), minimum region size of the 3D-printed 
patterns (1-3mm), and the resolution of the xy-positioning of the print features 
(~10µm) all combined nicely in designing and 3D-printing these implants. Design 
accuracy could be improved by up-sampling the optimized design and applying it 
to the high-resolution CT shape.  This extra step would also remove staircase 
effects from the design process from the surface of the implant.  
There were a number of assumptions in the modelling portion of this work. 
First was the assumption of using a measured effective modulus of large, regular 
scaffolds of homogenous pore microarchitecture as an input to model the 
mechanics of irregular patterns that did not always finish on a complete repeating 
unit. This assumption significantly simplified the model and enabled desktop 
implementation. Further, the model does not account for the anisotropy of the 
porous patterns or of layer-by-layer 3D-printed implants. We have shown27 that 
print direction can influence the strength of the implant: mechanical strength along 
to the print axis was 150% that of the mechanical strength in directions orthogonal 
to the print axis. A more accurate model would measure the modulus and directly 
model the porous strut designs. 
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Second, the magnitude and complexity of the incident loads were assumed 
and simplified from literature. In addition to the static load cases modelled in the 
examples, the CMF skeleton undergoes more complex cyclic loading from 
mastication and sharp impacts from collisions.  Additionally, the model combines 
all the input loads into a single case and minimizes the resulting deformation, 
rather than considering each load case separately.  
Third, Hooke's law is not well suited to modeling the mechanics of plastic 
fibers—it works on the premise that there is no plastic deformation, which is untrue 
in polycaprolactone and other thermoplastics used in 3D-printing. The results 
herein use Hooke's law and only accurately describe the small elastic deformation 
that occurs at low strains.   
Perspectives 
Other optimization goals for craniofacial implants are possible. For 
example, there could be a need to ensure diffusion throughout the porous space 
of the scaffold. Indeed, unit cells with specific permeability properties have been 
designed417,435. The objective function could be weighted to include these features. 
This design approach could also be applied to different additive manufacturing 
approaches. Different microarchitectures with a range of regenerative properties 
(mechanics, porosity, pore size, permeability, etc) could be prepared for the 
manufacturing approach. Then the algorithm could pattern them throughout the 





This chapter developed an approach to designing craniofacial implants 
while addressing conflicting design goals. The approach herein balanced those 
design goals and results in designs that demonstrate improved mechanical 
properties and were able to be 3D-printed. This process is readily applicable to 
defects of various portions of the craniofacial skeleton—however the improvement 
that results from patterns of different microarchitectures is most pronounced in 
large defects.  While the mechanical modeling used is simplistic, the resulting 
designs intuitively correspond to the applied load schemes and provide a 
mechanically improved design compared to homogenous scaffolds. Altogether, 
this study provides a design perspective to improve the mechanics of 3D-printed 




CHAPTER 10  
PORCINE MODEL OF CRANIOFACIAL BONE REGENERATION USING  
3D-PRINTED SCAFFOLDS AND STROMAL VASCULAR FRACTION CELLS 
 
Summary 
Human-scale, living, mammalian models are necessary for developing 
regenerative craniofacial bone treatments. Our regenerative 3D-printed scaffold 
and stem cell treatment demonstrated full regeneration of critical-sized defects in 
mice, but that study could not address the concerns of scale, mechanical 
integration, and immune interactions. Herein, we test that technology in a large 
preclinical animal model: the swine zygomatic arch. Scaffolds were designed, 3D-
printed, and within a design and manufacturing validation framework. The resulting 
scaffolds were implanted into ‘patient-specific’ matched osteotomies in the 
zygomatic arch of skeletally mature Yucatan mini-pigs. Concurrent with 
implantation, stromal vascular fraction cells were isolated from the pigs and 
seeded into the implants to model a point-of-care application. At 6-weeks and 3-
months, the scaffolds pore spaces were filled 40% and 60% with bone, 
respectively. This work demonstrates the regenerative ability of these patient-
specific 3D-printed scaffold in the context of full thickness craniofacial bone 
defects.  
Introduction 
Among craniofacial bone injuries, mid-face and periorbital injuries represent 
a unique surgical challenge due to the orbit and the buttressing structure of the 
zygomaticomaxillary complex. There is a high incidence of orbital fractures and 
severe globe injuries in mid-face injuries, conjoint with a high complication rate 
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(30%) with current treatment modalities that include malalignment, implant 
exposure, and infection.  
Stem cell and scaffold combination treatments represent a promising 
alternative to bone grafting or solid implants treatments. In particular, the stromal 
vascular fraction of the adipose tissue (SVF) contains stem cells that are readily 
accessible and applicable for bone regeneration. The passaged form of these 
cells, ASCs, have been the focus of a large amount of literature and are well 
characterized.  In human studies thus far, the outcomes of SVF in boney healing 
has focused on safety outcomes, and do not present convincing data for or against 
the role of SVF in bone metrics.  In mice, we have demonstrated that ASCs and 
SVF (in combination with the 3D-printed bone scaffold) lead to high levels of bone 
regeneration421.  
While tested in these small animal studies, only a few groups have tested 
SVF or ASCs for bone regeneration in large, preclinical animal models. Of note, 
Bhumirta et al. tested ASCs in a mandibular defect by seeding autologous ASCs 
into a decellularized bone graft and culturing in a bioreactor before implantation 
and found increased bone volume and vascularity, and reduced resorption of the 
implants379. Therefore, there is an urgent need to test the potential of the approach 
in a large-animal preclinical models, because small animal and human studies 
have only demonstrated the effectiveness of SVF in small scales, and that it can 
be safely used in humans, respectively. 
A living, mammalian model approximating human size is necessary for 
evaluation of scaffold and cell combination approaches.  Mathematical models or 
computer simulations cannot duplicate the complex immune responses or bone 
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healing and remodeling required to evaluate reconstructive surgery. Further, large 
animal testing is an important step in translating technology from the lab to the 
clinic because it demonstrates the safety, effectiveness, and implementation of the 
technology to the United States of America Food and Drug Administration and the 
surgeons that might adopt the approach. Only a large animal model can inform the 
mechanical integration of the implant, bone growth dynamics, and unforeseen 
complications.  
Swine is an advantageous species for the study interventions of the 
craniofacial bones before human implementation. The similarities of the oral 
maxillofacial region in swine and humans regarding anatomy, development, 
physiology, and disease occurrence allows the study of craniofacial skeletal 
structures in a clinically relevant manner436,437. Particularly, the constitution of the 
orbit and its position with respect to the periorbital bones are closer in anatomy 
and scale to humans than other preclinical models such as dog or monkey438,439. 
In order to test our 3D-printed scaffold and stem cell approach for bone 
regeneration, we developed a novel, zygomatic, full thickness, bone defect model 
in swine. The zygomatic arch has some anatomic complications: the maxillary 
sinus extends into the zygoma and connects this mucosal airway with the implant; 
the sinus also reduces the purchasing power of screws used along the maxillary 
edge of the defect. Compared to other craniofacial bone defects, a transcutaneous 
approach avoids complications with interfacing with the brain cavity or oral 
environment.  
To test the approach in immune competent swine, we developed a standard 
procedure to isolate autologous SVF from pigs, with comparable results to isolating 
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human SVF. Additionally, that isolation was optimized to happen within an 
intraoperative time period of forty minutes. Excised fat tissue from pig is very 
different from liposuction aspirate obtained from humans: it is exceedingly fibrous, 
solid at room temperatures, and often contaminated with muscle or dense fascia. 
The primary alterations to standard digestion were extensive mincing at the outset 
of the isolation, the increased concentration of collagenase, the shortening of the 
collagenase digestion period, and the overlap of the size filtering and red blood 
cell lysis steps.   
This study is designed to closely mimic the logistics of the envisioned 
clinical application: treatment in a single surgical session. First, a preoperative CT 
scan obtains the geometric information of the defect and the implant. Then the 
implant is designed, manufactured, and sterilized. Second, at the time of surgery, 
fat tissue is recovered from the patient and stem cells are isolated. While the cells 
are isolation from the tissue (a period of 30-40min), the surgeons implant the 3D-
printed bone. Finally, at the end of the surgery, the isolated cells are injected 
directly into the implanted bone. Third, the stability and regeneration of the implant 
is monitored over time with CT scans (Figure 10-1).  
Thus, this study has the following goals: (1) Design a non-healing defect to 
test bone regeneration in peri-orbital bone. An empty control group will show non-
healing nature of the defect. (2) Prepare scaffold implants for the model in 'patient 
specific' manner with design and manufacturing validation. (3) Use the defect 
model to assess the bone regeneration caused by 3D-printed bone scaffolds and 





To test our 3D-printed craniofacial scaffolds with SVF for periorbital bone 
regeneration, we compared the bone healing outcomes in three groups: (1) empty 
defects, (2) acellular 3D-printed implants, and (3) 3D-printed implants and SVF. 
We hypothesize: (1) that the 3D-printed, bioactive scaffold and stems cells enable 
the rapid formation of vascularized bone in the same shape as the implant and (2) 
that the untreated empty defect will not heal over the course of the study. The study 
occurred in two parts: first a small 6-week pilot study to test the approach and 
implant fixation, as well as test the non-healing nature of the defect; and second a 












Figure 10-1 Swing Zygomatic Implant Study Outline  
(A) Labelled (red box) region of interest on the zygomatic arch of swine 
in a pre-operative CT. (B) Using the pre-operative CT scan, an implant 
is designed. (C) To validate the design, a model is 3D-printed and the 
dimensions and rigidity is assessed. (D) Using a validated design, the 
implant is 3D-printed in PCL-DCB material. (E) The implant is scanned 
to confirm the presence of DCB particles throughout, and the open and 
structured porous network. Then in a single surgical procedure, SVF 
cells are isolated, placed in the implant, an osteotomy is created, and 
treated with the implant. (F) Post-operative CTs monitor the fate of the 









Figure 10-2 Designing the Zygomatic Defect in Cadaver Samples.  
(A) A transcutaneous approach is used to access the zygomatic arch. 
(B) A 2cm full thickness osteotomy is created in the body of the zygoma.  
osteotomy. (C) A (prototype) scaffold is placed in the osteotomy. (D) 
There is good agreement between the excised bone and the matched 
implant.  
 
Design of Animal Model 
A cadaver head of Yucatan swine was obtained from Exemplar Genetics 
(Sioux Center, IA), and a CT scan was conducted. The scan and the head were 
used to prototype the defect design and surgical approach. Given the anatomy of 
the zygomatic arch, a defect was designed between the anterior prominence and 
the posterior suture line. This defect position avoids the complicating curvature of 
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the prominence and reduces the potential of fracturing the suture line during the 
creation of the osteotomy.  
The defect was developed in collaboration with an expert maxillofacial 
surgeon to closely mimic current clinical procedure, and a characteristic width of 
2cm was chosen to model a non-healing critical size. Because this is a novel 
defect, we will establish that a full thickness defect of this size and location is non-
healing in swine. A transcutaneous surgical approach was selected because of 
anecdotal evidence of swine developing infection and serious complications with 
intra-oral approaches. This approach is a deviation from human care, where the 
general preference is intra-oral to prevent scarring on the cheek. Cadaveric 
exploration revealed the dense periosteum, attachments of the masseter muscle 
on the bottom rim and inside rim (Figure 10-2). There was an absence of 
complicating anatomy such as nerves or large blood vessels.  
A CT scan of each study animal was used to plan the osteotomies in an 
animal-matched manner. The scans were loaded into MIMICs software suite. A 
characteristic 2.0cm osteotomy was designed in each zygomatic arch (bilateral 
defects in each animal). The defects were, on average, 6mL in volume, and 2.0cm 
along the frontal contour and 1.5 cm along the interior contour. This 0.5cm 
decrease from exterior to interior width accommodates the curvature of the 
zygomatic arch, it allows both saw cuts to be perpendicular to the bone surface at 
their locations.  
Further the defects were approximately 2.5cm height and 1.5cm depth, a 
full thickness gap in the zygomatic arch. A control group of empty, non-treated 
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defects confirms that these defects do not spontaneously heal over the course of 
one year.  
Cutting guides were designed so the osteotomy precisely matches the 
design (Figure 10-3). The guides covered the entirety of the anterior surface of the 
defect, were 2mm in thickness, and contoured flush with the surface of the bone. 
This thin profile aided in placing the cutting guide in the incision site and left room 
for fingers and surgical tools to manipulate the site. The cutting guides were 









Figure 10-3: Cutting Guide Design  
 The cutting guide design (red) is a 3mm thick shell over the anterior 
surface of the osteotomy. It is 3D-printed in ABS, with a hole on the nasal 
side of the guide to ensure correct orientation.  
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Design of the Implant 
Implants were designed to exactly match the shape of the resected bone. 
The digital design of the osteotomy was used to create an implant that matches 
surface of the resected bone. The sinus cavity was removed from the design to 
create a uniform implant. Finally, fixation plates (1cm x 2cm x 2mm) were attached 
on the frontal surface of the implant to hold in place. The final design was exported 
to MATLAB slicing software (scafSLICR, chapter 8) to generate a final design that 
was 60% porous with 800µm pores throughout the body of the implant and 100% 
solid along the fixation arms (Figure 10-4). 
Design Validation  
To validate scaffold design, scaffolds were 3D-printed in ABS. The critical 
dimensions were measured and checked against the design value in mimics. The 
congruence of the print shape to the design shape was also confirmed. Errors in 
the dimensions and congruence were corrected by editing the MATLAB code 
which imported the designs from Mimics to the scafSLICR program.  
Mechanics of the tab attachment is depended on the number and location 
of 3d-printed fibers connecting the fixation tab to the porous region of the scaffold. 
This attachment was testing by hand: scaffold tabs were twisted with egg-cracking 
force. Additionally, the ABS scaffolds were placed in a bending rig and loaded with 
a 200g weight. Scaffolds that bent under handheld twisting or the rig were 









Figure 10-4: Zygomatic Implant Design Process.  
(A) The pre-operative CT was used as a base. A 2cm region (blue) 
between the notch (purple asterisk) and the curve of the maxilla (purple 
#) was used as the body of the implant, and fixation tabs were placed to 
hold the implant in the predicted osteotomy. (B) The resulting design had 
curving prominences on the front and back of the implant. It is exported 
to MATLAB. The blue region will become porous and the fixation tabs 
(red) will be solid. (C) The porous and solid regions are exactly designed 
in scafSLICR. (D) The design is transformed into matching GCODE 
instructions for the 3D-printer. Over 18 animals, the scaffold volumes 
(E), material volumes (F), and porous volumes (G) varied from animal 




















Figure 10-5 Zygomatic Scaffold Design Validation  
(A) The design of the implant with important characteristic dimensions 
labelled. (B) The prototype of the design 3D-printed in ABS to confirm 
the dimensions and orientation of manufacturing the design. (C) Rig to 
test the rigidity of the design, especially of the connection between the 




Manufacture of Bioactive Implant 
Scaffolds were manufactured of clinical-grade materials. Purac PC12 
(Corbion, Netherlands) was used for polycaprolactone. Bio-Oss granules 
(Geistleich, Australia) were used for decellularized bone. Materials were handled 
in a sterile manner whenever possible, however portions of the manufacturing 
process were completed on an open-air benchtop. Therefore, the scaffolds were 
extensively washed and sterilized before implantation.  
The Bio-Oss was cryo-milled as described in chapter 4. Then the Bio-Oss 
particles and Purac were cryo-milled at a 30:70 weight-weight ratio. This second 
cryo-milling process generated a well-mixed particulate of both ingredients. This 
particulate mixture was fed into a laboratory mixing extruder (Dynisco, Germany) 
to melt the mixture and prepare it as 2.8mm diameter filament to use in 3D-printing 
(Figure 10-6).  
The filament was loaded into a Lulzbot Taz5 3D-printer (Aleph Objects, 
Ohio), at 40mm/min, with a 500µm diameter brass nozzle, heated to 110°C, onto 
a glass bed heated to 40°C and covered with double-sided tape. Porous designs 
and corresponding GCODE files were prepared in scafSLICR (chapter 8). Final 
scaffolds had an average mass of 3g. 
To enable cell attachment, scaffolds were washed in 3M NaOH, and then 
washed with PBS 3x 20min. Scaffolds were then extensively washed in an ethanol 
ladder and then sterilized with ethylene oxide gas treatment.  
Manufacturing Validation 
Manufactured scaffolds were imaged with a stereoscope to validate critical 
dimensions and print quality. Width, height, and depth measurements with calipers 
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and the stereoscope confirmed that the scaffolds were manufactured to 
specification and within a tolerance of 200µm (Figure 10-7).  
Scaffolds were also scanned using cone beam computed tomography 
(Carestream C-arm, 65 kiloVolt peaks, 0.1mm resolution). Mimics was used to 
measure the connectivity of the porous network, the average pore size, the pore 
volume, the material volume, the surface-to-volume ratio, and the range and 
average density of the scaffold. The scans were also imported into MATLAB, 
where they were divided into 4mmx4mmx8mm sub-volumes. The density, porosity, 
and print quality were assessed across the sub-volumes (Figure 10-8, 10-9, 10-
10). 
 
Figure 10-6: Filament Manufacturing Process  
(A) A filament extruder mixes and extrudes the PCL-DCB powder as a 
3mm filament (1), which is then passed through a chilled water bath (2), 
and collected using a filament winder (3). (B) This process results in long 
filaments 1-3m in length. (C) Measurements of the diameter of two 
filaments at multiple points along the filament.   
 
 
Figure 10-7: Stereoscope Images of 3D-Printed PCL-DCB Implants.  
 (A) Interior side of implant, final print layer. (B) Exterior side of implant, 
where the support material was removed. (C) Maxillary and (D) 










Figure 10-8: Cone Beam CT Scans of the 3D-printed implants.  
(A) Semi-transparent rendering of the scan shows the porous, regular 
interior of the scaffold. (B & C) Interior view cutaways of the scaffold.  
(D) Average mineral density of the scaffolds (with standard deviation). 
(E) Average pore diameters of the scaffold. (F) Specific surface area of 









Figure 10-9 MATLAB validation of manufacturing  
(A)  CT scan of an implant. (B&C) the imported scan is divided into sub-
volumes (4mmx4mmx6mm, 120/scaffold). (D) Average mineral density 
of each individual sub-volume. (E) Effective porosity of each subregion. 
Some sub-volumes contain no portion of the scaffold. (F) Histogram of 
the average density of the sub-volumes. (G) Histogram of the effective 




Figure 10-10 Pore layer validation of print quality. 
The scan of the scaffold divided into 800µm thick planar sections parallel 
with the print bed plane. This shows porous regions that have the 
expected regular cross-hatch pattern and the solid regions that are 





In conducting research using animals, the investigator(s) adhered to the 
laws of the United States and regulations of the Department of Agriculture. The 
animal implantation study was conducted at the Louisiana State University under 
an approved Institutional Animal Care and Use Committee protocol (#18-037). A 
total of 10 skeletally-mature Yucatán minipigs (Sinclair Bio-Resources, Auxvasse, 
Missouri) were divided into three groups: (1) control (n=2) (2) treatment (n=6) and 
(3) bone graft (n = 2). Each pig was operated bilaterally to maximize the use of 
each animal. Pigs were 1-year old castrated males.  
The cell harvest and scaffold implantation procedure occurred after 12-
hours of food withdrawal. Intramuscular administration of ketamine (10mg/kg; 
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Vedco Inc.) midazolam (0.2 mg/kg; Hospira Inc.) and dexmedetomindine (2 µg/kg; 
Pfizer Animal Health) were used to sedate the animal. Anesthesia was induced 15 
min later with 5% isoflurane in 100% oxygen flow (1.5L/min) via facial mask.  The 
animals were intubated with a cuffed Murphy's endotracheal tube and anesthesia 
was maintained at 1.5% in a circular breathing system. Pigs were prepped and 
draped in standard sterile fashion (Figure 10-11).  
Following euthanasia, the animals were immediately decapitated, and the 
samples were shipped from Louisiana State University to Johns Hopkins University 
on ice. The skin covering the implant was reflected, and the zygomatic arch was 
cut at the anterior and posterior ends. Samples were fixed in agitated 10% formalin 
for one week at 4°C, where the solution was replaced daily. Thereafter, the 
samples were stored at 4°C and a PBS solution containing 1% sodium azide.  
Autologous Porcine SVF Isolation 
Subcutaneous fat (about 20g) was harvested from the dorsal lumbar region 
of each animal at the same time as the zygomatic defect procedure. Briefly, a 6cm 
skin incision was made approximately 3cm lateral from to dorsal midline at the 
level of L3-L6. The subcutaneous fat was sharply dissected and excised. A two-
layer closure followed: subcutaneous tissue (2-0 or 3-0 absorbable suture in a 
running or simple interrupted pattern) followed by skin (3-0 absorbable suture, 
intradermal pattern).  
The fat tissue was sterilely transferred to a cell culture biosafety cabinet, 
washed 3x in PBS. Any attached muscle tissue was carefully removed.  The tissue 
was then minced with sharp scissors into 2-3mm chunks.  
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Minced tissue was mixed 1:1 by volume with a solution of collagenase type 
1 at 4mg/mL and then incubated for 30min at 37°C and 200rpm. Then the solution 
was centrifuged twice at 300g for 5min at 25-37°C (warmed to prevent oil 
solidification). The supernatant was removed, and the pellet was resuspended in 
RBC lysis solution.  
To remove any remaining tissue chunks, the resuspended solution was 
filtered through a 500-micron stainless steel mesh (Utah Biodiesel Supply), and 
then a 100µm nylon cell filter. The filtered solution was spun down at 300g for 5min 
and the resulting cell pellet was termed 'SVF'.   
Isolated stromal vascular fraction cells were suspended in clinical grade 
fibrinogen-thrombin hydrogel (TISSEEL fibrin sealant, 2mL Duplojet frozen 
syringe, Bayer) at 5e6 cells / mL. The components of the TISEEL kit were each 
thawed and then diluted 1:5 with sterile saline before use. The thrombin and cells 
+ fibrinogen components were prepared in a dual syringe with the Duplojet mixer 
needle at total volumes of 5mL per defect.  
Osteotomy Creation, Scaffold Implantation, and Cell Injection 
Concurrently with the cell isolation, bilateral osteotomies were created in 
both zygomatic arches. A transcutaneous approach was used via a 6cm incision 
along the prominent ridge of the zygomatic arch. The incision was made in the 
malar region through the dermis, sub-cutaneous tissue and periosteum to expose 
the zygomatic bone.  Hemostasis was achieved with monopolar electrocautery. 
The attachments of the masseter muscle along the inferior edge were detached 
using a combination of blunt and sharp dissection, and electrocautery hemostasis. 
A sub-periosteal dissection was performed, exposing the body of the zygoma.   
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Thereafter, a laterally based zygomatic osteotomy was performed.  The 
custom cutting guide was placed onto the exposed bone, and the surgeon adjusted 
it until it exactly matched the contour of the underlying bone. A cautery tool was 
then used to mark the edges of the cutting guide along the bone. The resulting 
2.0cm osteotomy was performed with a reciprocating saw (27mm blade, Synthes) 
lateral to the infraorbital nerve and encompass the inferior lateral portion of the 
zygoma to minimize disruption of the origin of the masseter muscle. After the two 
sides were cut, the osteotomy bone was free moving. The surgeon elevated the 
bone and dissected the periosteum from the interior surface, and then fully excised 
the bone. The defect was washed with saline and filled with absorbent gauze until 
time of implantation.  
3D-printed bone scaffold implants were placed in the defects. Minimal 
trimming of two of the twenty-four implants was required—the implants were 
excellent fits with the osteotomies. Placed implants were fixed into place using self-
tapping screws through the fixation arms and adjacent bone. Four, 8mmx2mm 
screws (Synthes) were used to fixate the implants. Implants were rigidly fixed in 
place and firm under palpation.  
The TISEEL dual syringe was used to inject the cells into implant directly 
after it was fixed into the osteotomy. The surgeon inserted the needle into the 
porous surface of the implant and filled the implant and surrounding space with the 
cell-laden gel. Implants were 3mL porous, so there was excess gel and cells 
surrounding the osteotomy. Gelation was complete in 30 seconds, and the 




Figure 10-11: Pictures of the surgical process.  
The incision was along the prominent ridge of the zygomatic arch. After 
incision and periosteal dissection, the cutting guide was placed on the 
bone and the edges were marked with a cautery tool. A reciprocating 
saw was used to cut the borders of the osteotomy, and the bone piece 
was excised. After the implant was securing in place, the incision was 
sutured and bandaged.  
 
The defect was closed in a layer-wise fashion: the periosteal layer was 
closed with #0 PDS*II sutures, and the dermal layer was closed with BioSyn #2-0 
sutures. Finally, surgical glue was applied to the surface of the incision. Animals 
completed a course of antibiotics post-surgery.  
CT Assessment of Bone Formation 
CT scans were conducted four weeks before surgery, immediately post-
operatively, at six weeks, six months, and twelve months (GE lightSPeed16; 120 
kiloVolt peaks, 625µm resolution). Scans were analyzed in MIMICs (Materialise, 
Belgium). The volume of interest was labelled in the post-operative scans as the 
implant region between the cuts and was maintained across timepoints.  The range 
of mineral density and the average mineral density were recorded.  
CBC and Blood Serum Panel  
Blood was drawn at the CT timepoints and sent for a complete blood count 
and serum panel.    
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Results 
Design, Manufacture, and Validation of 3D-Printed Implants  
Each of the implants were unique to the animal and the side of the face they 
were designed to treat. The bone volume they were replacing ranged from 3.5mL 
– 5.3mL. They varied from 1.8cm – 3.2cm in height. The width and fixation 
hardware was kept consistent across all 36 implants. As a result of the anatomic 
variation, the volume of PCL-DCB material used in implants ranged from 2.11 to 
2.94 mL, and the porous volume from 1.4 to 2.6 mL.  
To validate the design and manufacturing process, prototype scaffolds for 
each defect were 3D-printed in ABS. These prototypes were used to identify 
problematic features the initial designs. Some of the interior contours of the 
designs were thin peak-like structures printed as globes. Based on the curvature 
of the zygomatic arch, the host-bone to implant edge sometimes had a sharp 
prominence which did not print well or easily broke off. Finally, in some implants 
the fixation tabs were placed too closely together and completely closed off the 
pores on the frontal surface of the implant. These defects were most clearly evident 
in the printed prototypes, and the corresponding designs were iterated to correct 
them (45% of designs were iterated).  
The ABS prototypes were also used to validate the mechanical integrity of 
the fixation tab. The implant tabs were twisted away from each other with egg 
cracking force, and they were assessed for deformation in a bridge test with a 200g 
load. If deformation was observed in the body of the tab, the design was iterated 
so the tab was thicker. More common, the interface between the fixation tab and 
the porous region failed. This delamination was resolved by changing the design 
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to include extensions of the fixation tab several millimeters deeper into the porous 
region of the implant, which resulted in more struts connecting the porous portion 
to the solid fixation tab.  
After the designs were validated, the scaffolds were printed in clinical grade 
materials and scanned with cone beam CT to assess the 3D-structure and mineral 
distribution throughout the material. The PCL-DCB scaffolds all had consistent 
average mineral densities: each scaffold had an average Hounsfield unit of ~1250, 
and standard deviation of 250. Across all the scaffolds the mean mineral density 
was 1404 HU,  and there was, on average, a standard deviation of 258 HU within 
each scaffold. The scans were also used to confirm there were no areas of 
unusually high density that might indicate metal particles from the cryo-milling or 
manufacturing process, however that is limited to the resolution of the scanner 
(100µm).  
The porous features of the scaffolds were validated in the CBCT scans. All 
scaffolds had a pore width of 0.800mm, which met design value (scaffold-to-
scaffold standard deviation of 0.032). The porous networks were all fully 
interconnected—there were no porous areas that were isolated from the outside 
of the scaffold. Although not a design parameter, the specific surface area (mm-1) 
of the scaffolds was measured: it ranged from 2.25 to 3.33, had a mean of 2.79, 
with scaffold-to-scaffold standard deviation 0.254. 
In MATLAB, the scan of the implant was divided into sub-volumes of 
4mmx4mmx6mm to validate mineral density across the different regions of the 
scaffold. The mineral density was extremely consistent across all of the sub-
volumes, across all of the scaffolds. The effective porosity of each sub-volume was 
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also measured. The majority of the sub-volumes were at the intended porosity 
(60%), however a significant fraction of the sub-volumes was at lower porosities. 
These might be lower due to over deposition at the edge of the scaffold.   
Finally, the scan was viewed as 800mm planar sections parallel to the print 
plant. This view enabled the inspection of each pore-layer. These views confirmed 
that the areas of low print quality were localized to the surface of the scaffold, and 
that the interior region was highly accurate.  
Surgical Outcomes and Point-of-Care Cell Isolation 
All animals recovered within two hours and were eating food normally within 
the same surgical day. Post-operation CT scans showed the implants were placed 
correctly in the defect and had contour lines which matched the zygomatic arch. 
Bone-scaffold volume within the osteotomy on the post op scan matched design 
values. Blood work six days post-operatively was normal. Additionally, blood work 
at 6-weeks and 3-months was also normative.  
Cells were successfully isolated within the intraoperative timeframe (Figure 
10-12). Osteotomy creation and implant placement averaged 35min, while cell 
isolation and transport time averaged 40min (Figure 10-13). The surgeries were 
ordered by animal weight from least to greatest, and the amount of fat obtained 
from the first pig was used for all future pigs in order to keep the number of cells 
placed into the defects consistent. The extra volume of gel and cell mixture was 
seeded into the scaffold to ensure filling of the complete pore space, and the 
surplus volume dispersed in the surrounding tissue pocket, to connect the implant 
with surrounding periosteum and soft tissue. 
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Figure 10-12: Isolation of SVF Cells from Swine.  
A. Fat harvested from the lumbar region. B. Fat tissue was washed 
extensively. C. Tissue was minced, digested with collagenase, and 
stromal vascular fraction cells were separated from the fat tissue via 
centrifugation (supernatant = fat, infranatant = collagenase, pellet = 
cells). D. Cells appeared on the hemocytometer and were counted. E. A 
fraction of the cells were plated and were confluent at 8 days. F. The 
weight of the animals. G. The amount of fat harvested from each animal. 
H. The yield of each isolation process.   
 
 
Figure 10-13 Surgical Timing for Acute Cell Isolation.  
 
In three of the twenty-four implants, the screws along the anterior edge of 
the implant displaced from the underlying bone. This partial fixation failure is likely 
due to lack of screw purchase in the thin wall of the maxillary sinus at that fixation 
point. However, these implants remained rigid to palpation and did not displace 
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from the osteotomy. One implant fractured and became mobile just after three 
months. Because the implant was intact at a CT-time-point one week prior, we 
assume the implant was fractured during transport for the imaging or during 
recovery from anesthesia.    
CT Analysis of Bone Regeneration  
Empty defects were non-healing over the time period. There was rounding 
of the defect edges, and the opening of the maxillary sinus into the defect closed 
over (Figure 10-14). The width of the defect along the anterior surface shrunk 2mm 




Table 10-1. Defect width in Untreated Osteotomies 
Defect # Post Op 6-week Change (mm) 
1 23.67 22.24 -1.43 
2 20.34 17.12 -3.22 
3 21.54 21.35 -0.19 
4 21.92 18.93 -2.99 
Average 21.87 19.91 -1.96 
 
 
Figure 10-14: Post-operative CT scans.  
A. Frontal view shows the successful placement and size of the 
osteotomy (red box). Frontal views (B & C) and superior views (D & E) 





In treated scaffold and cell groups, there was marked increase in bone 
volume and volume fraction over six weeks of healing (Figure 10-15). In post-
operative scans, the implant was visible. The contours and shape of the implant 
matched up with the surrounding bone as designed. To quantify bone volume, a 
threshold of 240 HU was used to separate bone from soft tissue, and the volume 
of interest was identified using the screw locations. The bone volume in the volume 
of interest at post-op was entirely due to the radiopacity of the scaffold. At 6 weeks, 
the scaffold structure was visibly less porous than at post-op. The bone volume 
increased between 1 and 1.4mL over those 6 weeks. Because the porous space 
available in the implant is on average 2.2mL, this is a striking amount of bone 
formation.  
In 3-month timepoints, the bone formation was greater. The average bone 
volume was 4.0 mL with a standard deviation of 1.3mL. The treatment resulted in 
had a majority of the defect volume being filled with bone: 75.0% ± 8.9%. This is 
an encouraging result that the implants continued to heal.   
251 
 
Figure 10-15 Bone Regeneration in Swine over Six Weeks.  
A. Front view of the implant (red box). B. top-down view of implant at 
post op, C. and at 6-weeks. D. Bone volume within the volume of interest 
– Thresholded at 180 HU. E. Volume fraction of the volume of interest 
filled with bone. F. and G. are the changes in D. and E, respectively, 
from post-op to 6 weeks.  
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Discussion  
We successfully manufactured our scaffolds in a design and manufacture 
validation framework. Further, we implemented the resulting scaffolds with point-
of-care autologous cells, and demonstrate that the scaffold and cell treatment 
supports bone regeneration in a large animal pre-clinical model. Importantly, we 
can conclude that the scaffold and SVF system does not prevent or inhibit the 
formation of bone. Nor does the system cause adverse events. While this study is 
limited by the short, 6-week nature of the timepoints, ongoing timepoints and 
additional animals continue to investigate the nature and effect size of this bone 
formation.  
The patient-specific design process introduces animal-to-animal variation in 
implant size and required the development of a process to rapidly validate the 
design. For financial and speed purposes, designs were prototyped in ABS (~$2 
vs $2000, and 20 min vs 3 hour per print). This validation proved to be an important 
step, as half of the designs were iterated once to correct deficiencies. This process 
improved the objective quality of the implants. 
Manufacturing validation was also implemented to confirm the critical 
quality attributes of the final product. In addition to the dimensional and mechanical 
validation during the design portion, the pore size, pore interconnectivity, and 
mineral distribution were assessed. These are critical features of the implant 
because they effect biologic outcomes: cells need pores of a certain size for 
seeding, nutrient transport, and tissue formation; the mineral must be present 
throughout the scaffold to act as a bone forming cue to the cells.  
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To the best of our knowledge, this study is the first test of the zygomatic full 
thickness defect in pig. The non-treated osteotomies in this study showed 
remodeling at the edges of the defect but did not heal, nor was there new bone 
formation on the scale seen in the treated group. While this study only looks at the 
early timepoint of 6-weeks, we feel that the defect will continue to be non-healing 
over the year-long course of this study.  
In treated animals, the scaffolds recreated the shape of the excised bone 
and, post-surgery, healed without changing the contour of the cheekbone. This 
excellent result is due in part to the exact design on the implant to match the 
excised bone, as well as the surgical technique using the periosteal envelope to 
supplant the fixation screws in holding the implant in place.  
To isolate SVF cells from pigs in an acute-use manner, we made alterations 
to the collagenase digestion by increasing the enzyme concentration and 
decreasing the reaction time. These alterations might be the cause of the variability 
in yield. Further, cells isolated with this process might be more traumatized and 
less viable that they otherwise might be. Flow cytometry to assess the viability, 
morphology, and markers of these cells is ongoing. Actual use of the SVF in 
humans would rely on an optimized, consistent protocol, likely using an automated 
device.  
One important shortcoming of this work is that a defect of this size in human 
would clinically be treated by an iliac crest graft rather than an implant. The current 
clinical need in the field is larger defects for which a solid implant or a bone graft 
is untenable. Future work would consider a larger defect of the zygomatic arch in 
swine, on the order of 5cm or the entirety of the zygomatic arch.  
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Conclusion 
This study made progress in translating the 3D-printed bone grafts to clinical 
use. It made advancements in the design and manufacture of implants of clinical 
scale and materials. The scaffolds manufactured with these advancements were 
implemented in a point-of-care approach in a large animal preclinical model using 
autologous SVF cells. As a result of the treatment, there was stark bone formation 
in the defects at 6 weeks and 3 months. These early results are promising, 
however long-term CT timepoints at 6 and 12 months will determine if the approach 
can fully regenerate the missing bone. Endpoint histology and high-resolution CT 
will inform the quality of the regenerated bone and the degree of its integration with 
the surrounding host bone. Overall, this study has made contributions to the design 
and manufacture validation of patient-specific 3D-printed implants, the acute-use 
of SVF for bone regeneration, and these two facets bring both this present 
technology and others closer to clinical use in humans.  









Figure 10-16 Validation and Verification Process for Zygomatic Implants.  
Top: A design control waterfall chart with the relevant correlate steps 
from this study in red text.  







Figure 10-17 Swine Implant Design.  
Top: the implant is designed to exactly match the excised bone from the 
zygomatic arch.  
Bottom: complications of the osteotomy site come from the curvature at 
the maxillary portion of the arch. Additionally, the screw locations (red 
arrows) on the maxillary portion dwell directly into the maxillary sinus 
cavity, which could result in a weaker fixation unless long screws that 

















Figure 10-20 Flow Chart for Manufacturing Verification of Implants via CBCT.  
 Mimics tools are used to assess the scaffold for pore size and porosity. 
Then the scan is imported into MATLAB, sub-divided into 216 smaller 










Conclusions and Contributions  
The work in the thesis was centered on two main goals: (1) scale the 3D-
printing system to human sizes and applications and (2) translate the scaffold with 
cells approach of boney regeneration to clinical grade components.  In scaling the 
biomaterial manufacturing system, we were able to print shapes accurate features 
and dimensions of human face bones. Further, these prints were designed with 
porous networks that varied in 3D-space according to mechanical design goals.  
The biomaterial system was transitioned to clinical grade components and 
testing models. All the of included materials (PCL, DCB, and TISEEL) are of 
human clinical grade. While we demonstrated the ability to isolate SVF from 
multiple donors with sufficient volumes and mineralizing ability, the cells were not 
isolated or prepared using clinical grade reagents and handling. There currently 
exists no FDA approved device or kit for isolation SVF that could be applied, 
however both GID and tissueGenesis are working towards FDA approval. Finally, 
the testing of the approach was scaled from small to large preclinical animal 
models demonstrated effective bone regeneration at both scales.  
The cells were extensively assessed for their vascular potential, as the rapid 
vascularization of the implant is key to preventing cell death (thereby enabling 
regeneration) and the enduring vascularization of the implant is critical to providing 
an enduring resistance to infection. While we found that ASCs can assemble into 
robust vascular networks, the assembly was inhibited by the hypoxic nature of an 
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implant environment. In murine animal trials, the small scaffolds were more 
robustly vascularized by SVF cells (likely due to the greater presence of ECs in 
SVF). Nevertheless, there is ongoing research to provide oxygen to the scaffold 
environment to enable vascular assembly from the cells.  
Barriers to Clinical Translation 
While the tools and data herein bring the approach closer to treating 
humans, there remain barriers to the translation and adoption of the technology. 
First, there are regulatory barriers—the approach uses combination of regulated 
medical products. The scaffold is an implanted orthopedic device (with significant 
safety concerns when it comes in contact with the brain cavity). The DCB particles, 
fibrin hydrogel, and cells are drugs or biologics. Such a combination product is 
complex and regulated in multiple dimensions. Second, an approved product 
would need to find systemic approval from Medicare/Medicaid and other insurance 
agencies in order for it to be widely used and reimbursed.  
Third, the product would need to compete with other well-established 
products. DePuy Synthes, Stryker, and Medtronic have patient specific implants 
on the market.  Successful marketing would depend on demonstrating cost and 
efficacy improvements relative to other treatment options.  Fourth, there might be 
barriers to licensing necessary technologies and products to prepare this 
product—while the patents on 3D-printed machines have expired, freedom to 
operate may be limited by the materials, processing, or methods.  
Fifth and finally, there are challenges to implementing the desired 
manufacturing and clinical delivery in a financially profitable manner. Point-of-care 
manufacturing seems infeasible, the workflow would require a CT, design with a 
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surgeon and design engineer, manufacturing a test and actual product, design and 
manufacturing validation, and shipping to the point-of-care.  
Broad Contributions to Regenerative Medicine and 3D-Printing 
Regardless of the barriers to the specific product envisioned throughout the 
dissertation, this work has made several contributions to the field that are broadly 
applicable and independently enable tissue engineering of craniofacial bones.  
Towards effecting boney regeneration, we identified SVF as an enabling agent of 
bone formation in mice, where implants with SVF cells in them demonstrated near 
100% regeneration of the defect bone volume. The promising regenerative 
outcomes of early time-points in swine is one of the few cases of SVF forming frank 
and observable amounts of bone.  
The comparison of different—clinically used—mineral dopants in 3D-printed 
scaffolds is one of the few head-to-head comparisons of these dopants and 
provides broadly relevant information about the relative bioactivity caused by these 
dopants.  
The different tools used to design and manufacture these scaffolds—
scafSLICR, the design optimization algorithm, and the process for design and 
manufacturing validation—are readily applicable to other material systems and 
manufacturing systems. 
Future Perspectives 
Throughout this work, we repeatedly asked the guiding question: “Is the 
current state of the technology enough to start treating humans? If not, what else 
does it need?” Much of the work in chapters 8, 9, and 10 were singularly focused 
on pushing the technology towards a first in human study. While there are specific 
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tasks to complete before bringing this specific technology to human cases, there 
are also a number of other interesting directions the research could encompass in 
the future.   
Model Dynamic Physical and Biologic Properties 
The output porous designs from scafSLICR were provoking because they 
provided an exactly defined digital model of 3D-printed implants. This model could 
be used to model different regenerative properties, such as diffusion of nutrients 
and waste products, cell seeding and growth, blood vessel assembly and ingrowth, 
and tissue formation. These properties could be modelled before manufacturing or 
implantation, enabling the iteration of the design process at lower costs and time 
burden. A good example of these types of modelling can be found in the doctoral 
dissertation of Carlier—albeit at mouse scales. Combing those models with the 
scales considered in this dissertation could increase understanding of why implant 
failure rates have remained high.  
Similar to modelling those biologic regenerative properties, the mechanical 
and material properties of the 3D-printed implants could be better modelled. An 
accurate model of the mechanics of the thin thermoplastic fibers combined with 
the porous design of the scaffold could be used to better predict the function of the 
scaffold in tension and shear, and thereby lead to improvements in the design of 
the fixation used in these implants. Additionally, these mechanics could be forecast 
as by modelling the degradation of the model. Pairing models of degradation, 
mechanics, and regeneration could provide a design basis for pediatric implants.  
Finally, these accurate models could provide improvements and 
justifications to the design process. The pore and porosity designs used throughout 
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this work are based on the literature surrounding porous implants, but that 
literature has not reached the scale or number of microarchitectures enabled in 
this work. Such studies in animals are prohibitive but well-suited to modelling.  
Increase Scaffold Functionality 
Changes to the scaffold functionality could also improve the regenerative 
outcomes and reduce the need for cell implantation. PCL is a well-defined 
biomaterial that has potential to enable more complicated drug delivery than the 
simple presentation of DCB particles. PCL could also be loaded with a long-lasting 
antibiotic to prevent infections over the life of the implant. There are stem cell 
activating pharmaceutical agents which could be included in the scaffold to 
increase stem cell circulation, homing, and function. Finally, scaffold could serve 
as tool to effect immune modulation, perhaps by releasing a cytokine profile to 
modulate T-cell and macrophage functions towards regeneration.  
The DCB integration can also be re-considered to increase efficacy. DCB 
particles could be localized to the surface of the structs using condensation or 
mineralizing processes. On the surface of the scaffold, but in a fixed position, the 
particles would interact more with the cells than they would when they are mostly 
encased in PCL, as they are here. Alternatively, the scaffold surface could be 
purposefully degraded in advance of implantation to increase the presentation of 
the embedded particles—this type of process would need to be paired with careful 
strut design to prevent the premature mechanical weakening of the scaffold.  
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APPENDIX A: SCAFSLICR EXAMPLES AND CODE 
Files available by request: ethan.nyberg@gmail.com or wgrayson@jhmi.edu    
   
Overview of scafSLICR 
This program takes 3D-shapes as an input and applies patterns of pores and struts 
to different regions. It then generates the GCODE necessary to manufacture that 
structure.  
 
Directory Set Up 
The scafSLICR.mlapp  file should be in the current MATLAB directory. The 
subdirectories  sub functions, Shapes, Properties, Output, and gcode should also 
be in the current directory.  
- sub functions contains the sub-functions and scripts needed.  
- Shapes contains some example shapes and the shapes used in these 
examples 
- Output is used to pass data from the slicing function back to the GUI, and 
where the final output gcode file is deposited.  
- gcode contains the gcode header and footer files applied to the gcode.  
 
Initialize the program with the scafSLICR command in command window, not by 







1. Printer Settings This tab contains all the settings needed to alter the printer 
(hardware) and material-specific settings of the slicing algorithm.  
2. Input. This tab contains the controls to input a shape and manipulate the 
porous properties throughout the shape.  
3. Output. This tab contains toolpath previews of the sliced design.  
 
Properties Buttons 
4. Save Properties. This button saves the printer and material settings to a 
file to re-use.  
5. Load Properties. This button loads previously saved printer settings.  
 
GCODE Header / Footer. The GCODE header and footer files are identified. 
These can be edited directly in the text files using standard programs (TextEdit or 
Notepad). The … buttons can be used to select different text files to use as the 
header and footer.   
6. Header. The GCODE header contains machine instructions to prepare the 
printer to manufacture the print. This text file is appended to the front of the 
shape-specific GCODE instructions.   
7. Footer. Similar to the header, these instructions are appended after the 
shape-specific print is completed and might move the extruder head out of 
the way, kick the bed out, and set the temperatures to cool off.  
  
Printer Settings Table (8) 
The Printer Property table contains the machine and material specific settings. 
See the table in the slicerFN section for explanation of each property.  
267 
 
Output Console (9) 
The output console is in the lower panel of the program. Status updates and 
errors are displayed here. The text can be edited to include user notes. This 







Load A Shape  
10. Load Matrix: Import a matrix (x x y x z). The values of each element / voxel 
can be used to pattern a design value in the shape. The scale of a voxel in 
the imported model is set on the printer settings table.  
11. Standard Shape: Click through the resulting dialog boxes to generate a 
cylinder or rectangular standard shape.  
12. Load STL: Import an STL. This process may take a minute or two 
depending on the size of the STL. It is assumed that the STL is scaled in 
millimeters.  
 
After the shape is loaded and patterned, it can be saved it as a matrix to re-use 
or manipulate further. Because loading matrices is faster than creating a 
standard shape or loading an STL, this format can speed up recurring designs.  
Matrices can be exported as to use in other modeling programs. 
 
19. Input Shape Window. This window shows the loaded shape (20) where the 
different colors (Legend 21) correspond to the voxel values in the table (15).  
 
Pattern Options (14A). Clicking a new pattern option from the dropdown menu 
will change the input shape and pore properties table to match that pattern. Some 
patterns require additional input via dialog boxes.  
 
- Incumbent Pattern 
- Homogenous 
- Linear X 
- Linear Y 
- Linear Z 
- Radial in XY 
- Radial in XYZ 
 
15. Porous Properties. This table displays the different regions of the shape 
(voxel values) and can be edited to assign different pore size and porosity to 
each region. This screenshot shows the same porous pattern applied to the 
different regions to result in a homogenous scaffold.  
 
16. & 17. Update Buttons. Because there are only certain manufacturable 
combinations of struts and pores, the update buttons below the table will fit the 
input pore size / porosity to the nearest manufacturable set.  
 
18. Slice. This button starts the slicing algorithm. Check all the inputs (printer 





Sliced Shape and Support Window (22). This window displays the sliced shape 
and its support (23). Blue is the print structure and red is support structure. Right-
click (24) gives the view options. X-Y view (25) and Y-Z view (26) both show the 





27. 2D Toolpath Previews. The tool paths are shown in the third tab. Each tool-
path is a separate color. The different layers can be viewed by moving the scroll 
bar (28) through the different z-levels.  
 
The generated GCODE is saved in the output folder as 'SlicedCode.gcode' (29), 
and it can be opened in a program such as Slicr or Repetier to ensure that the 




Using SlicrFn as MATLAB Function Directly 
 
The slicing function can be implemented programmatically in MATLAB instead of 




SlicrFn(V, VoxelSize, PoreDiameter, Porosity, Position) 
SlicrFn(___, Name, Value) 




V A 3D-volume matrix describing the shape to be sliced. Each 
unique value in V corresponds to a pore/porosity design 
choice.  
 
VoxelSize  The length of a voxel edge in mm. e.g. 0.100  
 
PoreDiameter A matrix corresponding to the ordered unique values of V,  
   where each element is the  pore size for that design choice.  
   Provided in mm. e.g. [ 0.800 0.400 1.200 ]  
 
Porosity A matrix corresponding to the ordered unique values of V, 
where each element is the   porosity for that 
design choice. Provided in fractions. e.g. [ 0.90 0.45 0.23 ]  
 
Position [ x_pos y_pos ] The initial x and y position of the printed 
scaffold on the print bed. The program places the origin of 




Name, Value pairs provide additional inputs to the slicing program.  
 
Table A-1 Additional SlicrFN Inputs 
Name Value Description 
Backtracking Boolean Option to backtrack along the last portion of 
the toolpath so that oozing and drawn strands 
do not close off the side pores. Default = true.  
BedTemp Celsius The temperature of the bed during printing. 
Degrees Celsius. Default = 100 
CreateBrim Boolean Option to create a brim around the perimeter 
of the object on the print bed. Default = true.  
ExtruderTemp  the heat setting of the nozzle during printing. 
In degrees Celsius. default = 285. If multiple 
extruders, provide as [ temp1 temp2].  
ExtrusionMultiplier 0.8 – 1.5 increases the material flow rate to account for 
over / under deposition of material. A value of 
1 would result in a perfect flow rate. Slight 
over deposition 1.05 is generally good. Default 
= 1.05 
FanHeight mm z-height at which the fan turns on. Default = 
1mm.  
FanPower 0 – 100 Intensity of the fan, when it is turned on. 
Default = 100.  
FilamentDiameter mm The diameter of the filament used. Default – 
2.85mm. If using multiple extruders, provide 
as [diam1 diam2].  




the diameter of the primary printer nozzle, and 
determines the width of a strand. Struts can be 
integer multiples of the strand width (1, 2, 3 
times the nozzle width.) default = 0.500mm. If 
multiple extruders provide as [diam1 diam2] 
PauseTime ms Option to pause at the end of each toolpath to 
let it cool before starting the next move. 
Default = 50. If 0, no pause time.  
PrintSpeed  
mm/min 
the speed of the nozzle. mm/min. default = 90.  
SupportPoreDiam mm The spacing between the support struts. 
Default = 1mm.  






By default, SlicerFn creates the outputs in the Output directory, and it saves 
three files:  
- preview.mat: contains the 3D-matrix Tt and the 1D-matrix Zz. Tt(:,:,Zz(i)) is 
the toolpaths selected for the ith print layer. Preview with imshow( 
Tt(:,:,Zz(i)) ).  
- Graphic_Matrix.mat: contains the 3D-matrices of the scaffold and support. 
Inspect with plot_3d  
- glines.mat: contains a string array of the different lines of gcode, which is 
ready to be packaged into a text file with start up and shut down machine 
specific gcode.  
 
If outputs are specified:  
 
gcode An array of the gcode commands. It does not include header / 
footer gcode, and should be compiled with those to create useful 
gcode files.  
 
toolPaths A structured output with two parts: 
 .z_heights is an array where each element is one of the slices and 
indicates the z-height of that slice 
 .ToolPaths is a 3D-matrix of the tool paths for each print layer. The 
nth member of       
.z_heights is height of ToolPaths.ToolPaths(:,:,n) 
 
preview  A structured output with two parts: 
  .scaffold is the graphic preview of the sliced scaffold 





Example 1: Zygomatic Scaffold 
 
load('Shapes/zygoma.mat') 
V = A;  
VoxelSize = 0.100;  
PoreDiameter = [ 0.3 0.5 0.7 1.0 ]; 
Porosity = [ 0.375  0.5 0.4118 0.500 ]; 
% Porosity and PoreDiameter must be the same length as the number of 
% non-zero unique values in V, and are ordered respectively to the 
% non-zero output of unique(V).   
position = [15 15];  
  
[glines, toolPaths, preview] = SlicrFn  (   V, ... 
                                            VoxelSize, ... 
                                            PoreDiameter, ... 
                                            Porosity, ... 
                                            position,... 
                                            'Backtracking', false,... 
                                            'BedTemp', 110,... 
                                            'CreateBrim', true,... 
                                            'ExtruderTemp', 285,... 
                                         'ExtrusionMultiplier', 1.1,... 
                                            'FanHeight', 1,...     
                                            'FanPower', 95,... 
                                          'FilamentDiameter', 2.85,... 
                                            'LayerHeight', 0.200,... 
                                            'NozzleDiameter', 0.500,... 
                                            'PauseTime', 200,... 
                                            'PrintSpeed', 600,... 
                                            'SupportPoreDiam', 0.95... 
                                            );    
                                            
%% Graph the output preview 
figure, p = plot_3d(preview.scaffold,0.1, 1); 
  
%% Complete the GCODE as file  
% Get GCODE Header and footer files 
    fileID = fopen(fullfile('gcode','header_abs.txt'),'r');   
    gstart = textscan(fileID,'%s','delimiter','\n'); 
    gstart = string(gstart{1}); 
    fclose(fileID); 
     
    fileID = fopen(fullfile('gcode','footer.txt'),'r');   
    gend = textscan(fileID,'%s','delimiter','\n'); 
    gend = string(gend{1}); 
    fclose(fileID); 
     
% Read GCODE lines into output file 
    fileID = fopen(fullfile('gcode','SlicedCode.gcode'),'w');  
    formatSpec = '%s\n'; 
    fprintf(fileID,formatSpec,gstart);     
    glines(glines == '')=[]; %remove empty dimensions 
    fprintf(fileID,formatSpec,glines'); 
    fprintf(fileID,formatSpec,gend); 
    fclose(fileID); 
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%Get GCODE Header and footer files 
    fileID = fopen(fullfile('gcode','header_abs.txt'),'r');   
    gstart = textscan(fileID,'%s','delimiter','\n'); 
    gstart = string(gstart{1});    fclose(fileID); 
     
    fileID = fopen(fullfile('gcode','footer.txt'),'r');   
    gend = textscan(fileID,'%s','delimiter','\n'); 
    gend = string(gend{1});    fclose(fileID); 
     
% Read GCODE lines into output file 
    fileID = fopen(fullfile('Output','Figure3_Cubes.gcode'),'w');  
    formatSpec = '%s\n'; 
    fprintf(fileID,formatSpec,gstart);     
 
VoxelSize = 0.100;  
PoreDiameter = [0.200 0.500 0.800 0.800 0.800] ;  
Porosity = [0.280 0.250 0.280 0.450 0.620] ;  
XPOS = 30; YPOS = 30;     position = [XPOS YPOS];  
  
for i = 1:length(PoreDiameter)  
[glines, toolPaths, preview] = SlicrFn  (   V, ... 
                                            VoxelSize, ... 
                                            PoreDiameter(i), ... 
                                            Porosity(i), ... 
                                            [XPOS YPOS],... 
                                            'Backtracking', false,... 
                                            'BedTemp', 110,... 
                                            'CreateBrim', true,... 
                                            'ExtruderTemp', 285,... 
                                            'ExtrusionMultiplier', 
1.1,... 
                                            'FanHeight', 1,...     
                                            'FanPower', 95,... 
                                            'FilamentDiameter', 
2.85,... 
                                            'LayerHeight', 0.200,... 
                                            'NozzleDiameter', 0.500,... 
                                            'PauseTime', 200,... 
                                            'PrintSpeed', 80,... 
                                            'SupportPoreDiam', 0.95... 
                                            );    
 glines(glines == '')=[]; %remove empty dimensions 
 fprintf(fileID,formatSpec,glines');  % Write to file                                                                         
if XPOS > 230, XPOS = 30; YPOS = YPOS+40; else, XPOS = XPOS+40; end %if                                                             
end %for loop 
 
%% Complete the GCODE as file  
    fprintf(fileID,formatSpec,gend); 
    fclose(fileID); 
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Example 3: Figure 4 Hybrid Scaffolds 
clearvars 
addpath('sub functions') 
    VV = ones(200,200);   
    VV(1:100, :) = 2;         VV = repmat(VV,1,1,100); 
    V = zeros(202, 202, 102);   V(2:201, 2:201, 1:101) = VV; 
 
%% Prepare the GCODE as file  
    fileID = fopen(fullfile('gcode','header_abs.txt'),'r');   
    gstart = textscan(fileID,'%s','delimiter','\n'); 
    gstart = string(gstart{1});    fclose(fileID); 
     
    fileID = fopen(fullfile('gcode','footer.txt'),'r');   
    gend = textscan(fileID,'%s','delimiter','\n'); 
    gend = string(gend{1});    fclose(fileID); 
     
% Read GCODE lines into output file 
    fileID = fopen(fullfile('Output','Figure4_Hybrid.gcode'),'w');  
    formatSpec = '%s\n'; 
    fprintf(fileID,formatSpec,gstart);     
 
VoxelSize = 0.100;  
PoreDiameter = [0.200 0.500; 0.500 0.800; 0.200 0.800; 0.800 0.800; 
0.800 0.800; 0.800 0.800] ;  
Porosity = [0.280 0.250; 0.250 0.280; 0.280 0.280; 0.280 0.450; 0.450 
0.620; 0.280 0.620];  
XPOS = 30; YPOS = 30;     position = [XPOS YPOS];  
  
for i = 1:length(PoreDiameter)  
[glines, toolPaths, preview] = SlicrFn  (   V, ... 
                                            VoxelSize, ... 
                                            PoreDiameter(i, :)', ... 
                                            Porosity(i, :), ... 
                                            [XPOS YPOS],... 
                                            'Backtracking', false,... 
                                            'BedTemp', 110,... 
                                            'CreateBrim', true,... 
                                            'ExtruderTemp', 285,... 
                                          'ExtrusionMultiplier',1.1,... 
                                            'FanHeight', 1,...     
                                            'FanPower', 95,... 
                                          'FilamentDiameter', 2.85,... 
                                            'LayerHeight', 0.200,... 
                                            'NozzleDiameter', 0.500,... 
                                            'PauseTime', 200,... 
                                            'PrintSpeed', 80,... 
                                            'SupportPoreDiam', 0.95... 
                                            );    
 glines(glines == '')=[]; %remove empty dimensions 
 fprintf(fileID,formatSpec,glines');  % Write to file                                                                              
if XPOS > 230, XPOS = 30; YPOS = YPOS+40; else, XPOS = XPOS+40; end %if                                                             
end %for loop 
 
%% Complete the GCODE as file  
    fprintf(fileID,formatSpec,gend); 
    fclose(fileID); 
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Example 4: Figure 5 Gradients in Cubes 
Choose the case to create the 3D pattern. 
 
Graded along Z 
 
VV = ones(200,200,200); 
num = 10; width = 200/num; x1=0; x2=width; 
        for i=1:num 
            VV(:,:, x1+1:x2) = i; 
            x1=x2; x2=x2+width; 
        end         
V=zeros(202,202,202); 
V(2:201, 2:201,1:201) = VV; 
 
Graded along X 
 
VV = ones(200,200,200); 
num = 10; width = 200/num; x1=0; x2=width; 
   for i=1:num 
      VV(:,x1+1:x2,:) = i; 
      x1=x2; x2=x2+width; 
   end         
V=zeros(202,202,202); 
V(2:201, 2:201,1:201) = VV; 
 
Graded along XY 
 
VV = ones(200,200); 
num = 10; width = 200/num; x1=0; x2=200; 
for i = 1:(num/2) 
    VV(x1+1:x2,x1+1:x2) = i; 
     x1=x1+width; x2=x2-width; 
end 
 VV = repmat(VV, [1, 1, 200]); 
V=zeros(202,202,202); 
V(2:201, 2:201,1:201) = VV; 
 
Graded along XYZ 
 
VV = ones(200,200, 200); 
num = 10; width = 200/num; x1=0; x2=200; 
for i = 1:(num/2) 
    VV(x1+1:x2,x1+1:x2, x1+1:x2) = i; 
     x1=x1+width; x2=x2-width; 
end 
V=zeros(202,202,202); 




VoxelSize = 0.200;  
PoreDiameter = ([ 0.2 0.3 0.5 0.6 0.8 0.8 0.6 0.5 0.3 0.2]'); 
Porosity = ([0.28 0.26 0.5 0.56 0.62 0.62 0.56 0.5 0.26 0.28]);  
position = [30 30];   
[glines, toolPaths, preview] = SlicrFn  (   V, ... 
                                            VoxelSize, ... 
                                            PoreDiameter, ... 
                                            Porosity, ... 
                                            position,... 
                                            'Backtracking', false,... 
                                            'BedTemp', 110,... 
                                            'CreateBrim', true,... 
                                            'ExtruderTemp', 285,... 
                                         'ExtrusionMultiplier', 1.1,... 
                                            'FanHeight', 1,...     
                                            'FanPower', 95,... 
                                           'FilamentDiameter', 2.85,... 
                                            'LayerHeight', 0.200,... 
                                            'NozzleDiameter', 0.500,... 
                                            'PauseTime', 200,... 
                                            'PrintSpeed', 80,... 
                                            'SupportPoreDiam', 0.95);                                               
% Get GCODE Header and footer files 
    fileID = fopen(fullfile('gcode','header_abs.txt'),'r');   
    gstart = textscan(fileID,'%s','delimiter','\n'); 
    gstart = string(gstart{1}); 
    fclose(fileID); 
     
    fileID = fopen(fullfile('gcode','footer.txt'),'r');   
    gend = textscan(fileID,'%s','delimiter','\n'); 
    gend = string(gend{1}); 
    fclose(fileID); 
     
% Read GCODE lines into output file 
    fileID = fopen(fullfile('output','Figure5-subpart.gcode'),'w');   
    formatSpec = '%s\n'; 
    fprintf(fileID,formatSpec,gstart); 
     
    glines(glines == '')=[]; %remove empty dimensions 
    fprintf(fileID,formatSpec,glines'); 
     
    fprintf(fileID,formatSpec,gend); 
    fclose(fileID); 
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load('Shapes/zygoma-5regions.mat')   
VoxelSize = 0.600;  
PoreDiameter = ([ 0.2 0.3 0.5 0.7 0.9]'); 
Porosity = ([0.3 0.3 0.5 0.5 0.8]);  
position = [30 30];  
  
[glines, toolPaths, preview] = SlicrFn  (   V, ... 
                                            VoxelSize, ... 
                                            PoreDiameter, ... 
                                            Porosity, ... 
                                            position,... 
                                            'Backtracking', false,... 
                                            'BedTemp', 110,... 
                                            'CreateBrim', true,... 
                                            'ExtruderTemp', 285,... 
                                         'ExtrusionMultiplier', 1.1,... 
                                            'FanHeight', 1,...     
                                            'FanPower', 95,... 
                                          'FilamentDiameter', 2.85,... 
                                            'LayerHeight', 0.200,... 
                                            'NozzleDiameter', 0.500,... 
                                            'PauseTime', 200,... 
                                            'PrintSpeed', 80,... 
                                            'SupportPoreDiam', 0.95... 
                                            );    
                                            
%% Complete the GCODE as file  
% Get GCODE Header and footer files 
    fileID = fopen(fullfile('gcode','header_abs.txt'),'r');   
    gstart = textscan(fileID,'%s','delimiter','\n'); 
    gstart = string(gstart{1}); 
    fclose(fileID); 
     
    fileID = fopen(fullfile('gcode','footer.txt'),'r');   
    gend = textscan(fileID,'%s','delimiter','\n'); 
    gend = string(gend{1}); 
    fclose(fileID); 
     
% Read GCODE lines into output file 
    fileID = fopen(fullfile('output','SlicedCode-
PorcineZygoma.gcode'),'w');  
    formatSpec = '%s\n'; 
    fprintf(fileID,formatSpec,gstart); 
    glines(glines == '')=[];  
    fprintf(fileID,formatSpec,glines');     
    fprintf(fileID,formatSpec,gend); 
    fclose(fileID); 
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Example 6: Orbital Bone  
clearvars 
addpath('sub functions') 
% Import STL 
file = 'Shapes\MassiveOrbitalScaffold.stl'; 
  
% Get the dimensions of the STL in millimeters. 
[stlcoords] = READ_stl(file); 
xmax = max(max( squeeze( stlcoords(:,1,:) ) )); 
ymax = max(max( squeeze( stlcoords(:,2,:) ) )); 
zmax = max(max( squeeze( stlcoords(:,3,:) ) )); 
xmin = min(min( squeeze( stlcoords(:,1,:) ) )); 
ymin = min(min( squeeze( stlcoords(:,2,:) ) )); 
zmin = min(min( squeeze( stlcoords(:,3,:) ) )); 
  
% Convert to voxel matrix where one voxel is 1mm 
V = double(VOXELISE(round((xmax-xmin)*1),... 
    round((ymax-ymin)*1),... 
    round((zmax-zmin)*1),... 
    fullfile(path,file),... 
    'xyz')); 
  
%% Weighted Average 
% V is the VOI, one voxel is 1mm 
[a,b,c] = size(V); 
d = size(V(:),1); 
output = V*0; 
for i=1:d 
    if V(i)==0, continue, end 
    [x,y,z] = ind2sub([a,b,c],i); 
    top = x + 4; if top>a, top = a; end 
    bottom = x - 4; if bottom<1, bottom = 1; end 
    left = y - 4; if left<1, left = 1; end 
    right = y + 4; if right>b, right = b; end 
    in = z - 4; if in<1,  in =1; end 
    out = z + 4; if out>c, out = c; end 
V_small = V(bottom:top, left:right, in:out); 




figure, plot_3d(output, 10, .5) 
  
%% Smooth the weighted average twice 
avg_out = output*0; 
  
for i=1:d 
    if V(i)==0, continue, end 
    [x,y,z] = ind2sub([a,b,c],i); 
    top = x + 8; if top>a, top = a; end 
    bottom = x - 8; if bottom<1, bottom = 1; end 
    left = y - 8; if left<1, left = 1; end 
    right = y + 8; if right>b, right = b; end 
    in = z - 8; if in<1,  in =1; end 
    out = z + 8; if out>c, out = c; end 
V_small = output(bottom:top, left:right, in:out); 
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V_small = V_small(:); 
V_small(V_small==0)=[]; 




figure, plot_3d(avg_out, 10, .5) 
avg_out1 = output*0; 
  
for i=1:d 
    if V(i)==0, continue, end 
    [x,y,z] = ind2sub([a,b,c],i); 
    top = x + 8; if top>a, top = a; end 
    bottom = x - 8; if bottom<1, bottom = 1; end 
    left = y - 8; if left<1, left = 1; end 
    right = y + 8; if right>b, right = b; end 
    in = z - 8; if in<1,  in =1; end 
    out = z + 8; if out>c, out = c; end 
V_small = avg_out(bottom:top, left:right, in:out); 
V_small = V_small(:); 
V_small(V_small==0)=[]; 
    avg_out1(i) = round(mean(V_small(:))); 
end 
  
figure, plot_3d(avg_out1, 10, .5) 
  
%% Bin smoothed range into 4 levels 
avg_sort = sort(avg_out(avg_out>0)); 
fifths = round(size(avg_sort, 1) / 5); 
  
figure, histogram(avg_out1(avg_out1>0)); hold on 
line([avg_sort(fifths), avg_sort(fifths)], ylim, 'LineWidth', 2, 
'Color', 'r'); 
line([avg_sort(fifths*2), avg_sort(fifths*2)], ylim, 'LineWidth', 2, 
'Color', 'r'); 
line([avg_sort(fifths*3), avg_sort(fifths*3)], ylim, 'LineWidth', 2, 
'Color', 'r'); 
line([avg_sort(fifths*4), avg_sort(fifths*4)], ylim, 'LineWidth', 2, 
'Color', 'r'); 
  
bin_out = avg_out; 
bin_out(0 < avg_out & avg_out  < avg_sort(fifths)) = 1; 
bin_out(avg_sort(fifths) <= avg_out & avg_out  < avg_sort(fifths*2)) = 
2; 
bin_out(avg_sort(fifths*2) <= avg_out & avg_out < avg_sort(fifths*3)) = 
3; 
bin_out(avg_sort(fifths*3) <= avg_out & avg_out  < avg_sort(fifths*4)) 
= 4; 
bin_out(avg_sort(fifths*4) <= avg_out & avg_out <= avg_sort(end)) = 5; 
  
figure, histogram(bin_out(bin_out>0)); 
figure, plot_3d(bin_out, .5, .5) 
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% Import STL 
file = 'Shapes/HemiMandible_001.stl'; 
 
% Get the dimensions of the STL in millimeters. 
[stlcoords] = READ_stl(file); 
xmax = max(max( squeeze( stlcoords(:,1,:) ) )); 
ymax = max(max( squeeze( stlcoords(:,2,:) ) )); 
zmax = max(max( squeeze( stlcoords(:,3,:) ) )); 
xmin = min(min( squeeze( stlcoords(:,1,:) ) )); 
ymin = min(min( squeeze( stlcoords(:,2,:) ) )); 
zmin = min(min( squeeze( stlcoords(:,3,:) ) )); 
  
% Convert to voxel matrix where one voxel is 1mm 
V = double(VOXELISE(round((xmax-xmin)*1),... 
    round((ymax-ymin)*1),... 
    round((zmax-zmin)*1),... 
    fullfile(file),... 
    'xyz')); 
  
V = flipud(permute(V,[3 1 2])); 
  
%% Rotate  
h(1) = figure; 






%% Rotation about each axes 
tx = 0; 
ty = 0; 
tz = 0; 
tx = pi*1.1 + pi/5; 
ty = pi/6 +pi/2; %about Z 
  
Rx = [1 0 0 0; ... 
    0 cos(tx) -sin(tx) 0; ... 
    0 sin(tx) cos(tx) 0;... 
    0 0 0 1]; 
Ry = [cos(ty) 0 sin(ty) 0; ... 
    0 1 0 0;... 
    -sin(ty) 0 cos(ty) 0;... 
    0 0 0 1]; 
Rz = [cos(tz) -sin(tz) 0 0; ... 
    sin(tz) cos(tz) 0 0;... 
    0 0 1 0;... 
    0 0 0 1]; 
  
% Complete Rotation Transformation 
t = Rx * Ry *Rz ; 
tform = affine3d(t); 
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% Transform Image 
V_rot = imwarp(V,tform, 'nearest'); 
  
% Crop V_rot 
Ibw = V_rot~=0; 
I_xy = sum(Ibw,3); 
I_x = squeeze(sum(I_xy,1)); 
I_y = squeeze(sum(I_xy,2)); 
I_xz = squeeze(sum(Ibw, 2));  
I_z = squeeze(sum(I_xz, 1)); 
  
x1 = find(I_x, 1, 'first'); 
x2 = find(I_x, 1, 'last'); 
y1 = find(I_y, 1, 'first'); 
y2 = find(I_y, 1, 'last'); 
z1 = find(I_z, 1, 'first'); 
z2 = find(I_z, 1, 'last'); 
V_rot = V_rot(y1:y2, x1:x2,z1:z2); 
  
h(2) = figure; 






% Depth-based Regions 
% V_rot is the VOI, one voxel is 1mm 
% Want to make shells from the outside --> inside 
% that are 3mm in thickness 
V = V_rot; 
output = V*0; 
V_shell = V>0; 
finished = false; 
i = 1; j = 1;  
while ~finished 
    shell = bwmorph3(V_shell, 'remove'); 
    if ~any(shell(:)) 
        finished=true; 
    continue 
    end 
    output = output + double(shell*i); 
    V_shell = V_shell-shell; 
    j = j+1;  
    if j>3 
        i = i+1; 
        j=1; 
    end %if 




%% Slice Scaffold 
output(output>3)=3; 
V = rot90(output);  
VoxelSize = 1;  
PoreDiameter = [ 0.8 0.4 0.1 ]'; 
Porosity = [ 0.6154 0.2857 0.0099 ]; 
% Porosity and PoreDiameter must be the same length as the number of 
% non-zero unique values in V, and are ordered respectively to the 
% non-zero output of unique(V).   
  
position = [15 15];  
  
[glines, toolPaths, preview] = SlicrFn  (   V, ... 
                                            VoxelSize, ... 
                                            PoreDiameter, ... 
                                            Porosity, ... 
                                            position,... 
                                            'Backtracking', false,... 
                                            'BedTemp', 110,... 
                                            'CreateBrim', true,... 
                                            'ExtruderTemp', 285,... 
                                        'ExtrusionMultiplier', 1.1,... 
                                            'FanHeight', 1,...     
                                            'FanPower', 95,... 
                                          'FilamentDiameter', 2.85,... 
                                            'LayerHeight', 0.200,... 
                                            'NozzleDiameter', 0.500,... 
                                            'PauseTime', 200,... 
                                            'PrintSpeed', 600,... 
                                            'SupportPoreDiam', 0.95... 
                                            );    
                                            
% Complete the GCODE as file  
% Get GCODE Header and footer files 
    fileID = fopen(fullfile('gcode','header_abs.txt'),'r');   
    gstart = textscan(fileID,'%s','delimiter','\n'); 
    gstart = string(gstart{1}); 
    fclose(fileID); 
     
    fileID = fopen(fullfile('gcode','footer.txt'),'r');   
    gend = textscan(fileID,'%s','delimiter','\n'); 
    gend = string(gend{1}); 
    fclose(fileID); 
     
% Read GCODE lines into output file 
    fileID = fopen(fullfile('gcode','SlicedCode.gcode'),'w');  
    formatSpec = '%s\n'; 
    fprintf(fileID,formatSpec,gstart);     
    glines(glines == '')=[]; %remove empty dimensions 
    fprintf(fileID,formatSpec,glines'); 
    fprintf(fileID,formatSpec,gend); 
    fclose(fileID);  
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Example 8: Throughput Testing Example 
 
Cylinders, with pore sizes 0.200mm to 0.800 in 0.2mm steps and print speed from 
100mm/min to 500mm/min  
 
 
Figure A-1: Example of Output GCODE Visualized in Repetier 
There are four scaffold designs (Pore sizes). These designs are 
repeated in sequence from left to right starting at the origin in the bottom 











he = ix; 
[x,y]=meshgrid(-(cx-1):(ix-cx),-(cy-1):(iy-cy)); 
c_mask=((x.^2+y.^2)<=r^2); 
V = repmat(c_mask, [1 1 he]); 
V(:,:, he-4:he)=0; 
V = double(V); 
  
%% Prepare the GCODE as file 
fileID = fopen(fullfile('gcode','header_abs.txt'),'r'); 
gstart = textscan(fileID,'%s','delimiter','\n'); 
gstart = string(gstart{1}); 
fclose(fileID);  
fileID = fopen(fullfile('gcode','footer.txt'),'r'); 
gend = textscan(fileID,'%s','delimiter','\n'); 




% Read GCODE lines into output file 
fileID = fopen(fullfile('Output','Figure9_Throughput.gcode'),'w'); 




VoxelSize = 0.100; 
PoreDiameter = [0.200 0.400 0.600 0.800] ; 
Porosity = [0.5 0.5 0.5 0.5] ; 
XPOS = 30; YPOS = 30; 
position = [XPOS YPOS]; 
printSpeeds = [20 40 80 100 110]; 
for j = 1:length(printSpeeds) 
for i = 1:length(PoreDiameter) 
     
    [glines, toolPaths, preview] = SlicrFn  (   V, ... 
        VoxelSize, ... 
        PoreDiameter(i)', ... 
        Porosity(i), ... 
        [XPOS YPOS],... 
        'Backtracking', false,... 
        'BedTemp', 110,... 
        'CreateBrim', true,... 
        'ExtruderTemp', 285,... 
        'ExtrusionMultiplier', 1.1,... 
        'FanHeight', 1,... 
        'FanPower', 95,... 
        'FilamentDiameter', 2.85,... 
        'LayerHeight', 0.200,... 
        'NozzleDiameter', 0.500,... 
        'PauseTime', 200,... 
        'PrintSpeed', printSpeeds(j),... 
        'SupportPoreDiam', 0.95... 
        ); 
     
    glines(glines == '')=[]; %remove empty dimensions 
    fprintf(fileID,formatSpec,glines');  % Write to file 
     
    if XPOS > 230, XPOS = 30; YPOS = YPOS+40; else, XPOS = XPOS+40; end 
%if 
     
end %for pore diameter loop 










scafSLICR Source Code 
function [varargout] = SlicrFn (V, VoxelSize, PoreDiameter, Porosity, 
Position, varargin) 
  
% V            Volume to be sliced 
% VoxelSize    Dimension of a voxel in mm 
% PoreDiameter Array of diameters in mm 
% Porosity     Array of diameters in mm 
% position     [ x_pos   y_pos ] 
  
%%% SlicrFn is a function that generates support structure for a desired 
%%% 3D volume, slices the volume into a porous scaffold according to input 
%%% patterns, generates a 3D preview of the sliced volume, and writes gcode 
%%% for the sliced volume and support 
  
%%% SlicrFn does not return any values, instead it saves the following 
%%% files to the output directory: 
% glines    gcode for the nozzle movements for a single scaffold 
% G matrix  (GraphicMatrix) -- binary matrix showing the sliced 3D 
% volume    Sliced volume without support structure 
  
%% Section 1: Inputs and Defaults 
V                   =   V; 
[a,b,c]             =   size(V); 
supportPoreDiam     =   1.5;  % mm 
bedTemp             =   110;    % Deg Celsius, Default ABS 
extruderTemp        =   285;    % Deg Celsius, Default ABS 
printSpeed          =   2100;   % mm / min, Default ABS 
createBrim          =   true;   % Default to create brim 
pauseTime           =   50;     % ms on each strut end, default in ABS 
% If zero, then pauseBoolean = False 
pauseBoolean        =   true; 
backtrackingBoolean =   true;   % Back track or not 
fanOnHeight         =   0.2;    % mm height where fan is turned on 
fanPower            =   100;    % 0 - 100 percent of fan power 
NozzleDiameter      =   0.500;  % in mm 
ExtrusionMult       =   1.01;   % Amount of over/under material flow 
rate 
LayerHeight         =   0.200;  % in mm, between each z-change 





    for i2=1:2:size(varargin,2) % Must be in ('Name', Value) pairs 
        switch varargin{i2} 
            case 'FanPower' 
                if varargin{i2+1} < 100.1 
                    fanPower = varargin{i2+1}; 
                end 
            case 'FanHeight' 
                fanOnHeight = varargin{i2+1}; 
            case 'Backtracking' % Input as boolean 
                backtrackingBoolean = varargin{i2+1}; 
            case 'PauseTime' 
                pauseTime = varargin{i2+1}; 
                if pauseTime == 0, pauseBoolean = false; end 
            case 'CreateBrim'   % Input as boolean 
                createBrim = varargin{i2+1}; 
            case 'PrintSpeed' 
                printSpeed = varargin{i2+1}; 
            case 'ExtruderTemp' 
                extruderTemp = varargin{i2+1}; 
            case 'BedTemp' 
                bedTemp = varargin{i2+1}; 
            case 'SupportPoreDiam' 
                supportPoreDiam = varargin{i2+1}; 
            case 'NozzleDiameter' 
                NozzleDiameter = varargin{i2+1}; 
            case 'ExtrusionMultiplier' 
                ExtrusionMult = varargin{i2+1}; 
            case 'LayerHeight' 
                LayerHeight = varargin{i2+1}; 
            case 'FilamentDiameter' 
                FilamentDiameter = varargin{i2+1}; 
        end % switch 




% Find the smallest feature and common multiple of the nozzle diameter so 
% that the strut widths are integer multiples of the nozzle diameter.  
features = [PoreDiameter' LayerHeight NozzleDiameter]; 
features(features==0)=[]; % Do not include features that are 0 (solid 
material) 
small_Feature = min(features); 
if small_Feature < VoxelSize 
    if mod(NozzleDiameter, small_Feature) ~= 0 
        g = gcd(NozzleDiameter*1000, small_Feature*1000); 
        small_Feature = g / 1000; 
    end 
    scale = VoxelSize / small_Feature; 
    V = imresize3(V, scale, 'nearest'); 
    VoxelSize = small_Feature; 
    [a,b,c]             =   size(V); 
elseif mod(NozzleDiameter, VoxelSize) ~= 0 
    g = gcd(NozzleDiameter*1000, VoxelSize*1000); 
    small_Feature = g / 1000; 
    scale = VoxelSize / small_Feature; 
    V = imresize3(V, scale, 'nearest'); 
    VoxelSize = small_Feature; 
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    [a,b,c]             =   size(V); 
end 
  
SliceThickness = ceil(PoreDiameter./VoxelSize);  %in voxels 
LayersPerSlice = ceil(PoreDiameter./LayerHeight); 
  
% For solid sections (pore = 0 or porosity = 0) make SliceThickness 
equal 
% to Layer Height in Voxels 
SliceThickness(SliceThickness==0) = ceil(LayerHeight / VoxelSize); 
LayersPerSlice(LayersPerSlice==0) = 1; 
  
%% Section 2: Support Shape 
% 1. Creates a volume of 1s the same size as the input volume. 
% 2. Subtract the input shape. 
% 3. Remove any whole columns--support from top to bottom. 
% 4. Remove the parts of any columns attached to the top. 
  
V_s = (ones(size(V)) - (V~=0));     % Same size at V, less V 
Z=size(V_s,3); 
Tops = V_s(:,:,Z); 
[iT, jT] = ind2sub(size(Tops),find(Tops)); 
for i3=1:size(iT,1) 
    if sum(V_s(iT(i3),jT(i3),:))==Z 
        V_s(iT(i3),jT(i3),:)=0; 
    else 
        A = find(~V_s(iT(i3),jT(i3),:)); 
        % Create a gap between the support and the actual print to make 
        % easier to remove the support...one voxel or ~0.1mm? 
        if A(1)>1, A(1) = A(1)-1; end 
        V_s(iT(i3),jT(i3),A(1):end)=0; 
    end 
end 
  
%% Section 3: Voxels as Design Input 
% Input a volume V, where each voxel corresponds to a pore size and 
% porosity ordered the same way unique(V) is ordered. 
  
% 3.1 Begin by finding the number of tool paths to make a strut in each 
design 
patternIDs = unique(V); patternIDs = patternIDs(2:end); 
numPatterns = size(patternIDs,1); 
strutNums = ceil((PoreDiameter ./ NozzleDiameter).*((1./Porosity')-1)); 
strutNums(strutNums==0) = 1; 
strutNums(strutNums~=strutNums)=1; % NaN catch for pore of 0 
strutWidths = strutNums*NozzleDiameter./VoxelSize; 
  
% 3.2 Create a template for each design. templateX and templateY are 
for 3D volume vs. linesX and linesY are 2D-toolpaths 
templateX = zeros(a,b,numPatterns+1); templateY=templateX; 
linesX=zeros(a,b,numPatterns); linesY=linesX; 
for q1=1:numPatterns 
    [templateX(:,:,q1), templateY(:,:,q1), linesX(:,:,q1), 
linesY(:,:,q1)] ... 




% Make template support, append to the other templates 
PoreDiameter(end+1) = supportPoreDiam; % Support Pore Diameter 
numPatterns=numPatterns+1; 
  
[templateX(:,:,numPatterns), templateY(:,:,numPatterns  ),... 
    linesX(:,:,numPatterns), linesY(:,:,numPatterns     )] ... 
    = templateFUNC(1, ceil(NozzleDiameter/VoxelSize), 
PoreDiameter(end)); 
  
% Combine the object volume and the support volume with the object 
support_voxel = rand*10; 
V = V + V_s.*support_voxel; 
patternIDs(end+1)=support_voxel; 
  
% 3.3 For each layer, for each density, convolve that range with the 
% appropriate template, resulting in a series of tool paths for each 
level. 
T = zeros(a,b,c); G = T; 
LayersPerSlice(end+1)=LayersPerSlice(end); 
SliceThickness(end+1)=SliceThickness(end); 
endpointlist = cell([c 1 1]); 
  
% z-index levels where print is happening 
print_levels = (LayerHeight/VoxelSize):(LayerHeight/VoxelSize):c; 
  
xdir_all = zeros(numPatterns, c); 
for k1=1:numPatterns 
    xdir_temp = [ones(SliceThickness(k1),1)' 
zeros(SliceThickness(k1),1)']'; 
    xdir_temp = repmat(xdir_temp,ceil(c/(SliceThickness(k1)*2)),1); 
    xdir_all(k1,:) = xdir_temp(1:c); 
    for q=1:c % for each z-level of V... 
        if k1==numPatterns % Support Design 
            H = (V(:,:,q)==patternIDs(end)).*linesX(:,:,end); 
            T(:,:,q) =  T(:,:,q)+2*H; 
            if ismember(q, print_levels) 
            endpointlist{q} = findpoints(H, endpointlist{q}, 'X'); end 
        elseif xdir_all(k1,q) %other designs if their x-direction 
            H = (V(:,:,q)==patternIDs(k1)).*linesX(:,:,k1); 
            T(:,:,q) =  T(:,:,q)+H; 
            G(:,:,q) =  
G(:,:,q)+((V(:,:,q)==patternIDs(k1)).*templateX(:,:,k1)); 
            if ismember(q, print_levels) 
            endpointlist{q} = findpoints(H, endpointlist{q}, 'X'); end 
        else 
            H = (V(:,:,q)==patternIDs(k1)).*linesY(:,:,k1); 
            T(:,:,q) =  T(:,:,q)+H; 
            G(:,:,q) =  
G(:,:,q)+((V(:,:,q)==patternIDs(k1)).*templateY(:,:,k1)); 
            if ismember(q, print_levels) 
            endpointlist{q} = findpoints(H, endpointlist{q}, 'Y'); end 
        end 
    end 





%% Section 4: Translate toolpaths into endpoints then into GCODE 
X=Position(1); Y=Position(2); Z=0.2; % Initial Position of the toolhead 
bot = 1; 
tiptop = c; 
top = bot+SliceThickness-1; 
glines = [];  
% Holder for each line of gcode. Will be dynamically updated. 
  
% Add any extruder and bed temperature adjustments 
glines = [glines [ 'M190 S' num2str(bedTemp) ' ;Adjust Bed Temp from 
Header Setting']]; 
glines = [glines [ 'M109 S' num2str(extruderTemp) ' ;Adjust Extruder 
Temp from Header Setting']]; 
  
if createBrim, glines = [glines makeBrim(V,0,0)]; end 
% writes gocde for initial skirt at Z = 0.2 
  
numSlice = 1;       o=1;        fanOn = true; 
Zz = zeros(ceil(c/(LayerHeight/VoxelSize)), 1); 
Tt = zeros(a, b, ceil(c/(LayerHeight/VoxelSize))); 
for i6 = print_levels   
    % Turn fan on 
    if (fanOnHeight > 1+i6*2*(LayerHeight/VoxelSize)) && fanOn 
        glines = [glines ['M106 S' num2str(round(fanPower*2.55)) '; fan 
power']]; 
        fanOn = false; % only add to code one time 
    end %if fanOnHeight 
     
    if (top>tiptop), top=tiptop; end 
    if (bot>=top), bot = top-1; end 
    if ~mod(o,LayersPerSlice), numSlice = numSlice+1; end 
  
    [code,X,Y] = writeCode3(endpointlist{i6},X,Y); % get commands for 
one print layer 
    if ~isempty(code), glines = [glines code]; end 
     
    % update z height 
    %   Pause when going up a layer 
    glines = [glines ['G0 Z' num2str(Z+LayerHeight) ';']]; 
    if pauseBoolean 
        glines = [glines ['G4 P' num2str(pauseTime)]]; 
    end 
     
    Zz(o) = Z; % Output for path preview 
    Tt(:,:,o) = T(:,:,i6); 
    Z = Z+LayerHeight; 
     
    bot = bot+SliceThickness; 
    top = top+SliceThickness; 
    o=o+1; 
end 
glines = [glines ['G0 X' n2sX(X) ' Y' n2sY(Y) ' Z' num2str(Z+15) '; 
Move away from scaffold']]; 
% Move print head away from print 




%% Section 5: Save Variables 
if nargout>2 % Scaffold Preview Output 
    graphics.scaffold = G; 
    graphics.support = V_s; 
    varargout{3} = graphics; 
end 
if nargout>1 % Tool Paths Output 
    preview.Z_heights = Zz; 
    preview.ToolPaths = Tt; 
    varargout{2} = preview; 
end 
if nargout>0 
    varargout{1} = glines; 
else 
    savefile = fullfile('Output', 'Graphic_Matrix.mat'); 
    save(savefile, 'G', 'V_s','-v7.3','-nocompression')   
    savefile2 = fullfile('Output','glines.mat'); 
    save(savefile2,'glines'); 
    savefile3 = fullfile('Output','preview.mat'); 
    save(savefile3,'Zz', 'Tt','-v7.3','-nocompression'); 
end 
  
    function C = findpoints(slice, endpointlist, dir) 
        if isempty(endpointlist) 
            index = 0; 
        else 
            index = endpointlist(end, end, end); 
        end 
         
        if dir=='X' 
            [slice, num] = bwlabel(slice,8); 
        else 
            [slice, num] = bwlabel(slice',8); 
            slice = slice'; 
        end 
         
        M = zeros(num*2,3); 
%matrix to collect each (x,y) endpoint and the corresponding path 
number 
         
        for k=1:2:(num*2)  
%find all of the end points for all paths in this slice 
            M(k:k+1,3) = k+index; 
            points = bwmorph((slice == ((k+1)/2)),'endpoints'); 
            [xt,yt] = find(points); 
            if size(xt)==1, continue, end 
            M(k,1) = xt(1); M(k,2) = yt(1); 
            M(k+1,1) = xt(2); M(k+1,2) = yt(2); 
        end 
         
        C = [endpointlist; M]; 
         




    function [glines] = makeBrim(V,X,Y) 
%%% making code for the brim (currently makes 2 squares/rings) 
%%% also this is hard coded to make a square...in the future we may 
want it to trace the first layer of the print 
        X = X-50; Y = Y-50; % Displace in Voxels 
        fildiam = 1.2*FilamentDiameter; 
        xmax = size(V,1)*1.2; ymax = size(V,2)*1.2; 
        numRings = 4; 
        ring  = numRings-1; 
        glines = strings(1,4*numRings+2); 
         
        glines(1) = ['G1 X' n2sX(X-ring*(fildiam)) ' Y' n2sY(Y-
ring*(fildiam)) ';']; 
        glines(2) = ['G1 Z' num2str(0.2) ';']; 
         
        for i = 3:4:4*numRings+1 
            glines(i) = ['G1 X' n2sX(xmax+ring*(fildiam)) ' Y' n2sY(Y-
ring*(fildiam)) ' E' extrude(distance(X-ring*(fildiam),Y-
ring*(fildiam),xmax+ring*(fildiam),Y-ring*(fildiam))) ';']; 
            glines(i+1) = ['G1 X' n2sX(xmax+ring*(fildiam)) ' Y' 
n2sY(ymax+ring*(fildiam)) ' E' extrude(distance(xmax+ring*(fildiam),Y-
ring*(fildiam),xmax+ring*(fildiam),ymax+ring*(fildiam))) ';']; 
            glines(i+2) = ['G1 X' n2sX(X-ring*(fildiam)) ' Y' 
n2sY(ymax+ring*(fildiam)) ' E' 
extrude(distance(xmax+ring*(fildiam),ymax+ring*(fildiam),X-
ring*(fildiam),ymax+ring*(fildiam))) ';']; 
            glines(i+3) = ['G1 X' n2sX(X-ring*(fildiam)) ' Y' n2sY(Y-
(ring-1)*(fildiam)) ' E' extrude(distance(X-(fildiam),ymax+(fildiam),X-
(fildiam),Y-(ring-1)*(fildiam))) ';']; 
            ring = ring-1; 
        end % for i:numRings 
    end % makeBrim Function 
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function [templateX, templateY, linesX, linesY] = templateFUNC(... 
            strutNum, strutWidth, PoreDiameter) 
        %%%%%%%%%%%%%%%  IN X %%%%%%%%%%%%%%%%%%%%%%%%%% 
        %% Create Template Base Units 
        poreX = zeros(a,ceil(PoreDiameter/VoxelSize)); %pore template 
        strutX = ones(a,strutWidth); %strut template 
         
        % Tool Path Template 
        lineX = zeros(size(strutX,1),ceil(NozzleDiameter/VoxelSize));  
% Start with a single toolpath 
        lineX(:,ceil(size(lineX,2)/2))=1;  
%Add a line of ones in the middle for the toolpath 
        lineX=repmat(lineX,[1 strutNum 1]);  
% Repeat the lines enough to create the single strut 
        linesX = cat(2, poreX, lineX);  
% pore and toolpaths for one unit (pore + strut) 
        linesX = repmat(linesX, [1 ceil(b/size(linesX,2))]);  
% Repeat the unit template for the width of the volume 
        linesX = linesX(1:a,1:b);  
% Crop the template to the exact size of the volume (Volume might not 
equal exact multiples of unit template) 
         
        % 3D Volume Template for Modeling and Visualization 
        templateX = cat(2, poreX, strutX);  
% pore and strut for one unit template 
        templateX = repmat(templateX, [1 ceil(b/size(templateX,2))]); 
        templateX=templateX(1:a, 1:b); 
         
        %%%%%%%%%%%%%%%% IN Y %%%%%%%%%%%%%%%%%%%%%%%%% 
        %% Create Template Base Units 
        poreY = zeros(b,ceil(PoreDiameter/VoxelSize)); %pore template 
        strutY = ones(b,strutWidth); %strut template 
         
        % Tool Path Template 
        lineY = zeros(size(strutY,1),ceil(NozzleDiameter/VoxelSize));   
        lineY(:,ceil(size(lineY,2)/2))=1;   
        lineY=repmat(lineY,[1 strutNum 1]);   
        linesY = cat(2, poreY, lineY);   
        linesY = repmat(linesY, [1 ceil(a/size(linesY,2))]);   
        linesY = linesY(1:b,1:a);   
        linesY = linesY'; 
         
        % 3D Volume Template for Modeling and Visualization 
        templateY = cat(2, poreY, strutY);   
        templateY = repmat(templateY, [1 ceil(a/size(templateY,2))]); 
        templateY=templateY'; 
        templateY=templateY(1:a, 1:b); 
         
    end % Template Func 
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function [gcode, finX, finY] = writeCode3(M, prevX, prevY) 
        % for slice of volume V, and previous pixel positions prevX, prevY 
        % writeCode creates gcode instructions for each XY-slice of toolpaths 
        % M is the list of points 
        % X and Y are the current positions. 
        d_thresh = 0.9*PoreDiameter(1)/VoxelSize; 
        num = size(M,1)/2; 
        gcode = strings(num*7,1); 
         
%%% calculate distance from current position to each point in M for 
first loop of k. It is recalculated at the end of the loop. 
        d = zeros(size(M,1),1); 
        for j = 1:size(M,1) 
            d(j) = distance(M(j,1),M(j,2),prevX,prevY); 
        end 
        [~,index] = min(d); % nearest point 
         
        %% writing code 
        %%% one movement along a line repeated for each tool path 
        for k=1:num 
            % 1. Check that nearest extrude move is long enough to do.  
            % 2. Move to closest (x,y) end of that move  
            % 3. Extrude along that move 
            % 4. Remove the entries from M 
  
            if mod(index,2) == 0 %index is even number so corresponding 
row is before 
                dist = distance(M(index,1),M(index,2),M(index-
1,1),M(index-1,2)); 
                prevX2 = M(index,1); prevY2 = M(index,2); %save for 
backtracking 
                if dist > 2*NozzleDiameter/VoxelSize 
                      
                    gcode((k*7)-6) = ['G1 X' n2sX(M(index,1))... 
                        ' Y'  n2sY(M(index,2)) ';']; %go to closest end 
                    gcode((k*7)-5) = ['G1 X' n2sX(M(index-1,1)) ' Y' 
n2sY(M(index-1,2))... 
                        ' E' extrude(dist) ';']; 
                    prevX = M(index-1,1); prevY = M(index-1,2); 
                end %if dist is great enough 
                M = [M(1:index-2,:);M(index+1:end,:)]; 
            else %index is odd number so corresponding row is after 
                dist = 
distance(M(index,1),M(index,2),M(index+1,1),M(index+1,2)); 
                prevX2 = M(index,1); prevY2 = M(index,2);  
%save for backtracking 
                if dist > 2*NozzleDiameter/VoxelSize 
                    %%% move to (x,y) that have smallest distance 
                    gcode((k*7)-6) = ['G1 X' n2sX(M(index,1))... 
                        ' Y'  n2sY(M(index,2)) ';']; %go to closest end 
                    gcode((k*7)-5) = ['G1 X' n2sX(M(index+1,1)) ' Y' 
n2sY(M(index+1,2))... 
                        ' E' extrude(dist) ';']; 
                    prevX = M(index+1,1); prevY = M(index+1,2); 
                end %if dist is great enough 
                M = [M(1:index-1,:);M(index+2:end,:)]; 
            end % mod(index) 
            d = zeros(size(M,1),1); 
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            for j = 1:size(M,1) 
                d(j) = distance(M(j,1),M(j,2),prevX,prevY); 
            end 
            [min_d,index] = min(d); % nearest point 
            %% Backtracking %% 
    % re-calculate distance from current position to each point in M 
            if backtrackingBoolean 
                if min_d > d_thresh 
                    U = distance(prevX,prevY,prevX2,prevY2);  
% vector magnitude 
                    if U < 4*PoreDiameter(1)/VoxelSize  
%if distance is less than 10 pixels (1mm?) then just use previous XY. 
                        backX = prevX2; backY=prevY2; 
                    else 
                        xu = (prevX-prevX2)/U; 
                        yu = (prevY-prevY2)/U; % Normalize the vector 
                        backX = prevX - 
4*(PoreDiameter(1)/VoxelSize)*xu;   
                        backY = prevY - 
4*(PoreDiameter(1)/VoxelSize)*yu; 
                    end 
         % Back track at a speed 30% slow than normal extruder speed 
gcode((k*7)-4) = ['G1 F' num2str(0.7*printSpeed) '; slow extruder 
speed']; 
gcode((k*7)-3) = ['G1 X' n2sX(backX) ' Y'  n2sY(backY) ';']; 
if pauseBoolean, gcode((k*7)-2) = ['G4 P'  num2str(pauseTime) ';']; end 
gcode((k*7)-1) = [' G1 X' n2sX(prevX) ' Y' n2sY(prevY) ';']; 
gcode((k*7)) = ['G1 F' num2str(printSpeed) '; return to normal speed']; 
                end % if min_d < thresh 
                gcode = gcode'; 
            end % if backtrackingBoolean 
        end % for k=1:num 
         
        if size(gcode,1) ~=1, gcode = gcode'; end 
        finX = prevX; finY = prevY; 
    end % writeCode3 Nested Function 
  
% Distance creates the sqrt distance between two cartesian points. 
    function d = distance(x1, y1, x2, y2), d = sqrt((x1-x2)^2+(y1-
y2)^2); end 
  
% Extrude creates an extrude command scaled to the voxel size 
    function e = extrude(dist) 
        e = num2str(ExtrusionMult*(LayerHeight / NozzleDiameter)... 
            *(VoxelSize*dist)*(NozzleDiameter^2)/(FilamentDiameter^2)); 
    end % extrude function 
  
% n2s turns numbers of voxels into the equivalent mm distance and 
translates it in xy according to the start position input.  
    function outString = n2sY(num) 
        y = Position(2); 
        outString = num2str(y+VoxelSize*num); end % n2sY Function 
    function outString = n2sX(num) 
        x = Position(1); 
        outString = num2str(x+VoxelSize*num); end % n2sX Function 
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Ethan Nyberg was born to Lori and Karl Nyberg in Fairfax, Virginia. He was raised in 
Northern Virginia, where his parents homeschooled him and his three younger sisters. 
Throughout his youth, Ethan enjoyed reading science fiction and is thrilled with the ways 
that those ideas are becoming reality. In particular, he was captivated with the idea of 
nanorobots controlled to rebuild the body.  
Throughout high-school and college, Ethan spent large portion of his life at the 
natatorium, with a successful career as an athlete, lifeguard, and coach. He also had a 
passion for the outdoors and adventure and was deeply involved with the Boy Scouts, 
with membership in the Order of the Arrow, and attained the rank of Eagle Scout.  
For the past 15 years, Ethan has been a student of martial arts, particularly 
Shotokan karate, teaching locally and competing on the national and international stage. 
Training with martial arts has imparted mental focus, a deep understanding of 
biomechanics, and has provided an enduring avenue of stress relief.  
Preparing to go to the University of Virginia, Ethan was going to major in a 
combination of literature and business, but thought last minute to give engineering a try 
instead. He took the first entry Biomedical Engineering class in physiology and fell in love 
with it.  He realized that there are already nanorobots in the body—cells—that we can 
engineer to heal and regenerate the body.  
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Ethan’s research at UVA in the Botchwey and Peirce-Cottler Labs granted him 
valuable experience with stem cells and vascular regeneration, and extensive training in 
rodent biomethodology. This experience gave him the idea of using a rapidly vascularized 
network as a platform for regeneration of different tissues. His first contact with 3D-
printing cells occurred in 2013, and the experience left him painfully aware of the 
complications and barriers to directly printing cells. Those difficulties (e.g. oozing gel into 
a petri dish) made him doubt that the cells really benefit from spatial manufacturing. Ethan 
graduated with high distinction from the University of Virginia in May, 2014 with a 
Bachelor’s of Science in Biomedical Engineering and a minor in business. Ethan was the 
Outstanding Student of the School of Engineering and Applied Science that year. He took 
the Fundamentals of Engineering exam that summer and is registered as EIT in the state 
of Virginia.  
In the fall of 2014, Ethan started the Johns Hopkins School of Medicine Biomedical 
Engineering PhD program. At JHU, Ethan worked at length with stem cells for 
vascularization and bone regeneration. The first year of medical school courses were 
some of the most worthwhile education since the intro to biomedical engineering 
physiology course at UVA. He added 3D-printing as a dominating research focus in his 
third year of graduate school, and saw opportunities to redevelop and scale the 3D-
printing systems in the Grayson Lab. Combining that 3D-printing system with the stem 
cell and vasculature approach resulted in the work in his doctoral dissertation.   
As a result of working for years to scale those technologies from the petri dish to 
the human craniofacial skeleton, Ethan developed an interest in regulatory science and 
affairs, particularly as applied to patient-specific design and manufacturing.  
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Ethan has authored or coauthored 6 peer reviewed journal articles, a book chapter. 
He has given or been an author of 18 oral and poster presentations. He an inventor on 
one patent pertaining to 3D-printing bone ECM.  During his academic training, Ethan 
taught undergraduate courses on Earth Systems Engineering Management, 
Nanoscience, Business and Ethics of Regenerative Medicine, and Engineering Design 
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Lecturer                         2016-2018 
• The Ethics and Business of Regenerative Medicine  
• Engineering Design Process for Craniofacial Orthopedics 
Designed and taught one course on the interweavings of business, ethics, and societal 
dimensions as relevant to recent advances and failures of regenerative medicine; 
similarly created and taught a course using craniofacial implants to teach the engineering 
design process.  
 
Graduate Teaching Assistant,           2017 
• Biomedical Engineering Modeling and Design   
Taught 12 sections the principles of modeling human systems and the design of medical 
devices. Provided feedback on writing technical reports, creating and giving 
presentations, and career advice.  
 
Teaching Academy, Johns Hopkins Center for Teaching and Learning       2016 
Completed a three-day course to develop teaching skills including: active learning, flipped 
classrooms, course design, and student assessment.  
 
Senior Teaching Assistant                      2013-2015 
• Earth Systems Engineering Management 
• Societal Dimensions of Nanotechnology 
Led discussions, lectured, redesigned course content, graded assignments, moderated 
forums, managed team of TAs, ran writing workshops, managed online course content 
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Outstanding Student Award, School of Engineering, UVA 2014 
To honor a (graduating) student who has exhibited service before self, integrity, and 
excellence and demonstrated outstanding academic performance, leadership, and 
service.  
  
Harrison Award    2013-2014 
A competitive grant to enable original undergraduate research at UVA.  Research Topic: 
The ability to engineer organic biological replacements or repairs for failed or diseased 
tissues such as bones, blood vessels and organs by leveraging emerging stem cell 
technology. 
 
Kinnier Fellowship 2012-2013 
A competitive fellowship for engineering students interested in academia; combining 
discussions with distinguished faculty from across the University of Virginia, focused on 
the nature of academia and teaching engineering, as well as a focused student-run 
outreach program on the opportunities of secondary education in engineering to local 
underprivileged high schools.  
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Finalist, Research Symposium, Johns Hopkins Dept. of Medicine 2018 
Winner, Student and Young Investigator Section, TERMIS-Americas 2017 
Travel Award, Graduate Student Association, Johns Hopkins  2016 
Medical Hackathon, 2nd Place Winner, Johns Hopkins 2015 
Phi Eta Sigma National Honor Society; University of Virginia 2011-2014 
National Residence Hall Honorary Association  2011-2013 
Dean’s List; University of Virginia  2010-2011 
Dean’s List; Northern Virginia Community College 2008-2010 
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Regulatory Affairs Professional Society, Training Fellow, Certificate 2018 
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Training and Practice of Clinical Staff 2016 
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Biomedical Engineering PhD Program Student Council       2014-2017 
• Managed recruitment and social activities  
• Chairperson for annual program retreat   
 
Research Experience for Intercity Students, Summer Employer     2015 
Mentored and employed students from local inner-city high-schools as lab technicians.  
 
Peer-Mentoring Program, Univ. Virginia. Co-founder, Mentor. 2012-2014 
Helped to conceive and design a peer-mentoring program to address the needs of 
students struggling academically, socially, mentally, or emotionally as they pursue an 
engineering degree. Organized and facilitated events and mentor training.  
 
Hobbies: Woodworking, open-water swimming, running, beach volleyball, karate, 
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